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Historical perspective and present clinical use
Like many other pharmaceuticals, coumarin anticoagulants owe their discovery to the 
appreciation of an unexpected adverse reaction. In 1924, a previously undescribed hemorrhagic 
disorder was reported in cattle, that resulted from the ingestion of spoiled sweet clover silage 
[1]. After the cause was traced to a toxic reduction of plasma prothrombin, Campbell and 
Link, in 1939, identified the hemorrhagic agent as dicoumarol (bishydroxycoumarin) [2]. Since 
then, several hundred derivatives of coumarin have been synthesized [3]. Warfarin was found 
to be more potent than dicoumarol and was first introduced as a rodenticide. Application of 
warfarin as an anticoagulant in humans came about when it was observed through accidental 
poisonings and suicide attempts that, except for its depression of clotting factor activity, 
warfarin had no other significant biological effects in humans. Warfarin was first introduced 
into human anticoagulant therapy in 1941 [4]. In 1954, a large multicenter clinical trial of the 
American Heart Association resulted in a report of seemingly favourable responses of patients 
with myocardial infarction to dicoumarol. The indications for long-term therapy with coumarin 
anticoagulants have broadened considerably since then. 
Coumarins are now prescribed for primary and secondary prevention of venous 
thromboembolism, for prevention of systemic embolism in patients with tissue or mechanical 
prosthetic heart valves or atrial fibrillation, for prevention of acute myocardial infarction in 
patients with peripheral arterial disease, for prevention of stroke, recurrent infarction, or death 
in patients with acute myocardial infarction, and for prevention of myocardial infarction in 
men at high risk [5]. Other drugs used for prevention or treatment of several thromboembolic 
diseases are unfractionated heparin or low-molecular-weight heparin (LMWH), thrombolytic 
and platelet inhibiting drugs, such as aspirin and glycoprotein IIb/IIIa antagonists. Heparins are 
often used together with coumarin anticoagulants in the acute treatment of thromboembolic 
disease because of their immediate anticoagulant effect. They are withdrawn once the 
coumarin anticoagulant is exerting its full effect. Therapy with heparins, thrombolytic and 
platelet inhibiting drugs are beyond the scope of this thesis and will not be discussed further. 
Mechanism of action of coumarin anticoagulants
Coumarin anticoagulants decrease the synthesis of vitamin K-dependent clotting factors II, VII, IX 
and X by inducing a functional deficiency of reduced vitamin K [5, 6]. The normal carboxylation 
of factors II, VII, IX and X requires reduced vitamin K, which is usually oxidized to vitamin K 
epoxide in the process. Reduced vitamin K is regenerated from the vitamin K epoxide by an 
epoxide reductase. Coumarin anticoagulants block this enzyme and prevent the regeneration 
of reduced vitamin K. Non-carboxylation of glutamic acid residues at the amino-terminal ends 
of factors II, VII, IX and X prevents them from binding to calcium and hence to phospholipids on 
blood platelets and endothelial cells at the site of injury. The defect in calcium binding results in 
the inability of these factors to participate in the clotting cascade [7]. Because they do not have 
any effect on the fully carboxylated clotting factors already in circulation, they do not produce 
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an immediate anticoagulant effect. The rate of clearance of the previously fully carboxylated 
factors and the half-life of the coumarin anticoagulant determine the time of onset of the 
anticoagulant effect [8].
Chemistry and pharmacokinetics of coumarin anticoagulants
The essential chemical characteristics of the coumarin derivatives for anticoagulant activity 
are an intact 4-hydroxycoumarin residue with a carbon substituent at the 3 position [9]. 
The most commonly used coumarins are acenocoumarol, phenprocoumon and warfarin. In 
North America, in the UK and in Scandinavia, warfarin is most commonly prescribed, whereas 
phenprocoumon and acenocoumarol are the first-line coumarin anticoagulants in other 
European countries. These compounds have an asymmetrical carbon atom in the substituent 
at the 3 position, and the available preparations of the drugs are mixtures of the two optical 
isomers [9]. In phenprocoumon and warfarin, the S-(−)-enantiomer has been reported to 
be more potent with respect to anticoagulant activity, while for acenocoumarol the R-(+)-
enantiomer seems to be several times more potent [10, 11].
Although the mechanism of action of these 3 coumarin anticoagulants is the same, their 
pharmacokinetic properties differ to some extent. They are all rapidly, and almost completely 
absorbed from the upper gastrointestinal tract with little interindividual variation [8]. All coumarin 
anticoagulants are highly protein bound and have low volumes of distribution. All three drugs 
are metabolized in the liver by cytochrome P450 enzymes, most importantly CYP2C9, to mostly 
inactive metabolites, which are excreted in urine and faeces [12-14]. The relative contribution 
of CYP2C9 to the metabolism differs between the three coumarins, as a consequence of 
the difference in structure. This enzyme plays a more important role in the oxidation of 
acenocoumarol and warfarin, than in the oxidation of phenprocoumon. Phenprocoumon is 
also, for approximately one-third, eliminated as free or conjugated parent-drug [8, 12, 15-17]. 
The hepatic biotransformation of warfarin appears to be stereoselective. CYP2C9 is the main 
enzyme that metabolizes the more potent S-(−)-enantiomer, whereas the R-(+)-enantiomer 
is preferentially metabolized by other CYP enzymes [14, 18]. For acenocoumarol, CYP2C9 has 
been identified as the enzyme metabolizing both enantiomers [15]. The elimination half-lives 
of the coumarin anticoagulants vary widely and thereby the duration of effect. Acenocoumarol 
is a short-acting anticoagulant with a half-life of 8 to 12 hours. Phenprocoumon has a half-life of 
65 to 170 hours and is a long-acting coumarin. Warfarin has an intermediate duration of effect 
with a half-life of 10 to 45 hours [8, 9]. A number of studies have suggested that longer-acting 
coumarins give a more stable anticoagulation than short-acting coumarins, which is thought to 
be associated with greater fluctuations in the plasma levels of factor VII with the shorter-acting 
drugs [19-21].
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Monitoring coumarin anticoagulant therapy
Because underanticoagulation is associated with an exponentially increasing risk of recurrent 
thrombosis, and overanticoagulation places patients at a heightened risk of bleeding [5, 22-24], 
anticoagulant therapy needs to be monitored. The benefit-risk ratio of treatment with coumarin 
anticoagulants is determined to a great extent by the difficulties inherent in the process of 
achieving and maintaining the therapeutic range of anticoagulation. These stem largely from 
the high degree of interindividual variability in the dose-response relationship and from the 
variation within individuals in this relationship over time. 
The prothrombin time (PT) test is the most common method for monitoring coumarin 
anticoagulant therapy [25]. This test responds to reduction of three of the four vitamin 
K-dependent coagulation factors (II, VII, and X). During the first few days of coumarin 
anticoagulant therapy, the prolongation of the PT reflects mainly a reduction of factor VII, while 
subsequently it also reflects a reduction of factors X and II. The PT assay is performed by adding 
calcium and thromboplastin to citrated plasma. Because commercial thromboplastins have 
different potencies, the PT can vary widely. In an effort to standardize oral anticoagulation, 
the international normalised ratio (INR) method has been adopted by most laboratories and 
clinicians [26]. With this method, the ratio of the patient’s PT is compared to the mean PT 
for a group of normal individuals. The ratio is adjusted for the sensitivity of the laboratory’s 
thromboplastin determined by the International Sensitivity Index (ISI). Thus, INR = (PT patient/
PT normal)ISI. Use of the INR permits physicians to obtain the appropriate level of anticoagulation 
independent of laboratory reagents and to follow published recommendations for intensity of 
anticoagulation. The optimal target range of coumarin anticoagulant therapy, as recommended 
by the Federation of Dutch Thrombosis Centers, lies between an INR of 2.5 and 3.5, or between 
3.0 and 4.0 [23, 27], depending on the indication for treatment. The necessary duration of 
treatment ranges from four weeks to lifelong.
Adequate and safe anticoagulation requires experience and a specialized organization 
[28]. In the Netherlands, the management of individual coumarin anticoagulant therapy 
is performed at one of 63 regional anticoagulation clinics located throughout the country 
[29]. Although each anticoagulation centre operates independently, many use one of several 
available computerised systems to assist with dosing schemes for coumarins. These systems 
evaluate INR results and in about one-half of cases, make a dosage recommendation that can 
be modified by the physician [23]. In the other half of cases, consisting mainly of patients who 
are unstable or have had complications or for whom the prescription of concomitant drugs 
has changed, the physician adjusts the dosage according to a standard operating procedure 
without a recommendation from the system. INR measurements and consequent adjustments 
of the dosing schedules usually occur at intervals of 1 to 6 weeks, dependent on the stability of 
the anticoagulant level. 
In the Netherlands, two coumarin anticoagulants are licensed: acenocoumarol (Sintrom 
Mitis®) and phenprocoumon (Marcoumar®). The choice of anticoagulant drug is essentially 
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made by the referring physician and is mainly based on his or her previous experience with 
these coumarins. Acenocoumarol is prescribed in about 75% of cases, whereas only 25% of the 
patients are treated with phenprocoumon. 
Genetic factors
The wide interindividual variation in coumarin anticoagulant dose requirement is partly 
genetically determined. Several cytochrome P450 enzymes contribute to oxidative metabolism 
of these anticoagulants. The most important of these is CYP2C9. The human gene coding for the 
CYP2C9 protein has been mapped to chromosome 10q24.2 and is greater than 55 kb in length 
[30, 31]. Over the past several years, multiple single-base pair substitution polymorphisms have 
been identified. In addition to the wild type allele (CYP2C9*1), at least eleven other CYP2C9 
alleles are now known to occur (http://www.imm.ki.se/CYPalleles/). These alleles encode CYP2C9 
enzymes with potentially different catalytic activity and specificity [32]. The two most common 
variant alleles are CYP2C9*2 and CYP2C9*3. Population distribution data suggest that these 
variant alleles are present in approximately 35% of Caucasian individuals, but are significantly 
less prevalent in African-American and Asian populations. In several clinical studies, possession 
of the CYP2C9*2 or CYP2C9*3 variant alleles has been associated with a significant decrease in 
mean warfarin dose requirement and an increased risk of adverse events, such as bleeding [33-
38]. Much less is known about the impact of CYP2C9 polymorphisms on acenocoumarol and 
phenprocoumon pharmacokinetics and clinical effects. Furthermore, the wide interindividual 
variation in warfarin dose requirement within the various CYP2C9 genotype groups may 
suggest that there are also other genetic factors involved. 
Environmental factors
In addition to known and unknown genetic factors, demographic factors, various disease states, 
drugs, and dietary factors can interfere with the response to coumarin anticoagulants. For 
example, the dosage of warfarin decreases by approximately 10% for each decade of life [39-41]. 
Hepatic dysfunction potentiates the response to coumarin anticoagulants through impaired 
synthesis of coagulation factors. Hypermetabolic states produced by fever or hyperthyroidism 
increase coumarin responsiveness, probably by increasing the catabolism of vitamin K-
dependent coagulation factors [42, 43]. In patients with heart failure the increased coumarin 
responsiveness is reported to be associated with hepatic congestion and redistribution of body 
water [44-48].
Concomitantly administered drugs can influence the pharmacokinetics of coumarin 
anticoagulants by altering its metabolic clearance or its rate of absorption from the intestine. 
Drugs can also influence the pharmacodynamics of coumarin anticoagulants by inhibiting the 
synthesis of vitamin K-dependent coagulation factors, increasing their metabolic clearance, or 
interfering with other pathways of hemostasis [5, 49-52]. Lists of drugs that have the potential 
to interact with coumarin anticoagulants and that have been reported to alter the prothrombin-
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time response have been published [49-52], but because of the descriptive nature of most of 
such reports, no cause-effect relation can usually be inferred from these lists. Only a small 
number of drug interactions that affect the pharmacokinetics and pharmacodynamics of 
coumarin anticoagulants have been well documented [53]. 
Subjects receiving long-term anticoagulant therapy are sensitive to fluctuating levels of 
dietary vitamin K [54, 55], which is provided predominantly by phylloquinone in plant material 
[55]. To some extent, vitamin K synthesized by intestinal bacteria may also be available to the 
human host, but this source is reported to be much less important [51]. There is only limited 
information in the literature however, on the association between dietary intake of vitamin K 
and overanticoagulation. 
Finally, variability in anticoagulant response also occurs as a result of patient non-compliance, 
the physician’s experience in handling coumarin anticoagulants and miscommunication 
between patient and physician [5, 56]. However, these topics will not be discussed in this 
thesis.
Aim and outline of this thesis
This introductory chapter has illustrated that various factors, such as genetic factors, drugs, 
diet and intercurrent diseases may affect anticoagulation levels. Most of the clinical and 
pharmacological data related to coumarin anticoagulants have so far been obtained from 
studying warfarin. Because of the different pharmacokinetic properties of each individual 
drug, the results of these studies can probably not be directly extrapolated to the other 
coumarin anticoagulants. Therefore, the aim of this thesis was to study the various genetic 
and environmental factors affecting the anticoagulation levels of acenocoumarol or 
phenprocoumon among outpatients of an anticoagulation clinic. In chapter 2 genetic factors 
influencing the coumarin anticoagulant level are examined. Chapter 2.1 describes how the 
coumarin anticoagulant dose is affected by polymorphisms of the cytochrome P450 enzyme 
2C9 allele. In chapter 2.2 we describe the influence of these polymorphisms on the occurrence of 
bleeding complications. CYP2C9 variant alleles seem to have several biological consequences. 
For instance, it has been associated with an increased risk of myocardial infarction in women 
[57]. Therefore, in chapter 2.3 the risk of myocardial infarction was studied in patients with a 
CYP2C9 variant allele compared to patients with the wild type genotype. Chapter 2.4 concerns 
the influence of apolipoprotein E genotype on the coumarin anticoagulant level. In chapter 3, 
several drugs are identified with a high risk of overanticoagulation during coumarin use. Chapters 
3.1 and 3.2 focus on antibacterial drugs and antifungal agents, chapters 3.3 on laxatives, and 
3.4 on nonsteroidal anti-inflammatory drugs as risk factors for overanticoagulation. The study 
described in chapter 4 aims at investigating the influence of heart failure on the anticoagulant 
level. The role of dietary intake of vitamin K as a risk factor for overanticoagulation is evaluated 
in chapter 5. Finally, in chapter 6 the strengths and limitations of this thesis are discussed, 
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together with the implications for coumarin anticoagulant therapy, and suggestions for future 
research are given. 
REFERENCES
 1. Schofield FW. A brief account of a disease of cattle simulating hemorrhagic septicaemia due to 
feeding sweet clover. Canadian Veterinary Record 1924; 3: 74.
 2. Campbell HA, Link KP. Studies on the hemorrhagic sweet clover disease. IV. The isolation and 
crystallization of the hemorrhagic agent. J Biol Chem 1941; 138: 21-33.
 3. Owen CA, Bowie EJW. The history of the development of oral anticoagulant drugs. In: Poller L, Hirsh 
J, editors. Oral anticoagulants. London, UK: Arnold; 1996. p. 1-8.
 4. Butt HR, Allen EV, Bollman JL. A preparation from spoiled sweet clover [3,3’methylene-bis-(4-
hydroxycoumarin)] which prolongs coagulation and prothrombin time of the blood: prelimanary 
report of experimental and clinical studies. Proceedings of Staff Meetings Mayo Clinic 1941; 16: 
388-95.
 5. Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, et al. Oral anticoagulants: mechanism of 
action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119: 8S-21S.
 6. Sadowski JA, Booth SL, Mann KG, Malhotra OP, Bovill EG. Structure and mechanism of activation of 
vitamin K antagonists. In: Poller L, Hirsh J, editors. Oral anticoagulants. London, UK: Arnold; 1996. p. 
9-21.
 7. Suttie JW, Jackson CM. Prothrombin structure, activation and biosynthesis. Physiol Rev 1977; 57: 1. 
 8. Shetty HG, Woods F, Routledge PA. The pharmacology of oral anticoagulants: implications for 
therapy. J Heart Valve Dis 1993; 2: 53-62.
 9. Majerus PW, Broze GJ, Miletich JP, Tollefsen DM. Anticoagulant, thrombolytic, and antiplatelet drugs. 
In: Hardman JG, Goodman Gilman A, Limbird LE, editors. Goodman & Gilman’s The Pharmacological 
basis of therapeutics. 9th ed. United States: McGraw-Hill; 1996. p. 1341-59.
 10. Chan E, McLachlan A, O’Reilly R, Rowland M. Stereochemical aspects of warfarin drug interactions: 
use of a combined pharmacokinetic-pharmacodynamic model. Clin Pharmacol Ther 1994; 56: 286-
94.
 11. Jähnchen E, Meinertz T, Gilfrich HJ, Groth U, Martini A. The enantiomers of phenprocoumon: 
pharmacodynamic and pharmacokinetic studies. Clin Pharmacol Ther 1976; 20: 342-9.
 12. He M, Korzekwa KR, Jones JP, Rettie AE, Trager WF. Structural forms of phenprocoumon and warfarin 
that are metabolized at the active site of CYP2C9. Arch Biochem Biophys 1999; 372: 16-28.
 13. Thijssen HH, Flinois JP, Beaune PH. Cytochrome P4502C9 is the principal catalyst of racemic 
acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab Dispos 2000; 28: 
1284-1290.
 14. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997; 73: 67-74.
 15. Hermans JJ, Thijssen HH. Human liver microsomal metabolism of the enantiomers of warfarin and 
acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. Br J 
Pharmacol 1993; 110: 482-90.
 16. Kohl C, Steinkellner M. Prediction of pharmacokinetic drug/drug interactions from in vitro data: 
interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants. Drug 
Metab Dispos 2000; 28: 161-8.
 17. Toon S, Heimark LD, Trager WF, O’Reilly RA. Metabolic fate of phenprocoumon in humans. J Pharm 
Sci 1985; 74: 1037-40.
 18. Yamazaki H, Shimada T. Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of 
R- and S-warfarin enantiomers. Biochem Pharmacol 1997; 54: 1195-1203.
 19. Breed WP, van Hooff JP, Haanen C. A comparative study concerning the stability of the anticoagulant 
effect of acenocoumarol and phenprocoumon. Acta Med Scand 1969; 186: 283-8.
General introduction 19
 20. Fekkes N, de Jonge H, Veltkamp JJ, Bieger R, Loeliger EA. Comparitive study of the clinical effect of 
acenocoumarol (Sintrom) and phenprocoumon (Marcoumar) in myocardial infarction and angina 
pectoris. Acta Med Scand 1971; 190: 535-40.
 21. Pattacini C, Manotti C, Pini M, Quintavalla R, Dettori AG. A comparative study on the quality of oral 
anticoagulant therapy (warfarin versus acenocoumarol). Thromb Haemost 1994; 71: 188-91.
 22. Hylek E, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann 
Intern Med 1994; 120: 897-902.
 23. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJM, Vandenbroucke JP, Briët E. Optimal 
intensity of oral anticoagulation therapy in patients with mechanical heart valves. N Engl J Med 
1995; 333: 11-7.
 24. Hylek E, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic 
anticoagulation for patients with nonrheumatic anticoagulation for patients with nonrheumatic 
atrial fibrillation. N Engl J Med 1996; 335: 540-6.
 25. Quick AJ. The prothrombin time in haemophilia and in obstructive jaundice. J Biol Chem 1935; 109: 
73-4.
 26. International Committee for Standardization in Haematology, International Committee on 
Thrombosis and Haemostasis: ICSH/ICTH recommendations for reporting prothrombin time in oral 
anticoagulant control. Thromb Haemost 1985; 53: 155-6.
 27. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial 
origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. Ann Neurol 1997; 42: 
857-65.
 28. Loeliger EA, van Dijk-Wierda CA, van den Besselaar AMHP, Broekmans AW, Roos J. Anticoagulant 
control and the risk of bleeding. In: Meade TW, ed. Anticoagulants and myocardial infarction: a 
reappraisal. New York, NY: John Wiley & Sons Inc; 1984. p. 135-77. 
 29. Van den Besselaar AMHP, van der Meer FJM, Gerrits-Drabbe CW. Therapeutic control of oral 
anticoagulant treatment in the Netherlands. Am J Clin Pathol 1988; 90: 685-90.
 30. Meehan RR, Gosden JR, Rout D, Hastle ND, Friedberg T, Adesnik M, et al. Human cytochrome P-450 
PB-1: a multigene family involved in mephenytoin and steroid oxidations that maps to chromosome 
10. Am J Hum Genet 1988; 42: 26-37.
 31. Goldstein JA, de Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. 
Pharmacogenetics 1994; 4: 285-99.
 32. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug 
metabolism. Br J Clin Pharmacol 1998; 45: 525-38.
 33. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 
CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-
9.
 34. Ogg MS, Brennan P, Meade T, Humphries SE. CYP2C9*3 allelic variant and bleeding complications. 
Lancet 1999; 353: 1124.
 35. Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin 
sensitivity and risk of overanticoagulation in patients on long-term treatment. Blood 2000; 96: 
1816-9.
 36. Margaglione M, Colaizzo D, D’Andrea G, Brancaccio V, Ciampa A, Grandone E, et al. Genetic 
modulation of oral anticoagulation with warfarin. Thromb Haemost 2000; 84: 775-8.
 37. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, et al. Association 
between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. 
JAMA 2002; 287: 1690-8.
 38. Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R. Influence of CYP2C9 and CYP2C19 
genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol 
Ther 2002; 72: 702-10.
 39. Gurwitz J, Avorn J, Ross-Degnan D, Choodnovskiy I, Ansell J. Aging and the anticoagulant response 
to warfarin therapy. Ann Intern Med 1992; 116: 901-4.
 40. Routledge P, Chapman P, Davies D, Rawlins MD. Factors affecting warfarin requirements: a 
prospective population study. Eur J Clin Pharmacol 1979; 15: 319-22.
 41. Wynne H, Cope L, Kelly P, Whittingham T, Edwards C, Kamali F. The influence of age, liver size and 
enantiomer concentrations on warfarin requirements. Br J Clin Pharmacol 1995; 40: 203-7.
20
C
ha
pt
er
 1
 42. Richards RK. Influence of fever upon the action of 3,3-methylene bis-(4-hydroxycoumarin). Science 
1943; 97: 313-6.
 43. Owens JC, Neely WB, Owen WR. Effect of sodium dextrothyroxine in patients receiving anticoagulants. 
N Engl J Med 1962; 266: 76-9.
 44. O’Reilly RA, Aggeler PM. Determinants of the response to oral anticoagulant drugs in man. 
Pharmacol Rev 1970; 22: 35-96.
 45. Killip T 3rd, Payne MA. High serum transaminase activity in heart disease. Circulatory failure and 
hepatic necrosis. Circulation 1960; 21: 646-60.
 46. Covert DF. Vitamin K control of the increased hypoprothrombinemic effect of dicumarol in 
congestive heart failure. Am J Med Sci 1952; 224: 439-45.
 47. Stats D, Davison S. The increased hypoprothrombinemic effect of a small dose of dicumarol in 
congestive heart failure. Am J Med Sci 1949; 218: 318-23.
 48. Bachmann K, Shapiro R. Protein binding of coumarin anticoagulants in disease states. Clin 
Pharmacokinet 1977; 2: 110-26.
 49. Harder S, Thürmann P. Clinically important drug interactions with anticoagulants. Clin Pharmacokinet 
1996; 30: 416-44.
 50. Freedman MD, Olatidoye AG. Clinically significant drug interactions with the oral anticoagulants. 
Drug Safety 1994; 10: 381-94.
 51. Koch-Weser J, Sellers EM. Drug interactions with coumarin anticoagulants. N Engl J Med 1971; 285: 
487-98.
 52. Koch-Weser J, Sellers EM. Drug interactions with coumarin anticoagulants. 2. N Engl J Med 1971; 
285: 547-58.
 53. O’Reilly RA. Warfarin metabolism and drug-drug interactions. In: Wessler S, Becker CG, Nemerson 
Y, eds. The new dimensions of warfarin prophylaxis. Vol. 214 of Advances in experimental medicine 
and biology. New York, NY: Plenum; 1996. p.205-12.
 54. O’Reilly R, Rytand D. Resistance to warfarin due to unrecognized vitamin K supplementation. N Engl 
J Med 1980; 303: 160-1.
 55. Suttie JW, Muhah-Schendel LL, Shah DV, Lyle BJ, Greger JL. Vitamin K deficiency from dietary vitamin 
K restriction in humans. Am J Clin Nutr 1988; 47: 475-80.
 56. Barcellona D, Contu P, Marongiu F. Patient education and oral anticoagulant therapy. Haematologica 
2002; 87: 1081-6.
 57. Yasar U, Bennet AM, Eliasson E, Lundgren S, Wiman B, de Faire U, et al. Allelic variants of cytochromes 
P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics 2003; 13: 715-20.
Chapter 2
Genetic factors affecting the coumarin anticoagulant level

Chapter 2.1
The risk of overanticoagulation in patients with cytochrome 
P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or 
phenprocoumon
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ABSTRACT
Cytochrome P4502C9 (CYP2C9) is the main enzyme implicated in coumarin anticoagulant 
metabolism. The variant alleles CYP2C9*2 and CYP2C9*3 are associated with an increased 
response to warfarin. However, an effect on acenocoumarol dose requirements appears to be 
absent for the CYP2C9*2 allele and the consequences for the metabolism of phenprocoumon 
have not yet been established. We investigated CYP2C9 polymorphisms in relation to the 
international normalised ratio (INR) during the first six weeks of treatment and its effect on the 
maintenance dose in a cohort of 1124 patients from the Rotterdam Study who were treated 
with acenocoumarol or phenprocoumon. There was a statistically significant difference in 
first INR between patients with variant genotypes and those with the wild type. Almost all 
acenocoumarol-treated patients with a variant genotype had a significantly higher mean INR 
and had a higher risk of an INR ≥ 6.0 during the first six weeks of treatment. A clear genotype-dose 
relationship was found for acenocoumarol-treated patients. For patients on phenprocoumon, 
no significant differences were found between variant genotypes and the wild type genotype. 
Individuals with one or more CYP2C9*2 or CYP2C9*3 allele(s) require a significantly lower dose 
of acenocoumarol compared to wild type patients. Phenprocoumon appears to be a clinically 
useful alternative in patients carrying the CYP2C9*2 and *3 alleles.
26
C
ha
pt
er
 2
.1
INTRODUCTION
Coumarin anticoagulants are extensively used for the treatment and long-term prevention of 
thromboembolic diseases [1, 2]. The main drawback is an enhanced risk of hemorrhage [3], 
which is strongly associated with the intensity of anticoagulation and sharply increases when 
the international normalised ratio (INR) is ≥ 6.0 [4, 5]. Anticoagulant therapy is considered 
effective and safe if the INR is kept within the therapeutic zone for as long as possible [6, 7]. It 
is increasingly appreciated that the response to coumarin anticoagulants is largely genetically 
determined [8]. Cytochrome P450 2C9 (CYP2C9) plays an important role in the metabolism of 
the coumarin anticoagulants warfarin, phenprocoumon, and acenocoumarol [9, 10]. Warfarin 
is the main coumarin anticoagulant used in the UK and USA, while acenocoumarol and 
phenprocoumon are preferentially used in continental Europe [11]. Allelic variants of CYP2C9, 
CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu), code for enzymes with approximately 12% and 
5% of the enzymatic activity of the wild type genotype CYP2C9*1 (Arg144/Ile359) respectively 
[12-14]. Both variant alleles have been associated with decreased warfarin dose requirements, 
more time to achieve stable dosing, a higher risk of bleeding during the initiation phase, and a 
significantly higher bleeding rate [15-23]. Mannucci [24] has suggested acenocoumarol as an 
alternative to warfarin in patients carrying the variant alleles CYP2C9*2 and CYP2C9*3. Recently, 
however, the CYP2C9*3 allele was also associated with low dose requirement for acenocoumarol 
[25-27]. The effect of the CYP2C9*2 allele on acenocoumarol sensitivity seems to be absent or 
not clinically relevant [25-27]. To our knowledge, the influence of CYP2C9 polymorphisms on 
dose requirements in patients on phenprocoumon therapy has not yet been reported. Carriers 
of the allelic variants will also be at enhanced risk of interactions with drugs that are inhibitors 
or substrates of CYP2C9 [11]. Most studies on the association between CYP2C9 polymorphisms 
and dose requirements of coumarin anticoagulants either excluded patients who were taking 
drugs that may interfere with coumarin metabolism [23, 27] or found no interaction with 
other CYP2C9 substrates or inhibitors [22, 26]. Furthermore, there is only limited information 
in the literature on the genotype-dose relationship because many studies did not distinguish 
between heterozygous and homozygous subjects for the allelic variants. 
The aim of the present cohort study was to investigate the effect of the CYP2C9*2 and 
CYP2C9*3 alleles on the stability of the anticoagulant level during the first six weeks of 
treatment, and on the maintenance dose of acenocoumarol or phenprocoumon in patients 
with and without use of CYP2C9 substrates or inhibitors. 
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METHODS
Setting
Data were obtained from the Rotterdam Study and from the regional outpatient anticoagulation 
clinic. The Rotterdam Study is a prospective population-based cohort study of neurologic, 
cardiovascular, locomotor and ophthalmologic diseases. All inhabitants of Ommoord, a 
suburb of the city of Rotterdam in the Netherlands, aged 55 years or over were invited in 
1990-1993 to participate in the study. The rationale, ethical approval and design of this study 
have been described elsewhere [28]. The cohort encompasses 7983 individuals who were all 
interviewed and investigated at baseline. The anticoagulation clinic monitors all inhabitants of 
Ommoord with an indication for anticoagulant therapy. The choice of anticoagulant is made 
by the physician. Almost all patients start with a standard dosing scheme of acenocoumarol 
(8-4-4 mg during day 1 up to day 3) or phenprocoumon (9-6-3 mg during day 1 up to day 3). 
Prothrombin times are monitored every one to six weeks by reference to the INR, dependent on 
the stability of the anticoagulant level. Doses are adjusted on the basis of the INR of the patient 
by computerised dose calculations. All data on dosing, laboratory, and clinical data as of 1984 
are fully computerised. For this study, data were used from January 1, 1985 through December 
31, 1998. For data on comedication, we used data from seven regional pharmacies where more 
than 99% of participants of the Rotterdam Study fill their prescriptions. Complete data on drug 
use from these pharmacies were available as of January 1, 1991. For those patients for whom 
we compared maintenance doses of coumarin anticoagulants during treatment episodes with 
and without CYP2C9 comedication, we therefore used only the data from the anticoagulation 
clinic after January 1, 1991. The pharmacy data include the Anatomical Therapeutical Chemical 
(ATC) code [29], the filling date, the total amount of drug units per prescription, the prescribed 
daily number of units, and product name of the drugs.
Cohort definition
The study cohort consisted of all 1312 patients in the Rotterdam Study, who started treatment 
with acenocoumarol or phenprocoumon in the study period between January 1, 1985 and 
December 31, 1998 and for whom there were INR data during their treatment. If a patient had 
multiple treatment episodes during the study period, all episodes were considered. We defined 
the follow-up period as the sum of all treatment episodes per patient. The cohort was followed 
until the last INR assessment, because of the end of their treatment, death or end of the study 
period, whichever came first. 
Outcomes
The average first and second INR on the standard start dosing scheme of acenocoumarol or 
phenprocoumon were calculated per CYP2C9 genotype. For each individual patient, the mean 
number of INR assessments, the mean INR and the occurrence of an INR ≥ 6.0 during the first 
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six weeks after start of the coumarin anticoagulant were assessed. The mean number of INR 
assessments was used as a measure of instability of the anticoagulant level. Patients who had 
a follow-up period of more than six weeks were included in the analyses on maintenance dose. 
The maintenance dose was defined as the mean dose (in mg per week) calculated over all 
treatment episodes from day 43 up to the end of each treatment episode. The mean INR was 
calculated over the same period. For patients who had treatment episodes with and without use 
of other CYP2C9 comedication, mean doses and mean INR were separately calculated during 
both episodes. The following substrates and inhibitors of the CYPC9 enzyme were considered as 
CYP2C9 comedication: amiodarone, carbamazepine, chloramphenicol, cimetidine, diclofenac, 
fluconazole, fluvastatine, losartan, miconazole, phenylbutazone, phenytoin, sulphadiazine, 
sulphamethizole, sulphamethoxazole, sulphinpyrazone, tolbutamide, trimethoprim, and 
zafirlukast [30].
Cofactors
The following patient characteristics were considered as potential determinants for affecting 
the coumarin maintenance dose: age, sex and body mass index. In addition, we considered 
the target INR (low, medium and high) as well as the mean INR level after the first six weeks of 
treatment.
Genotyping
Genotyping for the CYP2C9*2 and CYP2C9*3 allele variants was performed by using polymerase 
chain reaction followed by restriction enzyme digestion analysis (PCR-RFLP), as previously 
described by Aynacioglu et al [31]. Approximately 5 ng of genomic DNA was amplified in 35 
cycles of PCR: 1 min 94°C, 1 min 60°C (CYP2C9*2) or 1 min 62°C (CYP2C9*3) and 1 min 72°C, in a 
total volume of 10 µl, using primers P141 (5’-CACTGGCTGAAAGAGCTAACAGAG-3’) and P142 (5’-
GTGATATGGAGTAGGGTCACCCAC-3’) for CYP2C9*2, or P143 (5’-AGGAAGAGATTGAACGTGTGA-
3’) and P144 (5’-GGCAGGCTGGTGGGGAGAAGGCCAA-3’) for CYP2C9*3 (the bold nucleotide 
represents a mismatch to the genomic sequence). The PCR product was digested with Sau96 
(CYP2C9*2) or Styl (CYP2C9*3), and analysed on a 3% TBE/agarose gel with ethidium bromide 
staining. Assays were validated by direct sequencing (Big Dye terminator chemistry, Applied 
Biosystems, Foster City, CA, USA) on an ABI 310 genetic analyser (Applied Biosystems). All 
CYP2C9*2 and CYP2C9*3 heterozygote and homozygote variants detected were reanalysed. 
Patients in whom neither CYP2C9*2 nor CYP2C9*3 alleles were identified were regarded as wild 
type.
Statistical analysis
Allele and genotype proportions were tested for deviations from Hardy-Weinberg equilibrium 
by using a χ2-test. Independent-samples t-tests were used to compare the mean number of INR 
assessments and the mean INR during the first six weeks of treatment and during the rest of the 
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follow-up between carriers of variant alleles and the wild type genotype. Relative risks (RR) with 
95% confidence intervals (CI) were calculated to compare the proportion of patients with an INR 
≥ 6.0 between variant genotypes and the wild type genotype. For patients who had episodes 
of coumarin anticoagulant therapy with and without CYP2C9 comedication, paired-sampled 
t-tests were used to compare the difference in mean maintenance dose and mean INR between 
these episodes. A multivariate linear regression model was used to assess the effect of allelic 
variants on the coumarin maintenance dose, while controlling for differences in cofactors. This 
was only carried out for the treatment episodes without use of CYP2C9 comedication. Cofactors 
were included in the model if the point estimate changed by more than 5% upon inclusion of 
the cofactor in the model. All statistical analyses were performed with SPSS software (version 
10.0; SPSS, Chicago, Illinois, USA). To evaluate a genotype-dose relationship, a trend test was 
performed using a linear regression model with the mean maintenance dose as outcome 
variable and the genotypes as an ordinal set with 5 values.
RESULTS
Of the 1312 patients in the cohort, 29 were excluded because they used other coumarin 
anticoagulants than acenocoumarol or phenprocoumon, and 159 patients were excluded 
because of difficulties in genotyping (due to the suboptimal quality of the long-term storage of 
DNA of some samples). Consequently, there were 1124 patients available for analysis (Table 1). 
The mean age of these patients was approximately 72 years, and 47.2% of the patients were 
men. All patients were of Caucasian origin. There were 970 acenocoumarol-treated patients 
(86.3%) and 204 patients (18.1%) who used phenprocoumon. Fifty of these used both coumarin 
anticoagulants during the study period. The main indications for anticoagulation were: 
treatment of deep venous thrombosis, pulmonary embolism and short-term prophylactic 
treatment (low target INR level (2.5-3.5); 39.0% of patients), atrial fibrillation, myocardial 
infarction, coronary bypass, vascular surgery, stroke and transient ischaemic attacks (medium 
target INR level (3.0-4.0); 58.9%), and prosthetic heart valve (high target INR level (3.5-4.5); 2.1%). 
The range of the weekly maintenance dose was 1-56 mg for acenocoumarol and 0.8-84 mg for 
phenprocoumon. The mean follow-up time was 598 days (1.8 years). Patients had a median 
of 20 INR assessments during a median follow-up time of 279 days (0.8 years). There were 771 
patients (68.6%) with the wild type genotype, and 353 (31.4%) with a variant genotype. The 
frequencies of the CYP2C9*2 and CYP2C9*3 alleles were 13.5% and 4.0%, respectively. The 
cohort was in Hardy-Weinberg equilibrium when variant alleles were taken together (p  =  0.14). 
However, if the data were calculated only for the CYP2C9*3 allele, a lack of equilibrium were 
observed since no individuals homozygous for this allele were identified.
The mean first INR after a standard starting dose of acenocoumarol was higher in all variant 
genotypes than in the wild type genotype (95%CI: 2.7-2.9), but the differences compared to 
30
C
ha
pt
er
 2
.1
the wild type were only statistically significant for the CYP2C9*1/*2 (95%CI: 2.9-3.4) and the 
CYP2C9*2/*2 (95%CI: 3.2-4.5) genotypes (Figure 1). These differences could not be explained 
by the fact that patients with a variant genotype were targeted at a higher INR level (p  =  0.915 
for difference in target level between genotypes). For the second mean INR on acenocoumarol 
there were no significant differences anymore between the variant and the wild type 
genotypes. For phenprocoumon-treated patients the first INR tended to be lower in the variant 
than in the wild type genotype (95%CI: 2.8-3.4), but the difference only reached statistical 
significance for the CYP2C9*2/*3 genotype (95%CI: 1.3-2.7). Also for phenprocoumon, there 
were no statistically significant differences for the second INR. The mean number of INR 
assessments, the mean INR and the relative risk of overanticoagulation during the first 6 weeks 
after start of the coumarin anticoagulant are shown in Table 2 for all CYP2C9 genotypes. For 
acenocoumarol- and phenprocoumon-treated patients, there were no statistically significant 
differences in the mean number of INR assessments between variant genotypes and the wild 
Table 1. Characteristics of the study population
Variable Number of patients
(n = 1124)
Gender
 Male 530 (47.2%)
 Female 594 (52.8%)
Age, average (SD) 71.8 (8.1) years
Caucasian origin 1124 (100%)
Type of coumarin* 
 Acenocoumarol 970 (86.3%)
 Phenprocoumon 204 (18.1%)
Target INR level
 Low (2.5-3.5 INR) 438 (39.0%)
 Medium (3.0-4.0 INR) 662 (58.9%)
 High (3.5-4.5 INR) 24 (2.1%)
Weekly maintenance dose range
 Acenocoumarol 1 - 56 mg
 Phenprocoumon 0.8 - 84 mg
Follow-up time
 Mean 598 days
 Median 279 days
Genotype§
 CYP2C9*1/*1 771 (68.6%) 
 CYP2C9*1/*2 239 (21.3%)
 CYP2C9*1/*3 73 (6.5%)
 CYP2C9*2/*2 23 (2.0%)
 CYP2C9*2/*3 18 (1.6%)
 CYP2C9*3/*3 -
* Because 50 patients use both coumarins at any time during the study period, the total percentage is more than 100.
§ Hardy-Weinberg Equilibrium: χ2 = 5.435 (p = 0.14).
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Figure 1. Mean first and second INR for patients with standard start doses of acenocoumarol and 
phenprocoumon
Table 2. The mean number of INR assessments, the mean INR and the relative risk of overanticoagulation in 
relation to CYP2C9 genotype during the first 6 weeks after starting with acenocoumarol or phenprocoumon
Genotype N pat Mean n INR 
assessments 
(SEM*)
P† Mean INR 
(SEM∗)
P‡ N pat (%) 
with 
an INR ≥ 6.0
RR (95%CI)§
Acenocoumarol 970
 *1/*1 669 6.2 (0.12) - 2.9 (0.03) - 58 (8.7) -
 *1/*2 208 6.1 (0.21) 0.68 3.1 (0.05) 0.04 24 (11.5) 1.4 (0.8-2.3)
 *1/*3  57 5.9 (0.36) 0.49 3.1 (0.09) 0.15  8 (14.0) 1.7 (0.8-3.8)
 *2/*2  20 7.1 (0.93) 0.34 3.5 (0.19) 0.001  5 (25.0) 3.5 (1.2-10 )
 *2/*3  16 7.0 (1.09) 0.47 3.2 (0.12) 0.07  3 (18.8) 2.4 (0.7-8.8)
Phenprocoumon 204
 *1/*1 134 5.1 (0.21) - 3.5 (0.07) - 22 (16.4) -
 *1/*2  40 5.0 (0.36) 0.86 3.5 (0.11) 0.85  7 (17.5) 1.1 (0.4-2.8)
 *1/*3  19 5.6 (0.84) 0.38 3.7 (0.17) 0.22  3 (15.8) 1.0 (0.3-3.6)
 *2/*2   7 4.1 (0.77) 0.34 3.7 (0.42) 0.49  1 (14.3) 0.8 (0.1-7.4)
 *2/*3   4 6.3 (1.65) 0.35 2.8 (0.14) 0.10  - -
* Standard error of the mean.
† P-value for the difference in mean number of INR assessments between carriers of a variant allele and the wild type genotype.
‡ P-value for the difference in mean INR between carriers of a variant allele and the wild type genotype.
§ Relative risk (RR) of experiencing an INR ≥ 6.0 for carriers of a variant allele compared to the wild type genotype. 
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type genotype. The mean INR in patients on acenocoumarol was significantly higher in the 
CYP2C9*1/*2, CYP2C9*2/*2 and CYP2C9*2/*3 genotypes than in the wild type genotype. For 
phenprocoumon-treated patients, there were no statistically significant differences in mean 
INR between variant and wild type genotypes. There were 98 patients on acenocoumarol with 
an INR ≥ 6.0 during the first 6 weeks of treatment of whom 11 (11.2%) experienced a bleeding, 
and 33 on phenprocoumon with an INR ≥ 6.0 of whom 8 (24%) developed a bleeding. These 
numbers were too low for demonstrating a statistically significant difference between variant 
and wild type alleles. Although the percentage of acenocoumarol-treated patients with an INR 
≥ 6.0 tended to increase (trend test p  =  0.006) when comparing CYP2C9*1/*2, CYP2C9*1/*3, 
CYP2C9*2/*2 and CYP2C9*2/*3 genotypes with the CYP2C9*1/*1 wild type, the relative risk was 
only statistically significantly increased for the CYP2C9*2/*2 genotype (RR 3.5; 95%CI: 1.2-10.0). 
Patients with a variant genotype on phenprocoumon had no higher risk of overanticoagulation 
during the first 6 weeks of anticoagulant therapy.
Of the 970 patients who started with acenocoumarol during the study period, 835 had 
a follow-up period longer than 6 weeks and, for 754 of them, we had data available on 
acenocoumarol doses without use of CYP2C9 comedication. Of the 204 patients who started 
with phenprocoumon, 184 patients used the drug long enough to calculate maintenance 
doses and, for 173 of them, we had data available on the phenprocoumon dose without use of 
CYP2C9 comedication. The 143 short-term users of acenocoumarol (p  =  0.3) and 31 short-term 
users of phenprocoumon (p  =  0.8) had a similar proportion of variant alleles as long-term users. 
Table 3 summarizes the mean maintenance doses of acenocoumarol and phenprocoumon and 
the mean INR in relation to the CYP2C9 genotype during the treatment episodes without use 
Table 3. Mean maintenance dose and mean INR in relation to CYP2C9 genotype during treatment episodes 
without CYP2C9 comedication
Genotype N pat Mean dose (mg/week) 
(SEM*)
Difference with *1/*1 
(95%CI)†
Mean INR 
(SEM∗)
Difference with *1/*1 
(95%CI)‡
Acenocoumarol 754
 *1/*1 526 17.9 (0.31) - 3.2 (0.03) -
 *1/*2 159 15.5 (0.51) -2.3 [-3.5-(-1.2)] 3.3 (0.09)  0.1 (-0.02-0.2)
 *1/*3 46 13.9 (0.91) -3.5 [-5.4-(-1.5)] 3.2 (0.08)  0.01 (-0.2-0.2)
 *2/*2 15 13.1 (1.56) -5.0 [-8.4-(-1.7)] 3.4 (0.12)  0.3 (-0.02-0.6)
 *2/*3 8 11.8 (1.76) -7.2 [-11.7-(-2.6)] 3.1 (0.16) -0.03 (-0.4-0.4)
Phenprocoumon 173
 *1/*1 114 15.6 (0.66) - 3.5 (0.08) -
 *1/*2  35 14.0 (1.00) -1.6 (-4.0-0.9) 3.5 (0.07) -0.05 (-0.3-0.2)
 *1/*3  16 12.9 (1.65) -2.7 (-6.1-0.7) 3.2 (0.17) -0.3 (-0.8-0.1)
 *2/*2   5 10.0 (1.79) -5.2 (-11.0-0.7) 3.3 (0.21) -0.3 (-1.1-0.5)
 *2/*3   3 16.7 (5.46) -1.4 (-6.2-9.1) 3.6 (0.29) -0.02 (-1.0-1.0)
* Standard error of the mean.
† Difference in mean dose compared to the wild type genotype with a 95% confidence interval, adjusted for differences in age and mean INR.
‡ Difference in mean INR compared to the wild type genotype with a 95% confidence interval.
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of CYP2C9 comedication. The difference in mean maintenance dose, adjusted for differences 
in cofactors, and the difference in mean INR compared to the wild type genotype are also 
shown. For acenocoumarol, a genotype-dose relationship is suggested when comparing the 
CYP2C9*1/*1, CYP2C9*1/*2, CYP2C9*1/*3, CYP2C9*2/*2 and CYP2C9*2/*3 genotypes, with 
average maintenance doses of 17.9, 15.5, 13.9, 13.1 and 11.8 mg per week, respectively (trend 
test p<0.001). Also patients with only one CYP2C9*2 allele required a statistically significant 
lower dose of acenocoumarol than patients with the wild type genotype. The maintenance 
dose in patients with variant alleles on phenprocoumon was somewhat lower than in patients 
with the wild type genotype but this difference was not statistically significant, nor was there 
any decreasing trend (p  =  0.176). Age was an important factor in modulating the response to 
coumarin anticoagulants. For every year of age, there was a statistically significant decrease in 
acenocoumarol dose of 0.30 (95%CI: 0.24-0.36) mg per week. For phenprocoumon, the dose 
decrease was 0.19 (95%CI: 0.07-0.32) mg per week for every year of age. Neither sex, body 
mass index, nor the target INR level affected the mean maintenance dose of acenocoumarol 
or phenprocoumon.
Of the 283 patients who used acenocoumarol with and without CYP2C9 comedication, the 
maintenance dose was 0.6 mg per week lower during the treatment episodes with CYP2C9 
comedication (p < 0.001), while the mean INR was 0.1 unit higher during these episodes 
(p  =  0.008). For the 74 patients using phenprocoumon with and without CYP2C9 comedication, 
there was no statistically significant difference in mean maintenance dose (p  =  0.596), nor in 
mean INR (p  =  0.423), between the treatment episodes with and without CYP2C9 comedication. 
Numbers were too low to stratify these data on CYP2C9 genotype.
DISCUSSION
The main finding in this population-based cohort study is that individuals heterozygous for 
either CYP2C9*2 or CYP2C9*3, as well as those with two variant CYP2C9 alleles, required a 
significantly lower dose of acenocoumarol to reach the same level of anticoagulation compared 
to patients with the wild type genotype. We found a clear genotype-dose relationship for 
acenocoumarol-treated patients when comparing the CYP2C9*1/*2, CYP2C9*1/*3, CYP2C9*2/*2 
and CYP2C9*2/*3 genotypes with the wild type. The acenocoumarol maintenance doses for the 
CYP2C9 genotypes are in line with those recently published by Tassies et al. [27], except for 
the CYP2C9*2/*2 variant. They found similar maintenance doses for the CYP2C9*2/*2 and the 
wild type genotype (17.0 and 17.1 mg per week, respectively), while the maintenance dose for 
patients with the CYP2C9*1/*2 genotype was 14.4 mg per week. However, these doses were 
not adjusted for confounding factors. For phenprocoumon we did not find the same results as 
for acenocoumarol. This could partly be explained by the fact that the cytochrome P450 2C9 
enzyme plays a more important role in the oxidation of acenocoumarol and warfarin, than in 
34
C
ha
pt
er
 2
.1
the oxidation of phenprocoumon [9, 10]. On the other hand, numbers were small for some 
genotypes in phenprocoumon-treated patients, and this could have resulted in less precise 
estimates.
Due to the fact that CYP2C9 plays a more substantial role in the metabolism of acenocoumarol, 
patients treated with this coumarin anticoagulant may be more sensitive to interference by the 
use of other CYP2C9 substrates or inhibitors. As the reduction in maintenance dose in patients 
who had treatment episodes with, as well as without, CYP2C9 comedication was small but 
highly significant in acenocoumarol-treated patients, these results are in line with ours. There 
was no difference between these treatment episodes for patients on phenprocoumon.
During the initiation of the anticoagulant therapy several differences were found between 
variant genotypes and wild type patients. For acenocoumarol-treated patients, the first INR and 
the mean INR during the first 6 weeks of treatment tended to be higher in the variant genotypes 
than in the wild type patients, although the differences did not reach statistical significance in 
all variant genotypes. Patients with a variant genotype also appear to be at a higher risk of 
overanticoagulation than wild type patients. The reason why the differences in the first INR 
between the wild type and the variant genotypes were not present anymore during the second 
INR measurement is that, in anticoagulation clinics, doses are adjusted according to the INR-
value obtained during the first measurement. For patients on phenprocoumon, there were no 
differences in these parameters between variant genotypes and the wild type patients. Why 
the first INR in the variant genotypes on phenprocoumon tended to be lower than in the wild 
type patients, could possibly be explained by the fact that some of these patients switched 
from acenocoumarol to phenprocoumon because anticoagulant levels remained highly 
unstable on acenocoumarol, and they therefore started with a lower dose of phenprocoumon. 
Unfortunately, we had no data on individual starting doses to evaluate this. We defined the 
initiation phase of the anticoagulant therapy as the first 6 weeks of treatment, whereas this is 
sometimes defined as the first month of treatment. However, when we shortened our initiation 
phase to the first month of treatment, the results were similar.
The allele frequency for CYP2C9*2 found in our population falls within the wide range of 
reported allele frequencies among various Caucasian populations (8-19%) and is very close 
to those found in other Dutch, German and British populations [32]. Caucasians also exhibit 
a significant heterogeneity in CYP2C9*3 allele frequency (3.3-16.2%). Although the allele 
frequency for CYP2C9*3 in our population falls within this range, it is lower than those reported in 
other northern European countries [32]. The study population is at Hardy-Weinberg equilibrium 
for overall variant alleles. The expected number of patients homozygous for CYP2C9*3 is less 
than 2, and it is not surprising that no individuals were identified in our study population who 
were homozygous for CYP2C9*3. For phenotype prediction, variant alleles CYP2C9*2 and 
CYP2C9*3 can be taken together because there is no phenotype/genotype disagreement in 
the metabolism of coumarin anticoagulants for these variant alleles [33].
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In conclusion, individuals heterozygous for either CYP2C9*2 or CYP2C9*3, as well as those with 
two variant CYP2C9 alleles, require a significantly lower dose of acenocoumarol than wild type 
patients to reach the same level of anticoagulation. Patients who use other CYP2C9 substrates 
or inhibitors concomitantly need a significant lower dose of acenocoumarol. Phenprocoumon 
appears to be a useful clinical alternative in patients carrying the CYP2C9*2 and *3 alleles.
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Chapter 2.2
The risk of bleeding complications in patients with cytochrome 
P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or 
phenprocoumon
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ABSTRACT
Introduction: The principal enzyme involved in coumarin metabolism is CYP2C9. Allelic 
variants of CYP2C9, CYP2C9*2 and CYP2C9*3, code for enzymes with reduced activity. Despite 
increasing evidence that patients with these genetic variants require lower maintenance doses 
of anticoagulant therapy, there is lack of agreement among studies on the risk of bleeding and 
CYP2C9 polymorphisms.
Objective: To study the effect of the CYP2C9 polymorphisms on bleeding complications during 
initiation and maintenance phases of coumarin anticoagulant therapy.
Design: Population-based cohort study in a sample of the Rotterdam Study, a study in 7983 
subjects.
Subjects: All patients who started treatment with acenocoumarol or phenprocoumon in the 
study period from January 1, 1991 through December 31, 1998 and for whom INR data were 
available. 
Methods: Patients were followed until a bleeding complication, the end of their treatment, 
death or end of the study period. Proportional hazards regression analysis was used to estimate 
the risk of a bleeding complication in relation to CYP2C9 genotype after adjustment for several 
potentially confounding factors such as age, gender, target INR level, INR, time between INR 
measurements, and aspirin use. The effect of variant genotype on bleeding risk was separately 
examined during the initiation phase of 90 days after starting therapy with coumarins. 
Results: The 996 patients with analysable data had a mean follow-up time of 481 days (1.3 years); 
311 (31.2%) had at least 1 variant CYP2C9 allele and 685 (68.8%) had the wild type genotype. 
For patients with the wild type genotype, the rate of minor bleeding, major bleeding and fatal 
bleeding was 15.9, 3.4 and 0.2 per 100 treatment-years, respectively. For patients with a variant 
genotype, the rate of minor, major and fatal bleeding was 14.6, 5.4 and 0.5 per 100 treatment-
years. Patients with a variant genotype on acenocoumarol had a significantly increased risk for 
a major bleeding event (RR 1.83, 95%CI: 1.01-3.32). During the initiation phase of therapy we 
found no effect of variant genotype on bleeding risk.
Conclusion: In this study among outpatients of an anticoagulation clinic using acenocoumarol 
or phenprocoumon, having a variant allele of CYP2C9 was associated with an increased risk of 
major bleeding events in patients on acenocoumarol, but not in patients on phenprocoumon. 
Although one might consider the assessment of the CYP2C9 genotype of a patient for dose 
adjustment before starting treatment with acenocoumarol, a prospective randomised trial 
should demonstrate whether this reduces the increased risk of major bleeding events.
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INTRODUCTION
Coumarin anticoagulants are extensively used for the treatment and long-term prevention of 
thromboembolic diseases [1, 2]. The main drawback is an enhanced risk of hemorrhage [3], 
which is strongly associated with the intensity of anticoagulation and sharply increases when 
the international normalised ratio (INR) is ≥ 6.0 [4, 5].
There is increasing evidence that the response to coumarin anticoagulants is largely 
genetically determined [6]. Cytochrome P450 2C9 (CYP2C9) is the major enzyme involved in the 
metabolism of the coumarin anticoagulants warfarin, phenprocoumon, and acenocoumarol [7, 
8]. Warfarin is the main coumarin anticoagulant used in the United Kingdom and United States, 
while acenocoumarol and phenprocoumon are preferentially used in continental Europe [9]. 
Allelic variants of CYP2C9, CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu), code for enzymes 
with approximately 12% and 5% of the enzymatic activity of the wild type genotype CYP2C9*1 
(Arg144/Ile359), respectively [10-12]. Bleeding complications have been related to CYP2C9 
polymorphisms in several studies in patients receiving warfarin, but these findings could not 
be confirmed by others [13-17]. Tassies et al [18] were the first who reported on the influence 
of CYP2C9 polymorphisms on bleeding complications in patients on acenocoumarol therapy. 
They found no association between repeated bleeding episodes and CYP2C9 polymorphisms. 
Recently, Hummers-Pradier et al [19] reported an increased risk of bleeding in carriers of a 
CYP2C9*3 allele who were anticoagulated with phenprocoumon. The lack of agreement among 
studies on the risk of bleeding and CYP2C9 polymorphisms may have several explanations, 
including differences in selected populations, the presence of additional predisposing bleeding 
factors, the different coumarin anticoagulants under study, and the relatively small numbers 
of patients with variant genotypes. It has also been argued that the risk of bleeding may be 
especially high at the initiation of therapy in carriers of variant alleles, suggesting that once 
antithrombotic stability is attained, experienced clinicians are most likely to maintain a patient’s 
INR and minimize their bleeding risk regardless of CYP2C9 genotype [15, 16]. 
The aim of the present study was to investigate the effect of the CYP2C9 polymorphisms on 
bleeding complications during initiation and maintenance phases of anticoagulant therapy, in 
a large population-based cohort of acenocoumarol- and phenprocoumon-treated patients.
METHODS
Setting
Data were obtained from the Rotterdam Study, from the regional outpatient anticoagulation 
clinic and from hospitals in the Rotterdam area. The Rotterdam Study is a prospective 
population-based cohort study of neurological, cardiovascular, locomotor and ophthalmologic 
diseases. All inhabitants of Ommoord, a suburb of the city of Rotterdam in the Netherlands, 
CYP2C9 polymorphisms and hemorrhage 41
aged 55 years or over were invited in 1990-1993 to participate in the study. The Medical Ethics 
Committee of the Erasmus MC approved the study, and written informed consent was obtained 
from all participants. The rationale and design of this study have been described elsewhere 
[20]. The cohort encompasses 7983 individuals who were all interviewed and investigated at 
baseline. At the baseline examination of the Rotterdam Study, blood was taken and DNA was 
isolated. Since the start of the Rotterdam Study, cross-sectional surveys have been carried out 
periodically. In addition, participants are continuously monitored for major events through 
automated linkage with the files from the general practitioners of the patients. When an event 
or death has been reported, additional information is obtained by interviewing the GP and 
scrutinising information from hospital discharge records in case of admittance or referral. The 
anticoagulation clinic monitors all inhabitants of Ommoord with an indication for anticoagulant 
therapy. The choice of anticoagulant is made by the physician. Prothrombin times are monitored 
each one to six weeks by reference to the INR, target range, and stability of the anticoagulant 
level. Dosing of the coumarin is performed by a team of specialized physicians, with the aid 
of a computerized dosing program. This program evaluates the stability of the INR and, when 
possible, proposes a dosing schedule (i.e. in nearly 50% of the patients). In the other patients, 
dosing is done by the physician according to a standard operating procedure. All data on 
dosing, laboratory-, and clinical data (e.g. bleeding complications, hospital admissions) are 
fully computerised. Apart from data from the Rotterdam Study and from the anticoagulation 
clinic, we used hospital discharge diagnoses for case finding, gathered from all hospitals in the 
Rotterdam area. Hospital records were linked to the Rotterdam Study database. For potential 
bleeding cases identified in this way, copies of discharge letters were collected.
Cohort definition
The study cohort consisted of all 1135 patients in the Rotterdam Study, who started treatment 
with acenocoumarol or phenprocoumon in the study period between January 1, 1991 and 
December 31, 1998 and for whom there were INR data during their treatment. If a patient had 
multiple treatment episodes during the study period, only the first episode was considered. 
If a patient switched from one coumarin to the other, only the first coumarin was considered. 
The cohort was followed until the first occurrence of a bleeding complication, the last INR 
assessment because of the end of their treatment, death or end of the study period, whichever 
came first. 
Outcomes
Bleeding complications were subdivided into major and minor bleeding. Hemorrhages were 
classified as major if these led to death, necessitated hospitalisation, blood transfusion or 
surgery, or if these concerned intracranial-, intra-articular- or intra-muscular bleeding. Minor 
bleeding included all other bleeding complications, including skin bleeds of more than 10 cm 
in diameter and nose bleeds lasting for at least 30 minutes. 
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Genotyping
Genotyping for the CYP2C9*2 and CYP2C9*3 allele variants was performed by using polymerase 
chain reaction followed by restriction enzyme digestion analysis (PCR-RFLP), as previously 
described by Aynacioglu et al [21]. Approximately 5 ng of genomic DNA was amplified in 35 
cycles of PCR: 1 min 94°C, 1 min 60°C (CYP2C9*2) or 1 min 62°C (CYP2C9*3) and 1 min 72°C, in a 
total volume of 10 µl, using primers P141 (5’-CACTGGCTGAAAGAGCTAACAGAG-3’) and P142 (5’-
GTGATATGGAGTAGGGTCACCCAC-3’) for CYP2C9*2, or P143 (5’-AGGAAGAGATTGAACGTGTGA-
3’) and P144 (5’-GGCAGGCTGGTGGGGAGAAGGCCAA-3’) for CYP2C9*3 (the bold and 
underlined nucleotide represents a mismatch to the genomic sequence). The PCR product was 
digested with Sau96 (CYP2C9*2) or Styl (CYP2C9*3), and analyzed on a 3% TBE/agarose gel 
with ethidium bromide staining. All CYP2C9*2 and CYP2C9*3 heterozygote and homozygote 
variants detected were reanalyzed. Patients in whom neither CYP2C9*2 nor CYP2C9*3 alleles 
were identified were regarded as wild type. 
Statistical analysis
Genotype proportions were tested for deviations from Hardy-Weinberg equilibrium by using 
a χ2-test. Incidence rates of bleeding complications were calculated in the standard way, by 
dividing the number of events by the number of treatment-years. The association between 
CYP2C9 genotype and bleeding complications was evaluated using survival analysis techniques. 
Patients were divided into 2 groups based on genotype: wild type (CYP2C9*1/*1 homozygotes) 
and variant (1 or more of the mutant alleles CYP2C9*2 or CYP2C9*3). For each analysis, a relative 
risk (RR) and 95% confidence interval (95%CI) comparing variant and wildtype genotype 
groups were computed. We used Cox proportional hazards models to adjust for the potential 
confounding effect of age, gender, target INR level, INR, time between INR measurements, and 
aspirin use. We examined the effect of variant genotype on bleeding risk during the initiation 
phase of therapy by censoring the data at 90 days after starting therapy with coumarins. To 
study whether there is effect modification by the type of coumarin, stratified analyses were 
performed for subjects on acenocoumarol and phenprocoumon. Moreover, relative risks were 
separately calculated for carriers of a CYP2C9*2 allele (CYP2C9*1/*2 and CYP2C9*2/*2) and of 
a CYP2C9*3 allele (CYP2C9*1/3, CYP2C9*2/*3, and CYP2C9*3/*3). All statistical analyses were 
performed with SPSS software (version 10.0; SPSS, Chicago, IL). P values less than 0.05 were 
considered statistically significant. 
RESULTS
Of the 1135 patients in the cohort, 139 were excluded because of difficulties in genotyping (due 
to the suboptimal quality of the long-term storage of DNA of some samples). Consequently, 
there were 996 patients available for analysis (Table 1). The mean age of these patients was 
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71 years, and 47.5% of the patients were men. All patients were of Caucasian origin. There 
were 841 acenocoumarol-treated patients (84.4%) and 155 patients (15.6%) who used 
phenprocoumon. The main indications for anticoagulation were: treatment of deep venous 
thrombosis, pulmonary embolism and short-term prophylactic treatment (low target INR level 
(2.5-3.5); 36.6% of patients), atrial fibrillation, myocardial infarction, coronary bypass, vascular 
surgery, stroke and transient ischaemic attacks (medium target INR level (3.0-4.0); 60.9%), and 
prosthetic heart valve (high target INR level (3.5-4.5); 2.4%). The mean follow-up time was 481 
days (1.3 years). Patients had a median of 17 INR assessments during a median follow-up time 
of 210 days (0.6 years). There were 685 patients (68.8%) with the wild type genotype, and 311 
(31.2%) with a variant genotype. The frequencies of the CYP2C9*2 and CYP2C9*3 alleles were 
13.6% and 3.9%, respectively. Genotype proportions were in Hardy-Weinberg equilibrium 
(p = 0.14). 
The total number of bleeding episodes was 255, or 19.4 per 100 treatment-years (Table 2). 
Major bleeding occurred 4.0 times per 100 treatment-years, and in 4 cases bleeding resulted 
in death (0.3 per 100 treatment-years). The most frequent major bleeding complications were 
bleeding from the gastrointestinal tract, intracranial bleeding and gross hematuria. The mean 
Table 1. Characteristics of the study population
Variable Number of patients
(n = 996)
Age, average (SD) 71.4 (7.9) years
Gender
 Male 473 (47.5%)
 Female 523 (52.5%)
Caucasian origin 996 (100%)
Type of coumarin 
 Acenocoumarol 841 (84.4%)
 Phenprocoumon 155 (15.6%)
Target INR level
 Low (2.5-3.5) 365 (36.6%)
 Medium (3.0-4.0) 607 (60.9%)
 High (3.5-4.5) 24 (2.4%)
Follow-up time
 Mean 481 days
 Median 210 days
Genotype∗
 CYP2C9*1/*1 685 (68.8%) 
 CYP2C9*1/*2 210 (21.1%)
 CYP2C9*1/*3 63 (6.3%)
 CYP2C9*2/*2 23 (2.3%)
 CYP2C9*2/*3 15 (1.5%)
 CYP2C9*3/*3 0 (0%)
∗ Hardy Weinberg Equilibrium; χ2 = 5.400 (p = 0.14).
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INR (± SD) at the time of bleeding was 3.7 (± 1.9) for the minor bleeding complications and 5.4 (± 
5.1) for the major bleeding complications. This difference was however not statistically significant 
(p = 0.25). For patients with the wild type genotype, the rate of minor bleeding (n = 146), major 
bleeding (n = 31) and fatal bleeding (n = 2) was 15.9, 3.4 and 0.2 per 100 treatment-years, 
respectively. For patients with a variant allele, the rate of minor bleeding events (n = 57) was 14.6 
per 100 treatment-years, the rate of major bleeding events (n = 21) was 5.4 per 100 treatment-
years, and the rate of fatal bleeding events (n = 2) was 0.5 per 100 treatment-years. Kaplan-
Meier curves for time to a major bleeding event are shown in Figure 1. During the initiation 
phase of therapy there appeared to be no effect of genotype on the risk of a major bleeding 
event. The difference between variant genotypes and wild type patients became apparent after 
460 days of anticoagulant therapy. For all bleeding and minor bleeding events, we did not find 
an increased risk of bleeding in relation to variant genotype (Table 2). Patients with a variant 
genotype had a 57% higher risk of a major bleeding complication compared to patients with 
the wild type genotype, although this difference was not statistically significant. Relative risks 
for patients on acenocoumarol were 1.05 (95%CI: 0.78-1.42) for all bleeding, 0.89 (95%CI: 0.63-
1.26) for minor bleeding and 1.83 (95%CI: 1.01-3.32) for major bleeding complications. Relative 
risks for phenprocoumon-treated patients were 0.81 (95%CI: 0.42-1.56) for all bleeding and 0.76 
(95%CI: 0.37-1.54) for minor bleeding complications. Numbers were too low to calculate an 
adjusted relative risk for major bleeding complications in patients on phenprocoumon. During 
the initiation phase of therapy, we found no effect of variant genotype on bleeding risk, neither 
for all bleeding (RR 1.00, 95% CI: 0.62-1.61), nor for minor (RR 1.02, 95%CI: 0.61-1.69), and major 
bleeding events (RR 0.82, 95%CI: 0.21-3.19). For carriers of a CYP2C9*2 allele, relative risks for 
all bleeding (RR 1.11, 95%CI: 0.83-1.50), minor bleeding (RR 1.02, 95%CI: 0.73-1.43) and major 
bleeding events (RR 1.60, 95%CI: 0.85-3.04) were more or less the same as the hazards ratios 
for the combined variant genotypes. Relative risks for carriers of a CYP2C9*3 allele were 0.69 
Table 2. Observed bleeding complications (per 100 treatment-years) and relative risks (RR) for bleeding 
complications in patients having the CYP2C9 variant genotype
Total Variant 
genotype
Wild type 
genotype
RR (95%CI)  
Number patients 996 311 685 Unadjusted Adjusted
Treatment-years 1311.7 390.9 920.7
All bleeding 255 (19.4) 78 (20.0) 177 (19.2) 1.03 (0.79-1.34) 0.98 (0.75-1.29)
Minor bleeding 203 (15.5) 57 (14.6) 146 (15.9) 0.91 (0.67-1.24) 0.87 (0.64-1.18)
Major bleeding 52 (4.0) 21 (5.4) 31 (3.4) 1.58 (0.91-2.75) 1.57 (0.90-2.75)
 Digestive tract 28 (2.1) 12 (3.1) 16 (1.7) 1.74 (0.83-3.69) 1.72 (0.81-3.66)
 Intracranial 10 (0.76) 4 (1.0) 6 (0.65) 1.57 (0.44-5.57) 1.97 (0.53-7.29)
 Hematuria 3 (0.23) 1 (0.26) 2 (0.22) 1.16 (0.11-12.8) -
 Muscle joint hematoma 2 (0.15) 1 (0.26) 1 (0.11) 2.35 (0.15-37.5) -
 Other 9 (0.69) 3 (0.77) 6 (0.65) 1.16 (0.29-4.64) 1.04 (0.26-4.21)
Fatal bleeding 4 (0.30) 2 (0.51) 2 (0.22) 2.32 (0.33-16.5) 3.37 (0.41-27.8)
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(95%CI: 0.42-1.15) for all bleeding, 0.49 (95%CI: 0.26-0.94) for minor bleeding and 1.69 (95%CI: 
0.72-3.93) for major bleeding complications. 
DISCUSSION
The main finding in this population-based cohort study is that having a variant allele of CYP2C9 
was associated with an increased risk of major bleeding events in patients on acenocoumarol. 
The fact that we did not find such an association for phenprocoumon is probably explained by 
the fact that the CYP2C9 enzyme plays a minor role in its metabolism [8]. This is in line with an 
earlier study in which 37 out of 262 carriers of a variant allele and 67 out of 579 patients with 
the wild type genotype experienced an INR ≥ 6.0 [29]. In this study CYP2C9 variant alleles were 
associated with an increased risk of overanticoagulation in users of acenocoumarol but not in 
users of phenprocoumon [29]. It should be emphasized, however, that the number of patients 
on phenprocoumon in the current study was relatively small. Nevertheless, this aspect may 
be a reason to prefer phenprocoumon over acenocoumarol. In our study, CYP2C9 genotype 
was not associated with a higher rate of bleeding events during the first 90 days of therapy. A 
higher frequency of bleeding early in the treatment course has been reported in many [13, 14, 
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Figure 1. Proportion of patients without major bleeding event.
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16, 23-26] but not all [18, 27, 28] studies. As clearly pointed out by Landefeld and Goldman [25], 
studies that examine non-inception cohorts are likely to underestimate the true risk of bleeding 
by missing early events. We tried to reduce this selection bias by excluding prevalent users at 
the time the study started. Moreover, in a different study with an INR ≥ 6.0 as an outcome, [29] 
we did find a small but statistically significantly increased risk of overanticoagulation during 
the initiation phase in patients with CYP2C9 variant alleles on acenocoumarol. Forty out of 301 
carriers of a variant allele and 58 out of 669 patients with the wild type genotype experienced 
an INR ≥ 6.0 (RR 1.5, 95%CI: 1.1-2.2). These apparently different results during the initiation 
phase of therapy are possibly due to the fact that an INR ≥ 6.0 is a more frequent outcome than 
bleeding, which therefore has a higher chance to occur early after starting treatment. Because 
severe bleeding is much rarer, a longer period may be required to demonstrate a significant 
risk difference between persons with variant alleles and those with the wild type. Moreover, 
after administration of loading doses that are apparently too high for carriers of variant alleles 
because their INR increases too strongly, clinicians probably make rapid, downward dose 
adjustments before the bleeding risk is significantly increased. Our results are in line with 
Tassies et al [18], who found that carriers of the CYP2C9*3 allele on acenocoumarol were more 
prone to suffer overanticoagulation at the initiation of therapy. Also in that study, however, this 
was not associated with a higher rate of bleeding.
Reliable data are lacking on the true frequency of complications in patients on coumarin 
anticoagulants because of methodological limitations [30]. The incidences of minor bleeding 
events in our study are similar to those found in other observational studies [5, 22, 30]. The 
major bleeding rate of 4.0 per 100 treatment-years is somewhat lower than the 4.9 per 100 
treatment-years reported in a review of observational studies [22], but higher than the 2.7 [5] 
and 2.1 per 100 treatment-years reported by Van der Meer [30]. The studies reported by Van der 
Meer, however, were performed in a similar setting and with the same definitions of bleeding 
complications. The differences can possibly be explained by the fact that we used more data 
sources for case finding than the data from the anticoagulation clinic. In our study, major 
bleeding complications were not always reported in the database from the anticoagulation 
clinic. Usage of only this data would have resulted in lower incidence rates. Another possible 
explanation is that Van der Meer did not examine inception cohorts but also included prevalent 
users of anticoagulant therapy. In our study, the higher risk in patients with variant alleles on 
acenocoumarol was only found for major and fatal bleeding events but not for minor events. 
A possible explanation for this difference might be that patients are asked whether they had 
a bleeding event every time they visit the monitoring center. This will probably lead to an 
overrepresentation of bleeding, including false-positives and trivial cases. Such misclassification 
will be random for genotypes. It is known that random misclassification introduces a bias 
towards the null hypothesis. As severe bleeding is acute and unexpected, such misclassification 
does not occur.
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The allele frequency for CYP2C9*2 found in our study population falls within the wide range 
of reported allele frequencies among various Caucasian populations (8-19%) and is very close 
to those found in other Dutch, German and British populations [31]. Caucasians also exhibit a 
significant heterogeneity in CYP2C9*3 allele frequency (3.3-16.2%). Whereas the allele frequency 
for CYP2C9*3 in our population falls within this range, it is however lower than the ones 
reported in other northern European countries [31]. The study population is at Hardy-Weinberg 
equilibrium for overall variant alleles. For phenotype prediction, variant alleles CYP2C9*2 and 
CYP2C9*3 can be taken together because there is no phenotype/genotype disagreement in 
the metabolism of coumarin anticoagulants for these variant alleles [32]. 
In conclusion, having a variant allele of CYP2C9 was associated with an increased risk of 
major bleeding events in patients on acenocoumarol, but not in patients on phenprocoumon. 
Although one might consider the assessment of the CYP2C9 genotype of a patient for dose 
adjustment before starting treatment with acenocoumarol, a prospective randomised trial 
should demonstrate whether this reduces the increased risk of major bleeding events.
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Chapter 2.3
The risk of myocardial infarction in patients with reduced enzyme 
activity of cytochrome P450 CYP2C9
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ABSTRACT
Evidence suggests that certain human cytochrome P450 enzymes are partly responsible for 
the metabolism of endogenous substances involved in the regulation of vascular homeostasis. 
Genetic polymorphisms that code for these enzymes or use of drugs that inhibit these enzymes 
may therefore have pathophysiological consequences for cardiovascular diseases such as 
myocardial infarction. We investigated whether the variant alleles CYP2C9*2 and CYP2C9*3 
or use of CYP2C9 substrates were associated with an increased risk of myocardial infarction 
in 2210 men and 3534 women from the Rotterdam Study, a prospective population-based 
cohort study of individuals aged 55 years or older. In women, use of CYP2C9 substrates was 
significantly associated with incident myocardial infarction (RR 2.68, 95%CI: 1.60-4.49). The risk 
of myocardial infarction was fivefold in female users of CYP2C9 substrates with a variant allele. 
Neither the use of CYP2C9 substrates, nor the variant alleles were associated with an increased 
risk of myocardial infarction in men.
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INTRODUCTION
Myocardial infarction is a complex multifactorial and polygenic disorder that is thought to result 
from an interaction between the genetic makeup of an individual and various environmental 
factors [1, 2]. In general, the incidence of myocardial infarction increases with the number of 
conventional risk factors, including hypertension, diabetes mellitus, and hypercholesterolemia 
[2]. Although each risk factor itself is partly under genetic control, a family history of myocardial 
infarction is also an independent predictor. This suggests that additional susceptibility genes 
play an important role in this condition [1]. There is evidence that the human cytochrome 
P450 enzymes CYP2C8 and CYP2C9 are partly responsible for the metabolism of endogenous 
substances involved in the regulation of vascular homeostasis, notably the arachidonic acid 
metabolites 5,6-; 8,9-; 11,12-; and 14,15-epoxyeicosatrienoic acids (EETs) [3-7]. These EETs play 
a prominent role as a nitrous oxide/prostacyclin-independent component of endothelium-
dependent relaxation, which is particularly prominent in coronary, mesenteric, and renal 
arteries [3-5, 8, 9]. This system seems to have a more prominent role in females than in males 
[10, 11]. Polymorphisms in CYP2C8 and CYP2C9 enzymes may therefore have important 
pathophysiological consequences in cardiovascular diseases such as myocardial infarction. 
The CYP2C enzymes are predominantly expressed in the liver but also in the vascular smooth 
muscles and endothelial cells [3-5, 12, 13]. In a recent study, it was hypothesized that allelic 
variants of the CYP2C8 and CYP2C9 genes were associated with a modest increase in risk of 
myocardial infarction in women [14]. Apart from this genetic component, it is conceivable, that 
drugs that are metabolized by CYP2C9 can also affect levels of EETs, because several of these 
inhibit CYP2C9 enzymes. 
Therefore, the aim of the present follow-up study was to investigate whether the variant 
alleles CYP2C9*2 and CYP2C9*3 were associated with an increased risk of myocardial infarction 
in men and women. Furthermore, we determined the risk of myocardial infarction in male and 
female users of drugs that are metabolized by CYP2C9 and studied whether there was effect 
modification by CYP2C9 genotype.
METHODS
Setting
The Rotterdam Study is a prospective population-based cohort study of neurological, 
cardiovascular, locomotor and ophthalmologic diseases. All inhabitants of Ommoord, a suburb 
of the city of Rotterdam in the Netherlands, aged 55 years or older were invited in 1990-1993 to 
participate in the study. The Medical Ethics Committee of the Erasmus MC approved the study 
and written informed consent was obtained from all participants. The rationale and design 
of this study have been described elsewhere [15]. The cohort encompasses 7983 individuals 
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who were all interviewed and investigated at baseline. Since the start of the Rotterdam 
Study, cross-sectional surveys have been carried out periodically. In addition, participants are 
continuously monitored for major events through automated linkage with the files from the 
general practitioners of the patients. When an event or death has been reported, additional 
information is obtained by interviewing the GP and by scrutinising information from hospital 
discharge records in case of admittance or referral. More than 99% of participants have their 
drug prescriptions filled at 7 regional pharmacies, which are fully computerized. Complete data 
on drug use were available as of January 1, 1991. The pharmacy data include the Anatomical 
Therapeutical Chemical (ATC) code [16], the filling date, the total amount of drug units per 
prescription, the prescribed daily number of units, and the product name of the drugs. 
Cohort definition
For the present study, we included all patients in the Rotterdam Study from whom a blood sample 
was taken, whose CYP2C9 status was analyzed and who did not have a history of myocardial 
infarction as based on a patient’s interview, medical records from general practitioner or 
cardiologists, electrocardiography, and data on all hospital admissions. The cohort was followed 
until the first occurrence of a myocardial infarction, death or end of the study period, whichever 
came first. Follow-up started at the baseline examination and is continuously performed. For 
the present study, we used all data up to January 1, 2000. 
Outcome
Myocardial infarction was classified as present when a hospital discharge diagnosis of 
myocardial infarction was present, or, in case a patient was not hospitalised, when signs and 
symptoms, ECG recordings and cardiac enzyme data were diagnostic of myocardial infarction 
[17]. Two research physicians independently coded the possible cardiac events, according to 
the International Classification of Diseases, 10th version [18]. A cardiologist reviewed the coded 
events and performed the definitive coding. Only definite and probable cases were included 
in the analyses. The date on which an incident myocardial infarction was encountered was 
defined as the index date. 
Genotyping
Genotyping for the CYP2C9*2 and CYP2C9*3 allele variants was performed by using polymerase 
chain reaction followed by restriction enzyme digestion analysis (PCR-RFLP), as previously 
described by Aynacioglu et al [19]. All CYP2C9*2 and CYP2C9*3 heterozygote and homozygote 
variants detected were reanalyzed. Patients in whom neither CYP2C9*2 nor CYP2C9*3 alleles 
were identified were regarded as wild type.
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Drug exposure
We assessed exposure to the following CYP2C9 substrates and inhibitors (CYP2C9 drugs) 
on the index date (http://www.hcuge.ch/pharmacie/listemed/index.htm): aceclofenac, 
acenocoumarol, amiodarone, carbamazepine, celecoxib, chloroquine, clopidogrel, clozapine, 
cyclophosphamide, delavirdine, desogestrel, diclofenac, efavirenz, fluconazole, fluoxetine, 
flurbiprofen, fluvastatin, fluvoxamine, gemfibrozil, ibuprofen, imatinib, indometacin, irbesartan, 
losartan, mefenamic acide, meloxicam, metronidazole, miconazole, montelukast, naproxen, 
nateglinide, phenobarbital, phenprocoumon, phenylbutazone, phenytoin, pioglitazone, 
piroxicam, propofol, ritonavir, rosiglitazone, sildenafil, simvastatin, sulfamethoxazole, tamoxifen, 
tenoxicam, terbinafine, torasemide, valproic acid, verapamil, and zafirlukast. In order to prevent 
confounding by indication we excluded the following cardiovascular drugs: acenocoumarol, 
amiodarone, clopidogrel, fluvastatin, gemfibrozil, irbesartan, losartan, phenprocoumon, 
simvastatin, torasemide and verapamil.
Potential confounders and effect modifiers
Information was gathered at baseline on several potential confounders and effect modifiers 
such as age, gender, ethnic origin, body mass index (kg/m2) and smoking (classified as never/
former/current). At the research center, non-fasting blood samples were taken and serum total 
cholesterol and high-density lipoprotein (HDL) cholesterol was measured using an automated 
enzymatic procedure. Systolic and diastolic blood pressures from the right upper arm were 
measured twice with a random-zero sphygmomanometer with the patient in a sitting position. 
The mean of the two readings was used to determine blood pressure levels. Hypertension 
was defined as use of hypertensive medication for the indication high blood pressure, or as a 
systolic blood pressure of 140 mm Hg or over, or a diastolic blood pressure of 90 mm Hg or over 
[20]. Diabetes mellitus was considered present on the basis of use of antidiabetic medication, 
or a random or post-load glucose level higher than 11.0 mmol/l. Hypercholesterolemia was 
defined as use of lipid lowering medication or a serum total cholesterol higher than 6.5 mmol/l. 
Intima-media thickness (IMT) of the carotid arteries, measured by ultrasonography, was used 
as a measure of atherosclerosis. The maximum common carotid IMT was determined as the 
average of the maximum IMT of near- and far-wall measurements, and the average of left and 
right maximum common carotid IMT was computed [21]. To indicate no, mild, moderate, and 
severe thickening of the carotid wall, we divided the IMT into gender-specific quartiles. 
Statistical analysis
Allele and genotype proportions were tested for deviations from Hardy-Weinberg equilibrium 
(HWE) by using a χ2-test. 
The association between CYP2C9 genotype and myocardial infarction was evaluated using 
survival analysis techniques, for men and women separately. The reason for these a priori 
stratified analyses was that EET-induced vasodilatation is suggested to be more important 
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in females than in males. Patients were divided into 2 groups based on genotype: wild type 
(CYP2C9*1/*1 homozygotes) and variant (1 or 2 mutant alleles of CYP2C9*2, or CYP2C9*3). 
For each analysis, a relative risk (RR) and 95% confidence interval (95%CI) comparing variant 
and wild type genotype were computed. We used Cox proportional hazards models to adjust 
for the potential confounding effect of age, and additionally for cardiovascular risk factors, 
including body mass index, smoking, hypertension, diabetes mellitus, hypercholesterolemia, 
HDL cholesterol, and atherosclerosis. We tested for interaction between CYP2C9 genotype 
and atherosclerosis by adding an interaction term to the regression model: CYP2C9 variant 
genotype (0-1) x carotid IMT (1-4).
Cox proportional hazards regression for time-dependent variables was used to compute 
relative risks of myocardial infarction in male and female users of CYP2C9 drugs compared to 
non-users [22]. The multivariate model was adjusted for the abovementioned cardiovascular 
risk factors as well as for CYP2C9 genotype. We tested for interaction between the use of 
CYP2C9 drugs and CYP2C9 genotype by adding an interaction term to the regression model: 
use of CYP2C9 drugs (0-1) x CYP2C9 variant genotype (0-1).
For categorical covariates with missing values we incorporated missing indicator variables 
in the model. For subjects with missing data on covariates measured on a continuous scale, 
we imputed the gender-specific population mean. A P-value less than 0.05 was considered 
statistically significant. All statistical analyses were performed with SPSS software (version 
11.0.1; SPSS Inc., Chicago, USA).
RESULTS
From the initial 7983 participants of the Rotterdam Study, 1376 were excluded because a blood 
sample had never been drawn or no material was left for CYP2C9 genotyping. From the 6607 
remaining individuals, 92 subjects (1.4%) were excluded because of difficulties with genotyping. 
Subjects who experienced a myocardial infarction before the baseline examination (n = 771) 
were excluded. Consequently, there were 5744 individuals (2210 men and 3534 women) 
available for analysis. All patients were of Caucasian origin. There were 3808 patients (66.3%) 
with the wild type genotype, and 1936 (33.7%) with a variant genotype. The frequencies of 
the CYP2C9*2 and CYP2C9*3 alleles were 12.8% and 5.8%, respectively. Allele and genotype 
distributions were in Hardy-Weinberg equilibrium and frequencies were similar to other studies 
of Caucasian subjects [23]. The mean follow-up time of the study population was 7.0 years 
(standard deviation 2.1 years; range 18 days to 10.5 years). During follow-up, incident myocardial 
infarction occurred in 128 men and 95 women. Table 1 shows the baseline characteristics of the 
incident cases of myocardial infarction and the total cohort. As expected, for both men and 
women, incident cases of myocardial infarction had a more adverse cardiovascular risk profile 
than the total cohort.
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Table 2 shows that variant CYP2C9 genotype was not associated with myocardial infarction in 
men (RR 0.98, 95%CI: 0.68-1.42). For women, the adjusted relative risk was somewhat higher (RR 
1.21, 95%CI: 0.80-1.82), but also not statistically significant. The risk estimates did not change 
after adjusting for clinically relevant cardiovascular risk factors. For both men and women, 
atherosclerosis did not modify the association between variant CYP2C9 genotype and incident 
myocardial infarction.
Table 3 shows that the risk of myocardial infarction was statistically significantly increased in 
female users of CYP2C9 drugs (RR 2.68, 95%CI: 1.60-4.49), but not in male users (RR 1.26, 95%CI: 
0.64-2.49). The interaction term between use of CYP2C9 drugs and CYP2C9 genotype was 
Table 1. Baseline characteristics in men and women from the Rotterdam Study
Characteristic∗ Men (N = 2210) Women (N = 3534)
Patients with MI
(N = 128)
Cohort 
(N = 2210)
P Patients with MI 
(N = 95)
Cohort 
(N = 3534)
P
Age, years 69.2 ± 7.2 67.8 ± 8.2 0.001 72.5 ± 8.7 69.9 ± 9.5 <0.001
Body mass index (kg/m2) 25.7 ± 2.7 25.6 ± 2.9 0.958 27.5 ± 3.7 26.7 ± 3.9 0.050
Smoking (% current) 24.2 29.7 0.656 23.2 17.6 0.241
Hypertension (%) 57.8 47.6 0.016 64.2 51.3 0.001
Diabetes mellitus (%) 11.7 8.8 0.112 17.9 10.0 0.002
Hypercholesterolemia (%) 53.1 40.0 0.006 78.9 59.8 <0.001
HDL-cholesterol (mmol/L) 1.15 ± 0.24 1.23 ± 0.33 0.005 1.29 ± 0.37 1.44 ± 0.37 <0.001
Intima-media thickness (mm) 0.87 ± 0.14 0.84 ± 0.13 0.003 0.87 ± 0.14 0.81 ± 0.12 <0.001
Genotype 0.195† 0.183†
 CYP2C9*1/*1 (%) 87 (68.0) 1473 (66.7) 58 (61.1) 2335 (66.1)
 CYP2C9*1/*2 (%) 27 (21.1)  457 (20.7) 23 (24.2)  744 (21.1)
 CYP2C9*1/*3 (%) 12 (9.4)  211 (9.5)  9 (9.5)  323 (9.1)
 CYP2C9*2/*2 (%)  1 (0.8)   39 (1.8)  4 (4.2)   53 (1.5)
 CYP2C9*2/*3 (%)  1 (0.8)   21 (1.0)  1 (1.1)   61 (1.7)
 CYP2C9*3/*3 (%)  0    9 (0.4)  0   18 (0.5)
∗Values of continous variables are expressed as mean ± standard deviation. Categorical variables are expressed as percentage.
† P-value for Hardy Weinberg Equilibrium.
Table 2. Relative risks for incident myocardial infarction associated with CYP2C9 genotype for men and women
Number Events Model 1∗
RR (95%CI)
Model 2†
RR (95%CI)
Men
Wild type‡ 1473 87 1.00 (reference) 1.00 (reference)
Variant genotype§  737 41 0.96 (0.67-1.40) 0.98 (0.68-1.42)
Women
Wild type‡ 2335 58 1.00 (reference) 1.00 (reference)
Variant genotype§ 1199 37 1.25 (0.83-1.88) 1.21 (0.80-1.82)
* Model 1: adjusted for age.
† Model 2: adjusted for age, body mass index, smoking, hypertension, diabetes mellitus, hypercholesterolemia, HDL cholesterol and carotid IMT.
‡ CYP2C9*1/*1 homozygotes.
§ Patients with one or more of the variant alleles CYP2C9*2 or CYP2C9*3.
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not statistically significant in male users of CYP2C9 drugs (p = 0.398), and almost statistically 
significant in female users (p = 0.084). The adjusted relative risk of myocardial infarction in 
female users of CYP2C9 drugs with a variant genotype was 5.00 (95%CI: 2.55-9.83) as compared 
to women with the wild type genotype who did not use CYP2C9 drugs.
DISCUSSION
We found that women who used drugs that are metabolized by CYP2C9 had an increased risk 
of myocardial infarction, and that in women with allelic variants of CYP2C9 this risk was even 
higher. A potential explanation might be that this is the consequence of impaired formation 
of endogenous CYP2C9-derived vasoactive EETs, due to the concomitant inhibition of the 
enzyme by the CYP2C9 drugs and the decreased enzyme activity in patients with allelic 
Table 3. Relative risks for incident myocardial infarction associated with use of CYP2C9 drugs* and effect 
modification by CYP2C9 genotype for men and women
Number† Events‡ Model 1§
RR (95%CI)
Model 2**
RR (95%CI)
Men
No use of CYP2C9 drugs 340315 107 1.00 (reference) 1.00 (reference)
Use of CYP2C9 drugs  20829   9 1.35 (0.69-2.67) 1.26 (0.64-2.49)
P-value for statistical interaction 
CYP2C9 drugs * CYP2C9 genotype
0.398
Wild type; no use of CYP2C9 drugs 227082  70 1.00 (reference) 1.00 (reference) ††
Wild type; use of CYP2C9 drugs  13534   7 1.64 (0.75-3.56) 1.54 (0.70-3.35)††
Variant genotype; no use of CYP2C9 drugs 113233  37 1.07 (0.72-1.59) 1.06 (0.71-1.58) ††
Variant genotype; use of CYP2C9 drugs   7295   2 0.89 (0.22-3.64) 0.85 (0.21-3.48) ††
Women
No use of CYP2C9 drugs 548916  64 1.00 (reference) 1.00 (reference)
Use of CYP2C9 drugs  57732  19 2.79 (1.67-4.68) 2.68 (1.60-4.49)
P-value for statistical interaction 
CYP2C9 drugs * CYP2C9 genotype
0.084
Wild type; no use of CYP2C9 drugs 361749 40 1.00 (reference) 1.00 (reference) ††
Wild type; use of CYP2C9 drugs  38727  8 1.88 (0.88-4.05) 1.80 (0.84-3.86)††
Variant genotype; no use of CYP2C9 drugs 187167 24 1.16 (0.70-1.92) 1.14 (0.69-1.89) ††
Variant genotype; use of CYP2C9 drugs  19005 11 5.28 (2.69-10.36) 5.00 (2.55-9.83) ††
* Definition of CYP2C9 drugs: see text.
† In this time-dependent analysis, exposure in case patients and in the rest of the cohort is assessed at the time of the outcome in each case 
patient (index date). Because control patients can be used multiple times, the number of assessments is much larger than the number of 
individuals. Hence, crude relative risks cannot be calculated with the number in this table.
‡ 12 events in male and 12 events in female users of cardiovascular drugs excluded to prevent confounding by indication.
§ Model 1: adjusted for age.
** Model 2: adjusted for age, body mass index, smoking, hypertension, diabetes mellitus, hypercholesterolemia, HDL cholesterol, carotid IMT, 
and CYP2C9 genotype.
†† Model 2: adjusted for age, body mass index, smoking, hypertension, diabetes mellitus, hypercholesterolemia, HDL cholesterol, and carotid 
IMT.
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variants. Neither the use of CYP2C9 drugs alone, nor a variant genotype was associated with 
a significantly increased risk of myocardial infarction in men. These findings are in accordance 
with the study of Yasar et al, who found an increased risk in women but not in men [14]. The 
reason for this gender-based difference remains unclear but might be attributable, at least in 
part, to the differences in the levels of estrogen or other hormones between men and women. 
Population-based studies suggest that before menopause women have a delayed and less 
severe manifestation of cardiovascular diseases than men [24, 25]. This gender difference is 
thought to be due to an estrogen-stimulated enhanced capacity of endothelial cells of arterioles 
from females to produce nitric oxide [10]. These effects on vascular NO production require the 
chronic presence of estrogen [10] and are therefore probably diminished after menopause. 
Evidence suggests that important differences exist in the adaptation of the endothelium of 
arterioles from male and female rats to the lack of nitric oxide synthesis [11]. An augmented 
release of endothelial prostaglandins accounts for the preserved flow-induced dilation in 
arterioles of male rats, whereas a CYP-derived metabolite is responsible for the maintenance 
of flow-induced dilation in female rats [11]. Inhibition of this compensatory mechanism by 
use of CYP2C9-inhibiting drugs could therefore be the cause of the increased risk of incident 
myocardial infarction in postmenopausal women and the reason why we did not find such an 
association in men. The reason for the larger impact of drugs metabolized via CYP2C9 on the 
risk of myocardial infarction, as compared to the effect of the variant alleles CYP2C9*2 and 
CYP2C9*3, could be that the cardiovascular system is adapted to this permanently reduced 
enzyme activity in the case of the variant alleles and myocardial infarction mainly occurs when 
the CYP2C9 enzyme is suddenly blocked by use of CYP2C9 drugs.
Selection bias was negligible because our study population comprised all men and women in 
the Rotterdam Study. Furthermore, our study population was in Hardy-Weinberg equilibrium, 
suggesting that no selection has occurred among genotypes, which could have explained the 
observed association. Also, information bias is not likely, since all data on CYP2C9 genotype 
and myocardial infarction were recorded similarly for all participants without prior knowledge 
of our study hypothesis. Random misclassification of the outcome may have occurred due 
to measurement error but is unlikely as myocardial infarction is a diagnosis, which is usually 
fairly specific. Moreover, any random misclassification would tend to underestimate rather 
than overestimate the true risk. Potential confounding factors were dealt with in the analyses. 
Although we had no data on the presence and severity of coronary atherosclerosis, the 
extracoronary measure of atherosclerosis we used, has been demonstrated to be a reliable 
indicator of atherosclerosis because of its consistent associations with atherosclerosis in other 
arteries, cardiovascular risk factors, and future cardiovascular diseases [26]. As in all pharmaco-
epidemiological studies, confounding-by-indication is a potential problem. Therefore, we 
excluded all CYP2C9 drugs with the indication cardiovascular disease.
Although 12 different single nucleotide polymorphisms (SNPs) have been described in the 
coding region of the CYP2C9 gene (http://www.imm.ki.se/CYPalleles), we only analysed the 
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CYP2C9*1, *2, and *3 alleles, because these were the alleles reported in Caucasian populations 
[23]. Yasar et al [27] recently reported on a strong, but not complete, linkage between the 
CYP2C8*3 and CYP2C9*2 allelic variants. The CYP2C8*3 variant, with an allele frequency of 
13% in Caucasians, was associated with a markedly defective metabolism of arachidonic acid, 
corresponding to 35% of the CYP2C8*1 activity. It was speculated that for some substrates that 
are metabolised by both CYP2C8 and CYP2C9, like arachidonic acid, an impaired clearance 
in vivo previously exclusively attributed to the CYP2C9*2 variant could in part be explained 
by slow metabolism of the substrate by the associated CYP2C8*3 variant. The samples in the 
present study were not analysed for the CYP2C8*3 allele. It is conceivable that this variant could 
have had a risk modifying effect of the CYP2C9 gene on myocardial infarction.
In conclusion, this population-based cohort study shows a significant almost three-fold 
increased risk of incident myocardial infarction in women who used drugs that are metabolized 
by CYP2C9. This risk is even further increased in women with a variant allele.
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Chapter 2.4
Patients with an ApoE ε4 allele require lower doses of coumarin 
anticoagulants

ApoE polymorphisms and coumarin dose 63
ABSTRACT
Objective: Vitamin K is an essential cofactor for the synthesis of several blood coagulation 
factors. It has been suggested that the ApoE genotype has profound effects on vitamin K status. 
Therefore, we investigated whether this common genetic polymorphism influenced dose 
requirements and effects of coumarin anticoagulants. 
Methods: We did a cohort study in 1637 patients from an outpatient anticoagulation clinic 
treated with acenocoumarol or phenprocoumon. 
Results: To attain the same level of anticoagulation, patients with genotype ε4/ε4 and 
genotype ε3/ε4 required respectively 3.4 mg (95%CI: -6.0 to -0.9) and 0.8 mg (95%CI: -1.6 to 
0.1) acenocoumarol per week less than patients with genotype ε3/ε3. Patients homozygous for 
the ε2 allele required 3.5 mg (95%CI: 0.1 to 6.9) acenocoumarol per week more than patients 
with genotype ε3/ε3. The effect of the ε4 allele on the acenocoumarol maintenance dose was 
dose-dependent, while the effect of the ε2 allele was not. No significant dose difference was 
observed for phenprocoumon, possibly because of low numbers.
Conclusion: The ApoE genotype affects the dose requirements of acenocoumarol.
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INTRODUCTION
Vitamin K is an essential cofactor for carboxylation of the blood coagulation factors II, VII, IX, X, 
and several other calcium-binding proteins [1-3]. Coumarin anticoagulants inhibit vitamin K 
regeneration in the liver, and thereby reduce the synthesis of carboxylated blood coagulation 
factors [4]. Vitamin K from dietary or intestinal sources directly counteracts the effect of 
coumarin anticoagulants. The major dietary and circulating form of vitamin K is phylloquinone 
(vitamin K1) [5]. In plasma, vitamin K1 is bound to chylomicrons and chylomicron remnants 
[6]. The uptake of these vitamin K-rich lipoproteins by liver and other tissues is mediated by 
apolipoprotein E (ApoE), a constituent of chylomicron remnants, which binds to lipoprotein 
receptors [7]. ApoE is a polymorphic protein, defined by three alleles ε2, ε3, and ε4 at a single 
gene locus on chromosome 19. These alleles code for three isoforms of ApoE (E2, E3, and E4) that 
differ by one or both of two amino acid substitutions at sites 112 and 158, and thus determine 
the phenotype of the six genotypes resulting from the combination of any two of these alleles 
[8]. Chylomicron-remnant clearance is thought to be slowest in people with genotype ε2/ε2, 
faster in those with genotype ε3/ε3, and fastest in those with genotype ε4/ε4. Individuals with 
the heterozygous genotypes were reported to have clearance rates that are intermediate to 
those with the respective homozygous genotypes [9]. As a consequence, plasma vitamin K1 
levels are strongly influenced by ApoE genotype, being highest in those with the E2 isoform, 
intermediate in E3 and lowest in those with the E4 isoform [6,10,11]. The association between 
ApoE genotype and plasma vitamin K1 levels raise the possibility that the sensitivity to coumarin 
anticoagulants is also partly determined by ApoE genotype. 
Therefore, we investigated the effect of the ApoE genotype on the maintenance dose 
of acenocoumarol and phenprocoumon, on the International Normalised Ratio (INR), a 
standardized measure of anticoagulation, and on bleeding complications. 
METHODS
Setting
Data were obtained from a regional outpatient anticoagulation clinic and from the Rotterdam 
Study. The anticoagulation clinic monitors all inhabitants of Ommoord, a suburb of the city 
of Rotterdam in the Netherlands, with an indication for anticoagulant therapy. The choice of 
anticoagulant is made by the physician. Almost all patients start with a standard dosing scheme 
of acenocoumarol (8-4-4 mg during day 1 up to day 3) or phenprocoumon (9-6-3 mg during day 
1 up to day 3). The optimal target range of coumarin anticoagulant therapy, as recommended 
by the Federation of Dutch Thrombosis Centers, lies between 2.5 and 3.5 INR or between 3.0 
and 4.0 INR, depending on the indication for treatment. Some patients are targeted at a level 
between 2.0 and 2.5 INR because of contraindications. Prothrombin times are monitored each 
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one to six weeks by reference to the INR, dependent on the stability of the anticoagulant level. 
Doses are adjusted on the basis of the target range of the INR of the patient by computerised 
dose calculations. All data on dosing, laboratory-, and clinical data (e.g. bleeding complications) 
as of 1984 are fully computerised. For this study, data were used from January 1, 1985 through 
May 31, 2003. The Rotterdam Study is a prospective population-based cohort study of 
neurological, cardiovascular, locomotor and ophthalmologic diseases. All inhabitants aged 55 
years or older in Ommoord were invited in 1990-1993 to participate in the study. The rationale, 
ethical approval and design of this study have been described elsewhere [12]. The Rotterdam 
Study encompasses 7,983 individuals who were all interviewed and investigated at baseline. 
Cohort definition
The study cohort consisted of all 1983 patients from the anticoagulation clinic, who started 
treatment with acenocoumarol or phenprocoumon in the study period between January 1, 
1985 and May 31, 2003, for whom INR data from their treatment history were available, and 
whose ApoE status was analysed in the Rotterdam Study. If a patient had multiple treatment 
episodes during the study period, all episodes were considered. We defined the follow-up 
period as the sum of all treatment episodes per patient. The cohort was followed until the 
last INR-assessment because of the end of their treatment, death or end of the study period, 
whichever came first. 
Outcomes and confounders
The average first INR following the standard start-dosing scheme of acenocoumarol or 
phenprocoumon was calculated per ApoE genotype. Furthermore, the occurrence of 
overanticoagulation during the first six weeks of treatment and during the whole follow-up 
period was assessed. Overanticoagulation was defined as an INR ≥ 6.0, since at this INR-value 
the risk of bleeding sharply increases [13]. Patients, who had a follow-up period of more than six 
weeks, were included in the analyses on maintenance dose. The maintenance dose was defined 
as the mean dose (in mg per week) calculated over all treatment episodes from day 43 up to the 
end of each treatment episode. The mean INR was calculated over the same period. As a clinical 
outcome, we included all bleeding complications, including skin bleeds of more than 10 cm in 
diameter and nosebleeds lasting for at least 30 minutes.
As potential confounders we considered: age, gender, target INR level, measured 
INR, cytochrome P450 2C9 (CYP2C9) genotype, and use of statins. In the analyses on 
overanticoagulation and bleeding complications in relation to variant genotype, the mean 
time between the INR measurements was also taken into account.
Genotyping
DNA was used for ApoE genotyping [14]. The ApoE gene was amplified by the primer and 
amplification conditions described by Wenham and colleagues [15]. After amplification, the 
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PCR product was digested with the restriction enzyme HhaI and fragments were separated by 
electrophoresis on a 5% agarose gel. ApoE alleles were visualized by staining with ethidium 
bromide. We defined ε4 carriers as subjects with ε3/ε4, or ε4/ε4 alleles and ε2 carriers as subjects 
with ε2/ε3, or ε2/ε2 alleles. Hence, the ε2/ε4 genotype was excluded from these analyses to 
facilitate mutually exclusive categories. Subjects with genotype ε3/ε3 were regarded as the 
reference group.
Statistical analysis
Allele and genotype proportions were tested for deviations from Hardy-Weinberg equilibrium 
(HWE) by using a χ2-test. Independent-samples t tests were used for comparing the mean first 
INR after a standard start dose, the mean INR and the mean maintenance dose, between all 
variant genotypes and the ε3/ε3 genotype, and between ε2 or ε4 carriers and the reference 
genotype. The associations between ApoE genotype and overanticoagulation and between 
ApoE genotype and bleeding complications were evaluated using survival analysis techniques. 
For these analyses, patients were divided into 2 groups based on genotype: variant genotype 
(ε2/ε2, ε2/ε3, ε3/ε4, ε2/ε4, ε4/ε4) and reference genotype (ε3/ε3). For each analysis, a hazard 
ratio (HR) and 95% confidence interval (95%CI) comparing variant and reference genotype, were 
computed. These analyses were performed with SPSS software (version 10.0; SPSS, Chicago, IL). 
Then, ApoE genotype was examined as a determinant of coumarin dose over time. To analyse 
correlated data (repeated INR measurements and the subsequent doses in the same person), 
unbalanced repeated measurement analysis [16,17] was used with the Proc Mixed module of 
SAS (version 8.2). The general linear mixed model included coumarin dose as the outcome 
variable and ApoE genotype as well as age, gender, target INR, measured INR, CYP2C9 genotype, 
and use of statins as explanatory variables. To evaluate an allele-dose effect for the ε2 allele 
and for the ε4 allele, trend tests were performed using the same linear model with the mean 
maintenance dose as outcome variable and the allele dose as an ordinal set with 3 values (0, 1 
or 2 copies of the test allele). We tested for interaction between the ApoE ε4 allele and CYP2C9 
variant genotype by adding an interaction term to the model: CYP2C9 variant genotype (0-1) 
x ApoE genotype (0-1-2: non carriers-ε4 heterozygotes-ε4 homozygotes), assuming an allele-
effect relationship. P values less than 0.05 were considered statistically significant.
RESULTS
Of the 1983 patients in the cohort, 346 patients were excluded because of missing ApoE 
genotypes. Consequently, there were 1637 patients available for analysis (Table 1). The mean 
age of these patients was almost 75 years, and 44.3% of the patients were men. All patients 
were of Caucasian origin. There were 1490 acenocoumarol-treated patients (91.0%), and 220 
patients (13.4%) who used phenprocoumon. Seventy-six of them used both coumarins during 
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the study period. Fifty-four patients (3.3%) were targeted at an INR between 2.0 and 2.5, 765 
patients (46.7%) at an INR between 2.5 and 3.5, and 818 patients (50.0%) at an INR between 
3.0 and 4.0. The weekly maintenance dose of acenocoumarol ranged from 1 to 64 mg and of 
phenprocoumon from 1 to 58 mg. The mean follow-up time was 747 days (2.0 years). Patients 
had a median of 20 INR assessments during a median follow-up time of 238 days (0.7 years). 
Table 1 shows the distribution of patients by ApoE genotype. There were 216 ε2 carriers (ε2/
ε4 genotype excluded) and 429 ε4 carriers. The allele frequencies of the ε2, ε3 and ε4 alleles 
were 0.086, 0.758 and 0.156 respectively. There was no significant departure of genotype - and 
Table 1. Characteristics of the study population
Variable Number of patients
(n = 1637)
Age, average (SD) 74.8 (8.1) years
Gender
 Male 725 (44.3%)
 Female 912 (55.7%)
Caucasian origin 1637 (100%)
Type of coumarin* 
 Acenocoumarol 1490 (91.0%)
 Phenprocoumon  220 (13.4%)
 Unknown    3 (0.2%)
Target INR level
 Very low (2.0-2.5)  54 (3.3%)
 Low (2.5-3.5) 765 (46.7%)
 Normal (3.0-4.0) 818 (50.0%)
Weekly maintenance dose range
 Acenocoumarol 1 - 64 mg
 Phenprocoumon 1 - 58 mg
Follow-up time
 Mean 747 days
 Median 238 days
ApoE genotype
 ε2/ε2  16 (1.0%) 
 ε2/ε3 200 (12.2%)
 ε3/ε3 943 (57.6%)
 ε3/ε4 397 (24.3%)
 ε2/ε4  49 (3.0%)
 ε4/ε4  32 (2.0%)
CYP2C9 genotype
 *1/*1 1021 (62.4%)
 *1/*2  342 (20.9%)
 *2/*2   31 (1.9%)
 *1/*3  148 (9.0%)
 *2/*3   29 (1.8%)
 *3/*3    2 (0.1%)
* Because 76 patients used both coumarins at any time during the study period, the total percentage is more than 100.
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allele frequencies from Hardy-Weinberg equilibrium. Regarding the CYP2C9 genotype, there 
were 1021 patients (62.4%) with the wild type genotype (CYP2C9*1/*1 homozygotes), and 552 
(33.7%) with a variant genotype (1 or 2 of the mutant alleles CYP2C9*2 or CYP2C9*3). These 
allele and genotype proportions were also in Hardy-Weinberg equilibrium. 
In Table 2 the mean first INR after a standard coumarin-starting dose, the mean INR and the 
mean maintenance dose are shown per ApoE genotype. For acenocoumarol-treated patients 
with genotypes ε2/ε2, ε2/ε3, ε3/ε4, ε2/ε4 and ε4/ε4, the mean first INR was not statistically 
significantly different compared to genotype ε3/ε3. The differences in mean first INR between 
ε2 or ε4 carriers and the reference genotype were also not statistically significant. Patients 
with genotype ε2/ε2 on phenprocoumon had a statistically significantly higher first INR after a 
standard start dose. For acenocoumarol-treated patients, the mean INR during the maintenance 
phase was statistically significantly higher in patients with genotype ε2/ε2 and ε3/ε4, and 
in ε4 carriers compared to ApoE genotype ε3/ε3. For phenprocoumon-treated patients, the 
mean INR during the maintenance phase was statistically sigificantly higher in patients with 
genotype ε2/ε2 and statistically significantly lower in patients with genotype ε2/ε4 compared 
Table 2. The mean first INR after a standard start dose, the mean INR and the mean maintenance dose of 
acenocoumarol and phenprocoumon in relation to ApoE genotype
Genotype N pat Mean first 
INR (SEM*)
p-value† Mean INR 
(SEM∗)
p-value‡ Mean maintenance 
dose (mg/week) 
(SEM∗)
p-value§
Acenocoumarol 1490
 ε2/ε2   14 2.79 (0.39) 0.99 3.40 (0.04) <0.001 17.8 (0.33) <0.001
 ε2/ε3  174 2.85 (0.10) 0.62 3.21 (0.01) 0.60 14.9 (0.08) <0.001
 ε3/ε3  872 2.79 (0.05) - 3.23 (0.01) - 16.1 (0.04) -
 ε3/ε4  357 2.72 (0.05) 0.31 3.27 (0.01) <0.001 15.1 (0.06) <0.001
 ε2/ε4   46 3.00 (0.35) 0.33 3.21 (0.03) 0.67 13.7 (0.21) <0.001
 ε4/ε4   27 3.09 (0.17) 0.25 3.23 (0.03) 0.98 12.5 (0.16) <0.001
 ε2 carriers  188 2.84 (0.09) 0.64 3.24 (0.01) 0.59 15.2 (0.08) <0.001
 ε4 carriers  384 2.75 (0.05) 0.51 3.27 (0.01) <0.001 14.9 (0.06) <0.001
Phenprocoumon  220
 ε2/ε2    2 5.15 (0.65) 0.03 3.53 (0.05) 0.04 15.9 (0.35) <0.001
 ε2/ε3   33 3.20 (0.20) 0.42 3.41 (0.02) 0.62 13.6 (0.09) <0.001
 ε3/ε3  113 2.98 (0.13) - 3.40 (0.01) - 14.2 (0.09) -
 ε3/ε4   60 3.04 (0.18) 0.79 3.39 (0.02) 0.84 13.5 (0.10) <0.001
 ε2/ε4    4 2.53 (0.42) 0.52 3.21 (0.04) <0.001 11.8 (0.26) <0.001
 ε4/ε4    8 2.99 (0.34) 0.99 3.55 (0.09) 0.12 21.3 (0.61) <0.001
 ε2 carriers   35 3.31 (0.20) 0.21 3.42 (0.19) 0.29 13.9 (0.09) 0.009
 ε4 carriers   68 3.03 (0.16) 0.81 3.40 (0.02) 0.92 13.8 (0.10) 0.003
* Standard error of the mean.
† P-value for the difference in mean first INR after a standard start dose between the different ApoE genotypes and genotype ε3/ε3.
‡ P-value for the difference in mean INR between the different ApoE genotypes and genotype ε3/ε3. The dependency between the observations 
within a patient was not taken into account.
§ P-value for the difference in mean maintenance dose between the different ApoE genotypes and genotype ε3/ε3. The dependency between 
the observations within a patient was not taken into account.
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to ApoE genotype ε3/ε3. In these calculations however, all INR-measurements were considered 
as independent observations. For patients on acenocoumarol, the mean maintenance dose 
was statistically significantly lower in all ApoE genotypes compared to genotype ε3/ε3, except 
for those with genotype ε2/ε2. These patients had a significantly higher maintenance dose. 
For phenprocoumon-treated patients, those with genotypes ε2/ε2 and ε4/ε4 had a significant 
higher maintenance dose; all other genotypes had a significant lower maintenance dose 
compared to the reference genotype. The dependency between the observations was also 
here not taken into account. 
Table 3 summarizes the main findings of the study. For acenocoumarol-treated patients, 
ε2 homozygotes had a significantly higher maintenance dose, while patients homozygous 
for the ε4 allele had a statistically significantly lower maintenance dose than patients with 
genotype ε3/ε3. Individuals with the heterozygous genotypes had maintenance doses that 
were intermediate to those with the respective homozygous genotypes. These doses were 
not significantly different from the maintenance dose in patients with genotype ε3/ε3. The 
maintenance dose for ε4 carriers was also statistically significantly lower, while the dose for 
ε2 carriers was not significantly different from those with genotype ε3/ε3. The ε4 allele had a 
dose-dependent effect on the acenocoumarol maintenance dose, with a stepwise decrease 
Table 3. Difference in maintenance dose for the various ApoE genotypes compared to ApoE genotype ε3/ε3
Genotype N pat Difference in dose compared 
to ε3/ε3*† (mg/week) (SEM‡)
p-value§ (95%CI)**
Acenocoumarol 1490
 ε2/ε2   14 3.5 (1.8) 0.04 (0.1)-(6.9)
 ε2/ε3  174 -0.8 (0.6) 0.14 (-1.9)-(0.3)
 ε3/ε3  872 - - -
 ε3/ε4  357 -0.8 (0.4) 0.07 (-1.6)-(0.1)
 ε2/ε4   46 -1.3 (1.0) 0.18 (-3.3)-(0.6)
 ε4/ε4   27 -3.4 (1.3) 0.01 (-6.0)-(-0.9)
 ε2 carriers  188 -0.5 (0.5) 0.37 (-1.5)-(0.6)
 ε4 carriers  384 -1.0 (0.4) 0.02 (-1.8)-(-0.2)
Phenprocoumon  220
 ε2/ε2    2 1.1 (4.8) 0.82 (-8.5)-(10.7)
 ε2/ε3   33 -0.4 (1.3) 0.75 (-3.1)-(2.2)
 ε3/ε3  113 - - -
 ε3/ε4   60 -0.2 (1.1) 0.85 (-2.4)-(2.0)
 ε2/ε4    4 -3.2 (3.5) 0.37 (-10.1)-(3.8)
 ε4/ε4    8 0.8 (2.9) 0.78 (-4.9)-(6.5)
 ε2 carriers   35 -0.3 (1.3) 0.79 (-2.9)-(2.2)
 ε4 carriers   68 -0.1 (1.1) 0.92 (-2.2)-(2.0)
*  The mean acenocoumarol maintenance dose for genotype ε3/ε3 was 16.1 mg per week. 
The mean phenprocoumon maintenance dose for genotype ε3/ε3 was 14.2 mg per week.
† Adjusted for age, gender, target INR level, measured INR, CYP2C9 genotype, and use of statins.
‡ Standard error of the mean.
§ P-value for the difference in adjusted maintenance dose between the different ApoE genotypes and genotype ε3/ε3.
** 95% confidence interval for the difference in adjusted maintenance dose between the different ApoE genotypes and genotype ε3/ε3.
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of 0.9 mg per week per allele (p = 0.007). The ε2 allele had no dose-dependent effect on the 
acenocoumarol maintenance dose (p = 0.69). For patients on phenprocoumon, however, 
maintenance doses were not statistically significantly different from those with genotype 
ε3/ε3. CYP2C9 genotype did not modify the association between the ApoE ε4 allele and the 
maintenance dose. 
Patients with a variant genotype had a 21% higher risk of overanticoagulation during the 
first six weeks of anticoagulant therapy, compared to patients with genotype ε3/ε3, although 
this difference was not statistically significant (HR 1.21, 95%CI: 0.88-1.67). The total number of 
bleeding episodes was 241, or 9.0 per 100 treatment-years. Patients with a variant allele had a 
slightly but non-significantly higher risk for bleeding events (HR 1.12, 95%CI: 0.86-1.44).
DISCUSSION
The main finding in this cohort study is that individuals homozygous and heterozygous for 
the ε4 allele required a significantly lower dose of acenocoumarol, to reach the same level of 
anticoagulation, than patients with genotype ε3/ε3. Patients homozygous for the ε2 allele on 
acenocoumarol required a statistically significantly higher dose than patients with genotype 
ε3/ε3. The effect of the ε4 allele on the acenocoumarol maintenance dose was dose-dependent. 
Our results are in line with a previously reported small study of 30 patients on coumarins in which 
eight patients with the ApoE variant E4 (genotypes ε3/ε4 and ε4/ε4) had a significantly lower 
prothrombin content than the other 22 patients, but had used similar doses of phenprocoumon 
[18]. No adjustments were, however, made for potentially confounding factors. Unlike this 
study we found only an association between the ε4 allele and the maintenance dose in users of 
acenocoumarol, but not in users of phenprocoumon. This is possibly due to the relatively small 
number of subjects for some genotypes in phenprocoumon-treated patients in our study. In 
a previous study on CYP2C9 genotype and coumarin maintenance doses [19], differences in 
mean acenocoumarol dose compared to the wild type genotype (CYP2C9*1/*1) were -2.3, -3.5, 
-5.0 and -7.2 mg/week, respectively for genotypes CYP2C9*1/*2, CYP2C9*1/*3, CYP2C9*2/*2 
and CYP2C9*2/*3. So, the largest reduction in mean acenocoumarol dose found in the current 
study for ApoE genotype ε4/ε4, is comparable with the reduction in acenocoumarol dose found 
for genotype CYP2C9*1/*3. For patients on phenprocoumon, no significant differences were 
found between variant genotypes and the wild type genotype, comparable with the current 
study.
These data suggest that ApoE genotype has not only a profound effect on vitamin K status 
[6,10,11] but also on the response to coumarin anticoagulants. It is known that patients carrying 
a ε4 allele have an accelerated clearance of chylomicrons from the blood [9]. It has been 
hypothesized that after the accelerated uptake of the vitamin K-rich chylomicron remnants 
in the liver, vitamin K may be less abundantly available to hepatocytes for the synthesis of 
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biologically active coagulation factors because of a more extensive metabolism and excretion 
[6,18]. This implicates, that the ApoE ε4 allele not only enhances ApoE-receptor mediated hepatic 
extraction of chylomicron remnants from plasma, but also affects the intra-hepatocyte routing 
of extracted compounds, i.e. the entered vitamin K from chylomicrons is directly eliminated 
and bypasses the intra-cellular vitamin K dependent biochemical system. As a consequence, 
such patients would require a lower dose of coumarins, which competitively inhibit vitamin 
K, and might react with a stronger anticoagulation reponse upon therapeutic challenge with 
a standard dose of coumarin anticoagulants. However, the clinical consequences of carrying a 
variant allele seem to be mild. Patients with a variant genotype have a slightly increased INR but 
the risk of bleeding events seems to be negligible. It seems likely that even in patients with the 
ε4/ε4 genotype, regular monitoring of the INR strongly reduces the risk of bleeding. This is in 
contrast with a previous study on CYP2C9 and bleeding risk [20], where we found that carrying 
a variant allele of CYP2C9 was associated with an increased risk of major bleeding events in 
patients on acenocoumarol.
Most studies on ApoE and vitamin K, including our own, have focussed on the same 
polymorphism in the coding region of the apolipoprotein E gene. This coding polymorphism 
defines the ApoE isoforms E2, E3 and E4. However, in addition to this common genetic 
polymorphism, several other variations in the ApoE gene have been reported [21]. Of interest are 
polymorphisms identified in the promotor region. Their major impact is to affect the ApoE gene 
expression, and consequently, ApoE isoform concentrations [21-24]. Whether or not differences 
in absolute levels of ApoE are associated with coumarin anticoagulant doses deserves further 
investigation. The allelic frequencies found in our population are within the range of reported 
allele frequencies among other Caucasian populations. In Europeans and American Caucasians 
the relative frequency of the ε4 allele ranges from 0.10 to 0.23 [25-28]. 
Some potential limitations of our cohort study should be considered. Selection bias was 
probably negligible because we identified all users of coumarin anticoagulants in a defined 
population and difficulties with genotyping were random. Furthermore, our study population 
was in Hardy-Weinberg equilibrium, suggesting that no selection has occurred among 
genotypes, which could have explained the observed association. Also, information bias is not 
likely as all data on genotype and outcome were gathered prospectively and recorded similarly 
for all cohort members without prior knowledge of our study hypothesis. Potential confounding 
by age, gender, target INR level, measured INR, CYP2C9 genotype, and use of statins was dealt 
with in the multivariate analyses, although it seems largely redundant to adjust for additional 
confounding factors, because a confounding factor should be associated with ApoE genotype 
in order to distort the studied association.
In conclusion, individuals homozygous or heterozygous for the ε4 allele required a 
significantly lower dose of acenocoumarol, to reach the same level of anticoagulation, than 
patients with genotype ε3/ε3. Acenocoumarol-treated patients homozygous for the ε2 allele 
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required a significantly higher dose than those with genotype ε3/ε3. As all coumarins are 
competitors of vitamin K, it is likely that our results also apply to warfarin.
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Chapter 3
Drug interactions with coumarin anticoagulants

Chapter 3.1
Overanticoagulation associated with combined use of 
antibacterial drugs and acenocoumarol or phenprocoumon 
anticoagulants
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ABSTRACT
Introduction: Several case reports associated combined use of coumarins and antibacterial 
drugs with overanticoagulation. Despite the fact that these drugs are frequently prescribed 
concurrently, there is little quantitative information on the risks of such complications.
Objective: To study which antibacterial drugs are associated with overanticoagulation during 
therapy with coumarins.
Design: Population-based cohort study in a sample of the Rotterdam Study.
Subjects: All patients who were treated with acenocoumarol or phenprocoumon in the study 
period from April 1, 1991 through December 31, 1998 and for whom international normalised 
ratio (INR) data were available. 
Methods: Patients were followed until an INR ≥ 6.0, the end of their treatment, death or end 
of the study period. Proportional hazards regression analysis was used to estimate the risk 
of an INR ≥ 6.0 in relation to concomitant use of a coumarin anticoagulant and antibacterial 
drugs after adjustment for several potentially confounding factors such as age, gender, hepatic 
dysfunction, malignancies, and heart failure.
Results: Of the 1124 patients in the cohort, 351 had an INR ≥ 6.0. The incidence rate was 6.9 
per 10,000 treatment days. Sulfamethoxazole combined with trimethoprim most strongly 
increased the risk of overanticoagulation with an adjusted relative risk of 20.1 (95% confidence 
interval: 10.7-37.9). Stratification showed that the induction period of overanticoagulation 
varied between different antibacterial drugs. 
Conclusion: In this study among outpatients of an anticoagulation clinic using acenocoumarol or 
phenprocoumon, several antibacterial drugs strongly increased the risk of overanticoagulation. 
Awareness of these drug interactions and more frequent monitoring of INR values during the 
initial stages of antibacterial drug therapy are warranted to minimize the risk of bleeding 
complications.
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INTRODUCTION
Coumarin anticoagulants are extensively used for the treatment and long-term prevention of 
thromboembolic diseases [1, 2]. These drugs induce their anticoagulant effect by antagonising 
vitamin K, thereby impairing the biological activity of the vitamin K-dependent coagulation 
factors [3, 4]. The risk of bleeding, the main complication of coumarin anticoagulants, is 
influenced by the intensity of anticoagulant therapy [5-9], by the patient’s underlying clinical 
disorder [9, 10], and by the concomitant use of other drugs [2, 11, 12]. This risk sharply increases 
when the international normalised ratio (INR) is ≥ 6.0 [13, 14]. Growing experience with 
anticoagulant therapy, and increased understanding of drug interactions, has reduced the 
number of bleeding complications [15]. Several drugs can affect the prothrombin time during 
coumarin anticoagulant therapy by different mechanisms [11, 12, 16, 17]. During the past 
decades, many case reports associated the use of antibacterial drugs with overanticoagulation 
[18-24]. Prospective studies investigated this association, but these were conducted in young 
healthy volunteers, were only able to identify interactions that occur relatively frequently and 
were mostly limited to warfarin [25-31]. A recent case-control study suggested that antibacterial 
drugs are an important cause of overanticoagulation [32]. In that study, however, data on 
drug use came from patient interview and the sample size was too small to study the effect 
of different antibacterial agents on coumarins. Therefore, we conducted a follow-up study in 
a large population-based cohort to investigate which antibacterial drugs are associated with 
overanticoagulation during therapy with coumarins.
METHODS
Setting
Data were obtained from the Rotterdam Study and from the regional outpatient anticoagulation 
clinic. The Rotterdam Study is a prospective population-based cohort study of neurological, 
cardiovascular, locomotor and ophthalmologic diseases. All inhabitants of Ommoord, a suburb 
of the city of Rotterdam in the Netherlands, aged 55 years or over were invited in 1990-1993 to 
participate in the study. The rationale and design of this study have been described elsewhere 
[33]. The cohort encompasses 7983 individuals who were all interviewed and investigated 
at baseline. During baseline interview, data were gathered on medical history, and a food 
questionnaire was completed. During a subsequent visit to the research center, patients 
were examined and blood was taken for the assessment of electrolytes, liver enzyme levels, 
serum creatinine, serum albumin and several other laboratory values. The anticoagulation 
clinic monitors all inhabitants of Ommoord with an indication for anticoagulant therapy. The 
choice of anticoagulant is made by the physician. Prothrombin times are monitored each one 
to six weeks by reference to the INR, dependent on the stability of the anticoagulant level. 
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Doses are adjusted on the basis of the INR of the patient by computerised dose calculations. 
For this study data were used from January 1, 1991 through December 31, 1998. More than 
99% of participants fill their drugs at seven regional pharmacies, which are fully computerised. 
Complete data on drug use were available as of January 1, 1991. The pharmacy data include the 
Anatomical Therapeutical Chemical (ATC)-code [34], the filling date, the total amount of drug 
units per prescription, the prescribed daily number of units, and product name of the drugs. 
Cohort and outcome definition
The study cohort consisted of all 1124 patients in the Rotterdam Study, who were treated with 
acenocoumarol or phenprocoumon in the study period between April 1, 1991 and December 31, 
1998 and for whom there were INR data from the anticoagulation clinic during their treatment. 
The start date April 1 was chosen to ensure that at least 3 months of medication history from 
the pharmacy was available for every cohort member. The cohort included prevalent users of 
coumarins on the starting date and incident users during the study period. All cohort members 
were followed as of April 1, 1991 for prevalent users and from their first INR assessment for 
incident users. Both groups were followed until the first occurrence of an INR ≥ 6.0, the last INR 
assessment because of the end of their treatment, death or end of the study period, whichever 
came first. This means that during follow-up, all study members were anticoagulated and 
regularly assessed for their INR. The date on which an INR ≥ 6.0 was encountered was defined 
as the index date. 
Cofactors
The following baseline patient characteristics were considered as potential determinants for 
affecting the response of the INR to coumarin anticoagulants: gender, age, hepatic dysfunction 
(defined as serum aminotransferases > 2x the upper level of normal), hypoalbuminemia (≤ 
35 g/l), malignancies, hyperthyroidism, hypertension (systolic blood pressure ≥ 160 mm Hg 
and/or diastolic blood pressure ≥ 95 mm Hg or use of antihypertensives), heart failure, and low 
dietary intake of vitamin K (< 1 µg/kg/day). In addition, we considered duration of follow-up 
and whether the INR measurement on the index date was earlier than according to the INR 
monitoring scheme. Furthermore, to study the potentially confounding effect of fever or of the 
indication for treatment we studied the presence or absence of these features in the medical 
records of the general practitioners. We did this validation for all cases and a random sample 
from the remainder of the cohort who all had been treated with antibacterial drugs on the 
index date.
Statistical analysis
Incidence rates were calculated by dividing the number of cases of an INR ≥ 6.0 by the number 
of days on combined use of a coumarin anticoagulant and an antibacterial drug. To assess 
antibacterial drugs which were independently associated with an INR ≥ 6.0, all occurring 
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combinations of a coumarin anticoagulant and an antibacterial drug were included separately 
in a Cox proportional hazards regression model for time-dependent variables to compute 
relative risks and their 95% confidence intervals (95%CI) [35]. The model compares exposure to 
this combination on the index date of each case with that of all other non-censored subjects in 
the cohort on the same date as the case. To adjust for potential confounding, cofactors which 
were associated with an INR ≥ 6.0 in the univariate analysis were included in the multivariate 
model if this caused a change in the point estimate of more than 5 percent. In order to study the 
time interval between the first treatment day with an antibacterial drug and an INR value ≥ 6.0, 
we distinguished 2 intervals: 1-3 days and ≥ 4 days. Stratification by these time-intervals was 
performed because the induction period differs per mechanism by which antibacterial drugs 
may cause overanticoagulation. If possible, stratified analyses by the type of anticoagulant 
were performed. Moreover, separate analyses were performed for prevalent and incident users 
of coumarin anticoagulants on the starting date.
RESULTS
Of the 1124 patients in the cohort, 351 developed an INR ≥ 6.0 after April 1, 1991. The incidence 
rate was 6.9 per 10,000 treatment days. Baseline characteristics of cases and the total cohort 
Table 1. Characteristics of patients with an INR ≥ 6.0 and the total cohort
Patients with INR ≥ 6.0 Total cohort RR* (95%CI)
n = 351 n = 1124
Gender
 Male 177 (50.4%) 534 (47.5%) 1.00 Reference
 Female 174 (49.6%) 590 (52.5%) 1.44 (1.17-1.77)
Age (years, mean (SD))  73 (8)  72 (8) 1.04 (1.03-1.05)
 55-64  49 (14.0%) 218 (19.4%) 1.00 Reference
 65-74 152 (43.3%) 496 (44.1%) 1.28 (0.92-1.76)
 75-84 124 (35.3%) 340 (30.2%) 1.85 (1.33-2.58)
 ≥ 85  26 (7.4%)  70 (6.2%) 3.17 (1.96-5.14)
Type of anticoagulant
 Acenocoumarol 295 (84.0%) 951 (84.6%) 1.00 Reference
 Phenprocoumon  56 (16.0%) 173 (15.4%) 0.57 (0.43-0.76)
Hepatic dysfunction   3 (0.9%)  12 (1.1%) 3.75 (1.18-11.9)
Hypoalbuminemia   1 (0.3%)   2 (0.2%) 1.16 (0.16-8.30)
Malignancies  43 (12.3%)  94 (8.4%) 1.67 (1.21-2.30)
Hyperthyroidism  12 (3.4%)  37 (3.3%) 1.51 (0.85-2.70)
Hypertension 148 (42.2%) 434 (38.6%) 1.08 (0.86-1.35)
Heart failure  83 (23.7%) 141 (12.5%) 1.63 (1.27-2.09)
Low intake of vitamin K   7 (2.0%)  11 (1.0%) 3.74 (1.96-7.95)
* Univariate analyses of relative risks were performed with a Cox proportional-hazards model. Relative risks cannot be calculated with the 
numbers in this table because controls may later become cases.
Overanticoagulation associated with antibacterial drugs 83
are shown in Table 1. Women and older patients had a higher risk of an INR ≥ 6.0. The risk of 
overanticoagulation was lowest with phenprocoumon. Hepatic dysfunction, malignancies, 
heart failure and a low dietary daily intake of vitamin K were associated with an increased risk of 
an INR ≥ 6.0 in the univariate analysis. There was no difference in duration of follow-up between 
cases and the total cohort (mean 559±481 days). The INR measurement on the index date was 
earlier than planned in 8.6% of the cases and in 5.6% of the total cohort (p = 0.0048).
Twenty different antibacterial drugs were used during the study period, of which eleven were 
not used in cases. Thirty-eight cases (11%) used antibacterial drugs on the index date. Incidence 
rates for the individual antibacterial drugs are presented in Table 2. Eight antibacterial drugs 
were univariately as well as multivariately associated with overanticoagulation. The relative risk 
varied considerably between the different drugs (Table 2). Sulfamethoxazole combined with 
trimethoprim (co-trimoxazole) most strongly increased the risk of overanticoagulation. Only 
age and gender were associated with a change of the point estimate of more than five percent. 
After adjustment for these confounding factors the relative risk was 20.1 (95%CI: 10.7-37.9). 
There was no significant difference in the frequency of fever in cases on antibacterial drugs 
Table 2. Association between overanticoagulation (INR ≥ 6.0) and use of antibacterial drugs
Antibacterial drug Cases Cohort* IR† RRcrude (95%CI)
‡ RRadj. (95%CI)
§
n = 351 (No.) n = 1124 (No.)
Amoxicillin  8 180  32.0 11.1 (5.4-22.9) 10.5 (5.1-21.7)
Amoxicillin & enzyme inhitor  4 205  18.0 4.6 (1.7-12.4)  5.1 (1.9-13.9)
Amphotericin  0  11 P = 0.89
Azithromycin  0   2 P = 0.95
Cefalexin  0   3 P = 0.94
Cefixime  0   2 P = 0.95
Cefuroxime  0   4 P = 0.93
Ciprofloxacin  0  19 P = 0.85
Clarithromycin  3  69  78.7 11.0 (3.4-35.4) 11.7 (3.6-37.8)
Clindamycin  0  37 P = 0.80
Doxycycline  5 288  32.3 4.2 (1.7-10.2)  4.3 (1.8-10.4)
Erythromycin  0  78 P = 0.69
Flucloxacillin  0  25 P = 0.83
Norfloxacin  3  66  44.6 10.0 (3.1-32.1)  9.8 (3.0-31.6)
Ofloxacin  0  33 P = 0.81
Pheniticillin  1 219   0.2 1.2 (0.2-8.3)  0.9 (0.1-6.1)
Roxithromycin  0  14 P = 0.86
Sulfamethoxazole & trimethoprim 11 125 154.7 20.1 (10.7-37.7) 20.1 (10.7-37.9)
Trimethoprim  2  61  26.8 6.0 (1.4-25.2)  5.6 (1.3-23.1)
Vancomycin  1  10  15.9 17.7 (2.3-138.0) 13.6 (1.7-106.8)
* In this time-dependent analysis, exposure in cases and controls is assessed on every index date. As a consequence, the number of assessments 
in the reference group is much larger than the number of individuals. Hence, crude relative risks cannot be calculated with the numbers in 
Table 2.
† Expressed as the number of cases per 10,000 days on combined use of a coumarin and an antibacterial drug.
‡ If none of the cases was exposed, p-values are given instead of relative risks.
§ Adjusted for gender and age.
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and individuals in the rest of the cohort who were treated with antibacterial drugs on the index 
date. Similarly, there was no difference in the indication for antibacterial drugs between cases 
and the remainder of the cohort.
Stratification by time-interval revealed that the adjusted relative risks of overanticoagulation 
by antibacterial drugs were different for both time intervals (Table 3). Relative risks could not be 
established for both time periods for all antibacterial drugs because overanticoagulation only 
occurred in one of the time intervals for some drugs. For amoxicillin and sulfamethoxazole-
trimethoprim, relative risks were significantly increased for both time intervals. When comparing 
the relative risks for both time intervals, the antibacterial drugs with the highest relative risk 
1-3 days after start of use were clarithromycin, norfloxacin and trimethoprim. For amoxicillin, 
doxycycline, sulfamethoxazole-trimethoprim relative risks of overanticoagulation were most 
strongly increased ≥ 4 days after start of the antibacterial drug.
Stratified analyses by the type of anticoagulant could only be performed for amoxicillin and 
sulfamethoxazole with trimethoprim. For patients on acenocoumarol the adjusted relative risk 
of amoxicillin was 8.0 (95%CI: 3.5-18.4). For users of phenprocoumon the adjusted relative risk 
of amoxicillin was 22.4 (95%CI: 4.0-126.3). Sulfamethoxazole with trimethoprim was associated 
with an adjusted relative risk of overanticoagulation of 17.3 (95%CI: 8.6-34.9) in patients on 
acenocoumarol, and 14.3 (95%CI: 2.8-73.8) in patients on phenprocoumon. Numbers appeared 
to be too small to calculate risks in prevalent users on the starting date. In incident users risks 
were largely the same as in the total population (data not shown). 
DISCUSSION
The main finding in this population-based cohort study is that several antibacterial drugs were 
associated with a strongly increased risk of overanticoagulation during coumarin anticoagulant 
Table 3. Association between overanticoagulation (INR ≥ 6.0) and use of antibacterial drugs stratified by time 
interval*
Antibacterial drug RRadj. (95%CI)
† RRadj. (95%CI)
† RRadj. (95%CI)
†
overall 1-3 days ≥ 4 days
Amoxicillin 10.5 (5.1-21.7)  7.2 (1.8-29.7) 13.2 (5.6-30.8)
Amoxicillin & enzyme inhibitor  5.1 (1.9-13.9)  -  7.3 (2.7-19.9)
Clarithromycin 11.7 (3.6-37.8) 21.3 (5.0-90.6)  6.3 (0.9-46.3)
Doxycycline  4.3 (1.8-10.4)  2.9 (0.4-20.9)  5.2 (1.9-14.0)
Norfloxacin  9.8 (3.0-31.6) 19.3 (4.5-83.7)  5.0 (0.7-36.6)
Pheniticillin  0.9 (0.1-6.1)  -  0.9 (0.1-6.5)
Sulfamethoxazole & trimethoprim 20.1 (10.7-37.9) 16.6 (5.1-54.4) 23.2 (10.9-49.1)
Trimethoprim  5.6 (1.3-23.1)  9.0 (1.2-67.4)  4.1 (0.6-30.6)
Vancomycin 13.6 (1.7-106.8)  - 15.1 (1.9-120.0)
* Time interval is the interval between the first treatment day with an antibacterial drug and an INR ≥ 6.0.
† Adjusted for gender and age.
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therapy with acenocoumarol or phenprocoumon. It is likely that these results can be 
extrapolated to warfarin. Relative risks varied considerably between the different antibacterial 
drugs, especially after stratification for the time-interval between start of the antibacterial drug 
therapy and the moment of overanticoagulation. The strongest risk increase was associated 
with sulfamethoxazole-trimethoprim. This is in line with an earlier study [32].
Overanticoagulation may be caused by pharmacokinetic or pharmacodynamic interactions 
between antibacterial drugs and coumarins. Pharmacokinetic interactions may be caused 
by plasma protein binding displacement of coumarins or by inhibition of the metabolism of 
coumarins. Plasma protein binding displacement is a rapid and short-lived effect because the 
displaced molecules are rapidly metabolised. A small but transient increase in anticoagulant 
effect can occur [16]. Usually this mechanism plays a minor role compared to other mechanisms 
[16]. It may be clinically relevant in the elderly, however, in whom plasma protein binding 
decreases [36]. Unlike enzyme induction, which may take several days or even weeks to develop, 
inhibition of cytochrome P450 enzymes can occur within two to three days, depending on 
the elimination half-life of the inhibited drug [16]. Pharmacodynamic interactions may result 
from vitamin K deficiency by elimination of bacterial flora in the gut, and by direct inhibition 
of the synthesis of the vitamin K dependent coagulation factors [2, 16]. Pharmacodynamic 
mechanisms take at least several days to develop because of already circulating coagulation 
factors [16]. It has been stated that the contribution of bacterial synthesis to vitamin K status 
in man becomes important only when the dietary intake of the vitamin is markedly decreased 
[12, 37]. Unfortunately, we were not able to investigate this as there were no case patients in 
our study with a low daily intake of vitamin K who had used antibacterial drugs. Although 
acenocoumarol and phenprocoumon have a similar effect on the elimination of bacterial flora 
in the gut and the direct inhibition of the synthesis of vitamin K dependent coagulation factors, 
the pharmacokinetic properties differ distinctly. Especially the variability in elimination kinetics, 
could cause a difference in the contribution of the metabolic component. For amoxicillin, 
relative risks were significantly increased during both time intervals, suggesting that more 
than one mechanism may be involved. In the literature, nothing was found about possible 
pharmacokinetic interactions of coumarins with amoxicillin. Hence, the increased risk during 
the first days after start of amoxicillin is surprising. When amoxicillin was combined with an 
enzyme inhibitor, however, the relative risk was much lower. For clarithromycin, the relative risk 
of overanticoagulation was only significantly increased during the first 3 days after start of use. 
This is in accordance with the literature in which the most frequently suggested mechanism 
is the inhibition of the hepatic cytochrome P450 mixed-function oxidase system, resulting 
in a reduced clearance of coumarin anticoagulants and an increase in its effect [16, 18]. For 
doxycycline, several mechanisms have been suggested, but in all published case reports 
overanticoagulation developed within 7 to 10 days [23, 24]. Our data confirm this. For norfloxacin 
it is clear from our results that the rapid pharmacokinetic interactions are far more important 
than the delayed pharmacodynamic ones. Mechanisms suggested for norfloxacin to increase 
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prothrombin times are plasma protein binding displacement [16] and inhibition of metabolic 
clearance [38]. For sulfamethoxazole-trimethoprim the relative risk of overanticoagulation was 
strongly increased during the first 3 days of antibacterial drug therapy as well as thereafter. 
Sulfonamides can strongly displace coumarin anticoagulants from their plasma protein binding 
sites [16] and it has been suggested that sulfamethoxazole-trimethoprim, which is metabolised 
by the CYP2C9 isoenzyme, increases the anticoagulant effect by inhibiting the metabolism 
of the anticoagulant [39]. The degree of inhibition of the metabolism may be different for 
acenocoumarol and phenprocoumon [40] as acenocoumarol (like warfarin) is predominantly 
metabolised by CYP2C9 [41]. None of the other antibacterial drugs examined is metabolised 
by CYP2C9. Especially after ≥ 4 days, sulfamethoxazole is probably largely responsible for the 
increased prothrombin times considering the lower relative risk we found for trimethoprim 
alone. Vancomycin will probably, as a poorly absorbed drug, mainly reduce the bacterial 
synthesis of vitamin K and thereby increase the INR with a delayed onset [16]. This is compatible 
with our results. However, for vancomycin, as well as for trimethoprim, numbers were too small 
to draw firm conclusions.
Some potential limitations should be considered in the interpretation of our cohort study. 
Selection bias was probably negligible as we identified all users of coumarin anticoagulants 
in a defined population and because regular INR monitoring makes it unlikely that cases 
were missed. Also, information bias is not likely as all data on exposure and outcome were 
recorded similarly for subjects exposed and not exposed to combinations of antibacterial 
drugs and coumarin anticoagulants without prior knowledge of our study hypothesis. 
Potential confounding by gender, age, hepatic dysfunction, hypoalbuminemia, malignancies, 
hyperthyroidism, hypertension, heart failure, low dietary intake of vitamin K, differences in 
duration of follow-up and INR measurement as scheduled, was dealt with in the multivariate 
analyses. Whether the INR assessment on the index date was earlier than according to plan was 
taken into consideration because patients who are prescribed a known potentially hazardous 
combination are more likely to be monitored with short intervals. However, neither adjustment 
for this nor for the average number of assessments during follow-up changed our results. Fever 
may be a confounding factor as a hypermetabolic state produced by fever might potentiate 
the response to coumarin anticoagulants, probably by increasing the catabolism of vitamin K-
dependent coagulation factors [2]. There was, however, no significant difference between the 
frequency of fever in cases on antibacterial drugs and individuals in the rest of the cohort who 
were treated with antibacterial drugs on the index date. Furthermore, we excluded confounding 
by indication, as there was no significant difference in the indication for antibacterial agents 
between cases and the remainder of the cohort. Moreover, confounding by indication would 
not explain the variation in relative risks between antibacterial agents and would occur similarly 
for all antibacterial drugs.
In conclusion, in this population-based cohort study among outpatients of an 
anticoagulation clinic using acenocoumarol or phenprocoumon, several antibacterial drugs 
Overanticoagulation associated with antibacterial drugs 87
were strongly associated with overanticoagulation. The onset of overanticoagulation after 
start of antibacterial drug therapy varied between drugs. The risk was most strongly increased 
by a course of amoxicillin, clarithromycin, norfloxacin and sulfamethoxazole-trimethoprim. 
Awareness of these drug interactions and more frequent monitoring during the initial stages of 
antibacterial drug therapy to maintain patients on coumarins such as warfarin, acenocoumarol 
and phenprocoumon within the recommended therapeutic ranges may minimize the risk of 
bleeding complications.
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Chapter 3.2
Overanticoagulation associated with combined use of antifungal 
agents and coumarin anticoagulants
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ABSTRACT
Introduction: Several case reports have associated combined use of coumarins and antifungal 
agents with overanticoagulation. However, we are not aware of epidemiological studies that 
quantify the risk of overanticoagulation caused by antifungal agents. We conducted a follow-
up study in a large population-based cohort to investigate the antifungal agents that are 
associated with overanticoagulation during therapy with coumarins.
Methods: All patients in the Rotterdam Study who were treated with acenocoumarol or 
phenprocoumon in the study period from April 1, 1991 through December 31, 1998 and for 
whom international normalised ratio (INR) data were available, were followed until an INR ≥ 6.0, 
the end of their treatment, death or end of the study period. Proportional hazards regression 
analysis was used to estimate the risk of an INR ≥ 6.0 in relation to concomitant use of a coumarin 
anticoagulant and antifungal agents after adjustment for several potentially confounding 
factors such as age, gender, hepatic dysfunction, malignancies, and heart failure.
Results: Of the 1124 patients in the cohort, 351 had an INR ≥ 6.0. The incidence rate was 6.9 per 
10,000 treatment days. Oral miconazole most strongly increased the risk of overanticoagulation 
with an adjusted relative risk of 36.6 (95% confidence interval: 12.4-108.0).
Conclusions: In this study among outpatients of an anticoagulant clinic on coumarins, oral 
miconazole was especially strongly associated with overanticoagulation. Awareness of these 
drug interactions and more frequent monitoring of INR values during the initial stages of 
treatment with some antifungal drugs in patients on coumarins may minimise the risk of bleeding 
complications. The concurrent use of miconazole and coumarins should be discouraged.
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INTRODUCTION
Coumarin anticoagulants are used extensively for the treatment and long-term prevention of 
thromboembolic diseases [1, 2]. These drugs induce their anticoagulant effect by antagonising 
vitamin K, thereby impairing the biological activity of the vitamin K-dependent coagulation 
factors [3, 4]. The risk of bleeding, the main complication of coumarin anticoagulants, is 
influenced by the intensity of anticoagulant therapy [5-9], by the underlying clinical disorders 
of the patient [9, 10], and by the concomitant use of other drugs [2, 11, 12]. This risk sharply 
increases when the international normalised ratio (INR) is ≥ 6.0 [13, 14]. Growing experience 
with anticoagulant therapy, and increased understanding of drug interactions has reduced 
the number of bleeding complications [15]. Several drugs can affect the INR during coumarin 
anticoagulant therapy by different mechanisms [11, 12, 16, 17]. During the past decades, 
many case reports and small-scale experiments associated the use of antifungal agents 
with overanticoagulation [18-25]. Several reviews discussed the clinical evidence for and 
importance of interactions involving antifungal agents [26-31]. So far as we are aware, however, 
epidemiological studies quantifying the risk of overanticoagulation by antifungal agents in a 
nonselected population on coumarins have not been done before. Therefore we conducted a 
follow-up study in a large population-based cohort to investigate which antifungal agents are 
associated with overanticoagulation during therapy with coumarins. 
METHODS
Setting
Data were obtained from the Rotterdam Study and from the regional outpatient anticoagulation 
clinic. The Rotterdam Study is a prospective population-based cohort study of neurologic, 
cardiovascular, locomotor and ophthalmologic diseases. All inhabitants of Ommoord, a suburb 
of the city of Rotterdam in the Netherlands, aged 55 years or more were invited in 1990-1993 to 
participate in the study. The rationale and design of this study have been described elsewhere 
[32]. The cohort encompasses 7983 individuals who were all interviewed and investigated at 
baseline. The anticoagulation clinic monitors all inhabitants of Ommoord with an indication for 
anticoagulant therapy. The type of anticoagulant is chosen by the physician. INRs are monitored 
every one to six weeks, dependent on the stability of the INR. Doses are adjusted on the basis 
of the INR of the patient by computerised dose calculations. More than 99% of participants 
have their drug prescriptions filled at seven regional pharmacies, which are fully computerised. 
Complete data on drug use were available as of January 1, 1991. The pharmacy data include the 
Anatomical Therapeutical Chemical (ATC)-code [33], the filling date, the total amount of drug 
units per prescription, the prescribed daily number of units, and product name of the drugs.
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Cohort and outcome definition
The study cohort consisted of all 1124 patients in the Rotterdam Study, who were treated 
with acenocoumarol or phenprocoumon in the study period between April 1, 1991 and 
December 31, 1998 and for whom there were INR data from the anticoagulation clinic during 
their treatment. The start date of April 1, 1991 was chosen to ensure that at least 3 months 
of medication history from the pharmacy was available for every cohort member. The cohort 
included prevalent users of coumarins on the starting date and incident users during the study 
period. All cohort members were followed as of April 1, 1991 for prevalent users and from their 
first INR assessment for incident users. Both groups were followed until the first occurrence of 
an INR ≥ 6.0, the last INR assessment because of the end of their treatment, death or end of 
the study period, whichever came first. This means that during follow-up all study members 
underwent anticoagulation and were regularly assessed for the INR. The date on which an INR 
≥ 6.0 was encountered was defined as the index date. 
Exposure definition
We assessed exposure to the following antifungal agents on the index date: the imidazoles - 
bifonazole, butaconazole, clotrimazole, econazole, ketoconazole, miconazole, and sulconazole; 
the triazoles - fluconazole, itraconazole, and terconazole; the polyene macrolides - amphotericin 
and nystatin; the allylamine terbinafine; flucytosine; and griseofulvin. The different routes of 
administration were studied separately.
Cofactors
The following baseline patient characteristics were considered as potential determinants for 
affecting the response of the INR to coumarin anticoagulants: gender, age, hepatic dysfunction 
(defined as serum aminotransferases of greater than 2 times the upper level of normal), 
hypoalbuminemia (≤ 35 g/l), malignancies, hyperthyroidism, hypertension (either a systolic 
blood pressure ≥ 160 mm Hg or a diastolic blood pressure ≥ 95 mm Hg, or both, or use of 
antihypertensives), and heart failure. In addition, we considered duration of follow-up and 
whether the INR measurement on the index date was earlier than expected according to the 
INR monitoring scheme. We considered all agents as potentially confounding drugs that have 
have been associated with overanticoagulation in the medical literature or discontinuation of 
known inducers of cytochrome P450 (CYP) enzymes within the week before the index date [17, 
34]. The cessation of drugs that induce the microsomal oxidase system can down-regulate the 
metabolism of coumarins in patients who are stably anticoagulated. This may lead to increased 
levels of circulating anticoagulant and thereby cause overanticoagulation. Furthermore, to 
study the potentially confounding effect of fever or indication for treatment, we validated by 
reference to the medical records of the general practitioner all cases and a random sample from 
the remainder of the cohort who had been treated with oral antifungal agents on the index 
date.
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Statistical analysis
Incidence rates were calculated by dividing the number of cases of an INR ≥ 6.0 by the 
number of days on combined use of a coumarin anticoagulant and an antifungal agent. To 
assess antifungal agents that were independently associated with an INR ≥ 6.0, all occurring 
combinations of a coumarin anticoagulant and an antifungal agent were included separately in 
a Cox proportional hazards regression model for time-dependent variables to compute relative 
risks and their 95% confidence intervals (95%CI) [35]. The model compares exposure to this 
combination at the index date of each case with that of all subjects in the cohort who are at risk 
for the outcome of interest. To adjust for potential confounding, cofactors that were associated 
with an INR ≥ 6.0 in the univariate analysis were included in the multivariate model, in addition 
to gender and age, if this caused a change in the point estimate of more than 5 percent. If 
possible, separate analyses were performed for acenocoumarol and phenprocoumon.
RESULTS
Of the 1124 patients in the cohort, 351 had an INR ≥ 6.0 after April 1, 1991. The incidence rate 
was 6.9 per 10,000 treatment days. Baseline characteristics of patients with an INR ≥ 6.0 and the 
total population are shown in Table 1. Women and older patients had a higher risk of an INR 
≥ 6.0. The risk of overanticoagulation was lowest with phenprocoumon. Hepatic dysfunction, 
malignancies and heart failure were associated with an increased risk of an INR ≥ 6.0 in the 
univariate analysis. There was no difference in duration of follow-up between cases and the 
total cohort (mean ± SD, 559 ± 481 days). The INR measurement on the index date was earlier 
than planned in 8.6% of the cases and in 5.6% of the total cohort (p = 0.0048).
Nine different antifungal agents in different formulations were used during the study period; 
four of these were not used in cases (Table 2). Patients exposed to the following antifungal 
applications did not have a higher risk of overanticoagulation: bifonazole (cutaneous) (p = 0.95), 
clotrimazole (vaginal) (p = 0.97), fluconazole (oral) (p = 0.87), amphotericin (oral) (p = 0.89), 
nystatin (cutaneous) (p = 0.93) and terbinafine (both oral and cutaneous) (p = 0.76 and p = 0.82, 
respectively). Thirteen (4%) patients used antifungal agents on the index date. Four antifungal 
agents were univariately as well as multivariately associated with overanticoagulation (Table 2). 
The relative risk varied considerably between the different agents and the different routes of 
administration. Oral miconazole most strongly increased the risk of overanticoagulation. After 
adjustment for confounding factors, the relative risk was 36.6 (95%CI: 12.4-108.0). For the 
vaginal and cutaneous administration of miconazole, relative risks were substantially lower: 
4.3 (95%CI: 0.6-31.6) and 1.4 (95%CI: 0.4-4.3), respectively. None of the case patients receiving 
antifungal agents had fever on the index date or in the preceding week. Furthermore, there was 
no difference in the indication for antifungal agents between cases and the remainder of the 
cohort (mainly treatment of candidiasis, p = 0.87).
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Stratified analyses by type of anticoagulant could be performed only for oral miconazole. 
For patients on acenocoumarol, the adjusted relative risk of oral miconazole was 35.1 (95%CI: 
10.1-121.8). For users of phenprocoumon, the adjusted relative risk of oral miconazole was 16.5 
(95%CI: 1.3-212.6).
Table 1. Association between overanticoagulation (INR ≥ 6.0) and sociodemographic and comorbid conditions
Patients with
INR ≥ 6.0
Total study
Cohort
RR* (95%CI)
n = 351 n = 1124
Gender
 Male 177 (50.4%)  534 (47.5%) 1.00 Reference
 Female 174 (49.6%)  590 (52.5%) 1.44 (1.17-1.77)
Age (yrs, mean ± SD)  73 ± 8   72 ± 8 1.04 (1.03-1.05)
 55-64  49 (14.0%)  218 (19.4%) 1.00 Reference
 65-74 152 (43.3%)  496 (44.1%) 1.28 (0.92-1.76)
 75-84 124 (35.3%)  340 (30.2%) 1.85 (1.33-2.58)
 ≥ 85  26 (7.4%)   70 (6.2%) 3.17 (1.96-5.14)
Type of anticoagulant
 Acenocoumarol 295 (84.0%)  951 (84.6%) 1.00 Reference
 Phenprocoumon  56 (16.0%)  173 (15.4%) 0.57 (0.43-0.76)
Hepatic dysfunction†
 Absent 233 (66.4%)  757 (67.3%) 1.00 Reference
 Present   3 (0.8%)   12 (1.1%) 3.75 (1.18-11.9)
Hypoalbuminemia†
 Absent 243 (69.2%)  781 (69.5%) 1.00 Reference
 Present   1 (0.3%)    2 (0.2%) 1.16 (0.16-8.30)
Malignancies†
 Absent 308 (87.7%) 1030 (91.6%) 1.00 Reference
 Present  43 (12.3%)   94 (8.4%) 1.67 (1.21-2.30)
Hyperthyroidism†
 Absent 313 (89.2%) 1013 (90.1%) 1.00 Reference
 Present  12 (3.4%)   37 (3.3%) 1.51 (0.85-2.70)
Hypertension†
 Absent 161 (45.8%)  585 (52.0%) 1.00 Reference
 Present 148 (42.2%)  434 (38.6%) 1.08 (0.86-1.35)
Heart failure†
 Absent 268 (76.3%)  983 (87.5%) 1.00 Reference
 Present  83 (23.7%)  141 (12.5%) 1.63 (1.27-2.09)
* Univariate analyses of relative risks were performed with a Cox proportional-hazards model. Relative risks cannot be calculated with the 
numbers in this table because controls may later become cases.
† Totals do not add up to column totals because of missing values.
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DISCUSSION
The main finding in this population-based cohort study is that some antifungal agents were 
associated with a strongly increased risk of overanticoagulation during coumarin anticoagulant 
therapy with acenocoumarol or phenprocoumon. The strongest risk increase was associated 
with oral miconazole. In many countries warfarin is the coumarin of first choice. The results of 
our study, however, will largely apply to these countries as well. First, the difference in half-life 
between coumarins will only influence the time of onset and the duration of overanticoagulation 
[17], but not necessarily affect the baseline risk. Second, drugs that interact by inhibiting the 
isozyme CYP2C9 will affect both acenocoumarol and warfarin [36].
Relative risks varied widely between the different antifungal agents and between the different 
routes of administration. Displacement of anticoagulant drugs from protein binding sites [18, 
37] and inhibition of hepatic metabolism [26-31] has been suggested as potential causes. Plasma 
protein binding displacement usually plays a minor role compared to other mechanisms [16]. It 
may be clinically relevant in the elderly, however, in whom plasma protein binding decreases [38]. 
Antifungal agents, which act through inhibition of the fungal CYP, have the potential to inhibit 
Table 2. Association between overanticoagulation (INR ≥ 6.0) and use of antifungal agents
Antifungal agent Patients with 
INR ≥ 6.0
Total study 
cohort*
IR† RRcrude
‡ (95%CI) RRadj.
§ (95%CI)
n = 351 (No.) n = 1124 (No.)
Imidazoles
 Bifonazole, cutaneous 0   2  - P = 0.95
 Clotrimazole, cutaneous 1  13 61.3 20.0 (2.6-152.7) 13.8 (1.8-108.4)
 Clotrimazole, vaginal 0   1  - P = 0.97
 Ketoconazole, cutaneous 2 500  0.3 0.9 (0.2-3.8) 1.1 (0.3-4.3)
 Miconazole, oral 4  24 94.1 39.7 (13.5-116.4) 36.6 (12.4-108.0)
 Miconazole, vaginal 1  44  8.7 5.5 (0.8-40.2) 4.3 (0.6-31.6)
 Miconazole, cutaneous 3 589  1.4 1.2 (0.4-3.8) 1.4 (0.4-4.3)
Triazoles
 Fluconazole, oral 0   5  - P = 0.87
 Itraconazole, oral 1   9 25.1 15.2 (1.9-120.6) 13.9 (1.7-115.0)
Polyene macrolides
 Amphotericin, oral 0  11  - P = 0.89
 Nystatin, cutaneous 0   4  - P = 0.93
 Nystatin, oral 1  24  9.2 11.1 (1.5-81.7) 10.3 (1.4-76.6)
Allylamines
 Terbinafine, cutaneous 0  29  - P = 0.82
 Terbinafine, oral 0  49  - P = 0.76
* In this time-dependent analysis, exposure in case patients and in the rest of the cohort is assessed at the time of the outcome in each case 
patient (index date). Because control patients can be used multiple times, the number of assessments in the reference group is much larger than 
the number of individuals. Hence, crude relative risks cannot be calculated with the numbers in Table 2.
† Expressed as the number of patients with an INR ≥ 6.0 per 10,000 days on combined use of a coumarin anticoagulant and an antifungal agent.
‡ If none of the patients with an INR ≥ 6.0 was exposed, p-values are given instead of relative risks.
§ Adjusted for gender, age, malignancies and heart failure.
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human CYP-dependent drug metabolism as well [26, 37, 39]. Ketoconazole and itraconazole, 
for instance, are potent inhibitors of CYP3A4, whereas fluconazole and miconazole are potent 
inhibitors of CYP2C9 [30]. CYP2C9 is the principal enzyme that catalyses biotransformation 
of acenocoumarol and warfarin [40, 41]. Phenprocoumon is also metabolised by CYP2C9 but 
probably to a lesser extent [36]. 
Although oral application of miconazole is primarily intended for local oral and gastrointestinal 
treatment, 25% to 30% is systemically absorbed [42]. As expected, we found that the highest 
relative risk for miconazole was via the oral route, whereas the relative risk was barely increased 
after cutaneous application of miconazole. Although the relative risk was increased after 
vaginal administration of miconazole, the risk increase was not statistically significant. Despite 
this, it is possible that sometimes sufficient amounts of miconazole are absorbed through 
this route to interact with coumarins. This would be in line with a case report that suggested 
that the daily administration of miconazole to an inflamed postmenopausal atrophic vaginal 
epithelium might lead to potentiation of coumarin anticoagulants [19]. The fact that we found 
a twice-stronger risk increase by miconazole in patients on acenocoumarol than in patients on 
phenprocoumon is explained by the fact that phenprocoumon is metabolized to a lesser extent 
by CYP2C9 than acenocoumarol. Potent inhibitors of CYP2C9, like miconazole, may completely 
suppress the body clearance of (S)-acenocoumarol, converting it from a clinically inactive 
drug into a potent anticoagulant [40]. Ketoconazol, administered by the cutaneous route, is 
assumed not to interact with coumarins. Although two case patients were exposed to topical 
ketoconazole on the index date, the relative risk of overanticoagulation was not increased. For 
cutaneous clotrimazole and oral itraconazole and nystatin we found a statistically significant 
increase in relative risks. It should be emphasized, however, that these figures should be 
cautiously interpreted because they are based on only one case per agent. Our results suggest 
that terbinafine can be safely coadministered with coumarins. This is in accordance with the 
literature, according to which terbinafine only inhibits the isozyme CYP2D6 [30]. In addition, it 
should be emphasized, however, that numbers were low. Hence, the absence of an association 
does not exclude the possibility of such an interaction in some vulnerable individuals. 
Some potential limitations of our cohort study should be considered. Selection bias was 
probably negligible because we identified all users of coumarin anticoagulants in a defined 
population and because regular INR monitoring makes it unlikely that cases were missed. 
Further, information bias is not likely because all data on exposure and outcome were recorded 
similarly without prior knowledge of our study hypothesis. Potential confounding by gender, 
age, hepatic dysfunction, hypoalbuminemia, malignancies, hyperthyroidism, hypertension, 
heart failure, differences in duration of follow-up and INR measurement as scheduled was dealt 
with in the multivariate analyses. Whether the INR assessment on the index date was earlier than 
according to plan was taken into consideration because patients who are prescribed a known 
potentially hazardous combination are more likely to be monitored at short intervals. However, 
neither adjustment for this nor adjustment for the average number of assessments during 
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follow-up changed our results. Fever may be a confounding factor, because a hypermetabolic 
state produced by fever might potentiate the response to coumarin anticoagulants, probably by 
increasing the catabolism of vitamin K-dependent coagulation factors [2]. There was, however, 
no statistically significant difference between the frequency of fever in cases on antifungal 
agents and individuals in the remainder of the cohort who were treated with antifungal agents 
on the index date. Furthermore, we excluded confounding by indication, because there was 
no statistically significant difference in the indication for antifungal agents between cases and 
users of these agents in the remainder of the cohort. A limitation of our study, however, is that 
numbers were low.
In conclusion, in this population-based cohort study among outpatients of an 
anticoagulation clinic on coumarins, oral miconazole was especially strongly associated with 
overanticoagulation. Awareness of these drug interactions and more frequent monitoring 
during the initial stages of some antifungal drugs in patients on coumarins may minimise the 
risk of bleeding complications. The concurrent use of miconazole and coumarins should be 
discouraged. 
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Chapter 3.3
Overanticoagulation associated with combined use of lactulose 
and coumarin anticoagulants
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ABSTRACT
Some medical textbooks on drug interactions take note of the potential interaction between 
laxatives and coumarin anticoagulants, but epidemiological evidence that this interaction is of 
practical importance is lacking. We conducted a follow-up study in a large population-based 
cohort to investigate which laxatives are associated with overanticoagulation during therapy 
with acenocoumarol or phenprocoumon. Of the 1124 patients in the cohort, 351 developed 
an international normalised ratio ≥ 6.0. The only laxative with a moderate but significantly 
increased relative risk of overanticoagulation was lactulose (relative risk 3.4, 95% confidence 
interval: 2.2-5.3). In view of the widespread use of lactulose, especially among the elderly, 
awareness of this potential drug interaction is required.
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INTRODUCTION
Coumarin anticoagulants are extensively used for the treatment and long-term prevention 
of thrombo-embolic diseases [1]. The risk of bleeding, the main complication of coumarin 
anticoagulants, is influenced by the intensity of anticoagulant therapy [2,3], by the underlying 
clinical disorders of the patient [3], and by the concomitant use of other drugs [4]. This risk 
sharply increases when the international normalised ratio (INR) is ≥ 6.0 [5]. Several drugs can 
affect the INR during coumarin anticoagulant therapy by different mechanisms [4]. Laxatives, 
which shorten the transit time in the gut, might be expected to decrease the absorption of both 
vitamin K and coumarin anticoagulants. Despite warnings in the medical literature, there seems 
to be no epidemiological evidence that this interaction is of any practical importance [6]. 
Therefore, we conducted a follow-up study in a large population-based cohort to investigate 
whether laxatives are associated with overanticoagulation during therapy with coumarins. 
METHODS
The study cohort consisted of all 1124 patients in one anticoagulation clinic, who were treated 
with acenocoumarol or phenprocoumon in the study period between April 1, 1991 and December 
31, 1998 and for whom there were INR data during their treatment. All cohort members were 
followed until the first occurrence of an INR ≥ 6.0, the last INR assessment because of the end of 
their treatment, death or end of the study period, whichever came first. For laxatives for which 
an association was found, a dose and duration effect was studied. The duration of exposure to 
a laxative on the day of overanticoagulation was divided into tertiles: ≤ 27 days; > 27 days to 
≤ 97 days; and > 97 days. Doses were divided into tertiles: ≤ 7.5 gram; > 7.5 gram to ≤ 12 gram; 
and > 12 gram. The following baseline patient characteristics were considered as potential 
determinants for affecting the response of the INR to coumarin anticoagulants: gender, age, 
hepatic dysfunction, hypoalbuminemia, malignancies, hyperthyroidism, hypertension, heart 
failure, and low dietary daily intake of vitamin K. Incidence rates were calculated by dividing 
the number of cases of an INR ≥ 6.0 by the number of days on combined use of a coumarin 
anticoagulant and a laxative. To assess laxatives which were independently associated with an 
INR ≥ 6.0, all occurring combinations of a coumarin anticoagulant and a laxative were included 
separately in a Cox proportional hazards regression model for time-dependent variables to 
compute relative risks and their 95% confidence intervals (95%CI) [7]. To adjust for potential 
confounding, cofactors that were associated with an INR ≥ 6.0 in the univariate analysis were 
included in the multivariate model, in addition to gender and age, if this caused a change in the 
point estimate of more than 5 percent. 
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RESULTS
Of the 1124 patients in the cohort, 351 developed an INR ≥ 6.0 after April 1, 1991. The incidence 
rate was 6.9 per 10,000 treatment days. Women and older patients had a higher risk of an INR 
≥ 6.0. The risk of overanticoagulation was lowest with phenprocoumon. Hepatic dysfunction, 
malignancies, heart failure and a low dietary daily intake of vitamin K were associated with an 
increased risk of an INR ≥ 6.0 in the univariate analysis.
Eight different laxatives were used during the study period, of which three were not used 
in cases. The remaining five laxatives and the relative risks of overanticoagulation are given in 
Table 1. Fifty-one cases (15%) used laxatives on the index date. Lactulose was the one agent 
which was univariately as well as multivariately associated with overanticoagulation. After 
adjustment for confounding factors the relative risk was 3.4 (95%CI: 2.2-5.3).
Stratification by the duration of laxative exposure on the day of overanticoagulation revealed 
a significantly protective effect of lactulose during the first 27 days of use, the relative risk being 
0.5 (95%CI: 0.3-0.8). The relative risk was 1.7 (95%CI: 0.9-3.0) for > 27 days to ≤ 97 days and 2.1 
(95%CI: 1.2-3.7) for more than 97 days of lactulose use. A clear dose-effect relationship could 
not be detected. The relative risks for the subsequent dose levels were 1.7 (95%CI: 0.9-3.1), 2.0 
(95%CI: 1.0-4.9) and 1.9 (95%CI: 0.9-4.0).
DISCUSSION
The main finding in this population-based cohort study is that among laxatives, only lactulose 
was associated with an increased risk of overanticoagulation during coumarin anticoagulant 
therapy with acenocoumarol or phenprocoumon. Laxatives shorten the transit time in the 
gut and might be expected to decrease the absorption of both the coumarin anticoagulants 
and vitamin K. If the absorption of vitamin K is stronger impaired than that of coumarins, 
overanticoagulation might occur. It seems likely that such effects on the INR would more or 
Table 1. Association between overanticoagulation (INR ≥ 6.0) and use of laxatives
Laxative Patients with INR ≥ 6.0 Total population* RRcrude† (95%CI) RRadj.‡ (95%CI)
n = 351 n = 1124
Liquid paraffin  1  135 1.2 (0.2-8.9) 0.7 (0.1-5.5)
Colocynthine preparation  4  430 2.3 (0.8-6.1) 1.9 (0.6-6.1)
Psyllium seeds  4  983 1.0 (0.4-2.6) 1.3 (0.3-5.1)
Wheat fibre  6  975 1.5 (0.7-3.4) 2.0 (0.6-6.3)
Lactulose 36 3521 2.6 (1.8-3.6) 3.4 (2.2-5.3)
* In this time-dependent analysis, exposure in case patients and in the rest of the cohort is assessed at the time of the outcome in each case 
patient (index date). Because control patients can be used multiple times, the number of assessments in the reference group is much larger than 
the number of individuals. Hence, crude relative risks cannot be calculated with the numbers in Table 1.
† If none of the patients with an INR ≥ 6.0 was exposed, P-values are given instead of relative risks.
‡ Adjusted for gender, age, heart failure, low dietary intake of vitamin K.
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less apply to all laxatives. In addition to that, the long-term oral administration of paraffin 
may interfere with the absorption of the fat-soluble vitamin K and result in a deficiency of this 
substance and an increase in INR. The fact that we did not find an association for paraffin may 
have had two reasons. The first is that there is no real association, all the more as the medical 
literature mentions only a theoretical possibility that paraffin affects the response to coumarin 
anticoagulants. The second may be that in our study population paraffin was only used on a 
short-term basis. With the administration of lactulose the colonic pH will decrease below pH 7.4 
[8,9]. This could theoretically have resulted in an increase in the absorption of phylloquinone 
(vitamin K1) and menaquinone (vitamin K2) in the colon [10,11]. This is in line with the observed 
protective effect during the first month of lactulose therapy. During long-term use, however, 
another mechanism seems to play a role. We can only speculate about this mechanism, but the 
biologically most plausible one is that lactulose has its influence on the faecal flora responsible 
for menaquinone production. Reported effects of lactulose on the faecal flora are conflicting, 
but counts of the menaquinone-producing bacteria were reported to decrease after lactulose 
administration [12]. The fact that only lactulose and none of the other laxatives was associated 
with a significantly increased risk of overanticoagulation could have been due to the lower 
exposure to these agents in our study. Although our study pertained to the coumarins 
acenocoumarol and phenprocoumon, it is likely that the results can be extrapolated to warfarin, 
because here vitamin K plays a similar role.
In conclusion, in this population-based cohort study among outpatients of an anticoagulation 
clinic on coumarins, lactulose was associated with overanticoagulation. In view of the 
widespread use of lactulose, especially among the elderly, awareness of this potential drug 
interaction is required.
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Chapter 3.4
Allelic variants of cytochrome P450 2C9 modify the interaction 
between NSAIDs and coumarin anticoagulants
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ABSTRACT
Introduction: Cytochrome P450 2C9 (CYP2C9) plays a key role in the metabolism of coumarin 
anticoagulants and nonsteroidal anti-inflammatory drugs (NSAIDs). Because CYP2C9 is a 
genetically polymorphic enzyme, genetic variability could play an important role in the 
potential interaction between NSAIDs and coumarins. We investigated whether NSAIDs were 
associated with overanticoagulation during therapy with coumarins, and evaluated the effect 
of the CYP2C9 polymorphisms on this potential interaction.
Methods: We conducted a population-based cohort study among patients of an anticoagulation 
clinic who were treated with acenocoumarol or phenprocoumon between April 1, 1991 and May 
31, 2003 and whose CYP2C9 status was known. Patients were followed until an international 
normalised ratio (INR) ≥ 6.0, end of treatment, death or end of the study. Proportional hazards 
regression analysis was used to estimate the risk of an INR ≥ 6.0 in relation to concomitant use 
of a coumarin anticoagulant and NSAIDs after adjustment for several potentially confounding 
factors. In order to study effect modification by CYP2C9 genotype, stratified analyses were 
performed for wild type patients and patients with a variant genotype.
Results: Of the 973 patients in the cohort, 415 had an INR ≥ 6.0. Several NSAIDs increased the 
risk of overanticoagulation. The risk of overanticoagulation was almost fourfold in coumarin-
treated patients on NSAIDs with a variant allele.
Conclusions: Several NSAIDs increased the risk of overanticoagulation. Allelic variants of CYP2C9 
modified this risk. Awareness of this drug interaction and more frequent monitoring of the INR 
of patients receiving these drugs are warranted.
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INTRODUCTION
Coumarin anticoagulants are associated with life-threatening drug-drug interactions because 
they exhibit a narrow therapeutic range, high protein binding and cytochrome P450 (CYP)-
dependent, capacity-limited hepatic clearance [1]. A considerable number of interactions with 
coumarin anticoagulants have been reported and summarised in a number of comprehensive 
reviews [1-5]. Nonsteroidal anti-inflammatory drugs (NSAIDs) increase the risk of bleeding in 
patients on coumarin anticoagulants, mainly due to inhibition of platelet aggregation [1, 2]. 
This pharmacodynamic interaction, however, is not accompanied by a change in prothrombin 
time as measured by the international normalised ratio (INR) [6, 7]. The cytochrome P450 2C9 
(CYP2C9) enzyme plays a key role in the metabolism of coumarin anticoagulants and NSAIDs [8]. 
This raises the possibility of a pharmacokinetic drug interaction resulting in an increased INR. 
CYP2C9 is a genetically polymorphic enzyme. Allelic variants of CYP2C9, CYP2C9*2 (Arg144Cys) 
and CYP2C9*3 (Ile359Leu), code for enzymes with approximately 12% and 5% of the enzymatic 
activity of the wild type genotype CYP2C9*1 (Arg144/Ile359) respectively [9-11]. Therefore, 
genetic variability might play an important role in this potential drug interaction.
In view of the risks of an increased INR, such as bleeding, we investigated whether NSAIDs 
were associated with overanticoagulation during therapy with coumarin anticoagulants and 
evaluated the effect of the CYP2C9 polymorphisms on this potential interaction.
METHODS
Setting
Data were obtained from the regional outpatient anticoagulation clinic, and from the Rotterdam 
Study, a prospective population-based cohort study in which 7983 inhabitants aged 55 years 
or over participate since 1990. The Medical Ethics Committee of the Erasmus MC approved the 
study, and written informed consent was obtained from all participants. The rationale and design 
of this study have been described elsewhere [12]. All participants were extensively interviewed 
and investigated at baseline. Blood was taken for the assessment of several laboratory 
values. The anticoagulation clinic in the Rotterdam-Rijnmond area monitors all inhabitants of 
Ommoord with an indication for anticoagulant therapy. The choice of anticoagulant is made 
by the physician. Prothrombin times are monitored every one to six weeks by reference to the 
INR, depending on the stability of the anticoagulant level. Doses are adjusted on the basis of 
the target range of the INR of the patient by computerised dose calculations. We used data 
from April 1, 1991 through May 31, 2003 that were linked to the Rotterdam Study. More than 
99% of participants fill their drug prescriptions at seven regional pharmacies, which are fully 
computerised. Complete data on drug use were available as of 1 January 1991. The pharmacy 
data include the Anatomical Therapeutical Chemical (ATC)-code [13], the filling date, the total 
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amount of drug units per prescription, the prescribed daily number of units, and product name 
of the drugs.
Cohort and outcome definition
The study cohort consisted of all 973 patients in the Rotterdam Study who were treated with 
acenocoumarol or phenprocoumon between April 1, 1991 and May 31, 2003, for whom INR 
data from their treatment history were available, and whose CYP2C9 status was known. The 
start date of April 1 was chosen to ensure that at least 3 months of medication history from 
the pharmacy was available for every cohort member. All cohort members were followed as of 
April 1, 1991 for prevalent users of coumarins and from their first INR assessment for incident 
users. Both groups were followed until the first occurrence of an INR ≥ 6.0 (at which level the risk 
of bleeding sharply increases), the last INR assessment because of the end of their treatment, 
death or end of the study period, whichever came first. The date on which an INR ≥ 6.0 was 
encountered was defined as the index date.
Genotyping
Genotyping for the CYP2C9*2 and CYP2C9*3 allele variants was performed by using polymerase 
chain reaction followed by restriction enzyme digestion analysis [14]. All CYP2C9*2 and 
CYP2C9*3 heterozygote and homozygote variants were reanalyzed. Patients in whom neither 
CYP2C9*2 nor CYP2C9*3 alleles were detected were regarded as wild type.
Cofactors
The following baseline patient characteristics were considered as potential confounders 
or effect modifiers: gender, age, target INR level, hepatic dysfunction (defined as serum 
aminotransferases > 2x the upper level of normal), hypoalbuminemia (≤ 35 g/l), malignancies, 
hyperthyroidism, hypertension (systolic blood pressure ≥ 140 mm Hg and/or diastolic blood 
pressure ≥ 90 mm Hg or use of antihypertensives), heart failure, low dietary intake of vitamin K 
(< 1 µg/kg/day) and CYP2C9 genotype. In addition, we considered use of antibacterial drugs on 
the index date, duration of follow-up and whether the INR measurement on the index date was 
earlier than according to the INR monitoring scheme. Furthermore, we gathered data on the 
indication for NSAIDs from medical records. We did this validation for all cases and a random 
sample from the remainder of the cohort who all had been treated with NSAIDs on the index 
date.
Statistical analysis
Allele and genotype proportions were tested for deviations from Hardy-Weinberg equilibrium by 
using a χ2-test. Incidence rates of overanticoagulation were calculated by dividing the number 
of cases of an INR ≥ 6.0 by the number of days on combined use of a coumarin anticoagulant 
and an NSAID. To assess NSAIDs which were independently associated with an INR ≥ 6.0, all 
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occurring combinations of a coumarin anticoagulant and an NSAID were included separately in 
a Cox proportional hazards regression model for time-dependent variables to compute relative 
risks and their 95% confidence intervals (95%CI) [15]. The model compares exposure to this 
combination on the index date of each case with that of all other non-censored subjects in the 
cohort on the same date as the case. To adjust for potential confounding, cofactors that were 
associated with an INR ≥ 6.0 in the univariate analysis were included in the multivariate model 
if this caused a change in the point estimate of more than 5 percent. In order to study effect 
modification, patients were stratified as wild type (CYP2C9*1/*1 homozygotes) and variant (1 
or 2 of the mutant alleles CYP2C9*2 or CYP2C9*3). These analyses were also performed for the 
separate coumarins.
RESULTS
Of the 973 patients in the cohort, 415 had an INR ≥ 6.0 at an incidence rate of 5.1 per 10,000 
treatment days. Baseline characteristics of patients with an INR ≥ 6.0 and the total cohort are 
shown in Table 1. Women and older patients had a significantly higher risk of an INR ≥ 6.0. 
There were 668 patients (68.7%) with the wild type genotype, and 305 (31.3%) with a variant 
genotype. The frequencies of the CYP2C9*2 and CYP2C9*3 alleles were 13.5% and 4.1%, 
respectively. Allele and genotype proportions were in Hardy-Weinberg equilibrium. All patients 
were of Caucasian origin. None of the individual genotypes had a statistically significantly 
higher risk of overanticoagulation than the wild type genotype. The risk of overanticoagulation 
was lowest with phenprocoumon. Patients targeted at higher INR levels had a higher risk of 
overanticoagulation, but the differences with the lowest target level were not statistically 
significant. Hepatic dysfunction, hypoalbuminemia, malignancies and heart failure were 
associated with an increased risk of an INR ≥ 6.0 in the univariate analysis. Patients who used 
antibacterial drugs on the index date had a significantly higher risk of overanticoagulation (RR 
4.85, 95%CI: 3.57-6.58). There was no difference in duration of follow-up between patients with 
an INR ≥ 6.0 and the total cohort (mean ± SD, 763 ± 737 days). The INR measurement on the 
index date was earlier than scheduled in 16.7% of the cases and in 10.9% of the total cohort 
(p = 0.001).
Fourteen different NSAIDs were used during the study period, of which 6 were not used in 
patients with an INR ≥ 6.0 (Table 2). Thirty-five cases (8.4%) used NSAIDs on the index date 
(Table 1). Incidence rates for the individual NSAIDs are presented in Table 2. Four NSAIDs were 
univariately as well as multivariately associated with an INR ≥ 6.0. There was no difference in the 
indication for NSAIDs between cases and the remainder of the cohort (mainly osteoarthritis).
Because numbers per individual NSAID were too low to study effect modification by CYP2C9 
genotype, exposure to NSAIDs was pooled. Table 3 shows the effect of the CYP2C9 genotype 
on the drug interaction between coumarin anticoagulants and NSAIDs. The interaction term 
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between CYP2C9 genotype and the pooled exposure was highly statistically significant 
(p = 0.009). The adjusted relative risk of the pooled exposure was 1.62 (95%CI: 1.03-2.57) in 
patients with the wild type genotype, and 3.76 (95%CI: 2.09-6.79) in patients with a variant 
genotype (Table 3). Stratified analyses by the type of anticoagulant revealed a statistically 
significant interaction term between exposure and CYP2C9 genotype for patients on 
acenocoumarol (p = 0.02) but not for phenprocoumon (p = 0.14).
Table 1. Baseline characteristics of patients with an INR ≥ 6.0 and the total cohort
Patients with 
INR ≥ 6.0
Total cohort RR* (95%CI)
n = 415 n = 973
Gender
 Male 206 (49.6%) 475 (48.8%) 1.00 Reference
 Female 209 (50.4%) 498 (51.2%) 1.70 (1.40-2.06)
Age (yrs, mean (SD))  72 (7)  71 (8) 1.03 (1.02-1.05)
 55-64  75 (18.1%) 222 (22.8%) 1.00 Reference
 65-74 191 (46.0%) 438 (45.0%) 1.19 (0.91-1.55)
 75-84 132 (31.8%) 272 (28.0%) 1.64 (1.23-2.19)
 ≥ 85  17 (4.1%)  41 (4.2%) 2.47 (1.45-4.22)
Genotype
 *1/*1 282 (67.9%) 668 (68.7%) 1.00 Reference
 *1/*2  88 (21.2%) 205 (21.1%) 1.08 (0.85-1.37)
 *2/*2  11 (2.7%)  20 (2.1%) 0.98 (0.53-1.78)
 *1/*3  27 (6.5%)  63 (6.5%) 1.46 (0.99-2.18)
 *2/*3   7 (1.7%)  17 (1.7%) 1.62 (0.77-3.44)
 *3/*3   -   - -
Type of anticoagulant
 Acenocoumarol 349 (84.1%) 825 (84.8%) 1.00 Reference
 Phenprocoumon  66 (15.9%) 148 (15.2%) 0.60 (0.46-0.78)
Target level
 2.0-2.5 INR   1 (0.2%)  25 (2.6%) 1.00 Reference
 2.5-3.5 INR 104 (25.1%) 344 (35.3%) 4.64 (0.65-33.4)
 3.0-4.0 INR 310 (74.7%) 603 (62.0%) 4.98 (0.69-35.7)
 3.5-4.5 INR   -   1 (0.1%) -
Hepatic dysfunction   6 (1.4%)  12 (1.2%) 4.41 (1.93-10.1)
Hypoalbuminemia   1 (0.2%)   2 (0.2%) 21.8 (2.73-175)
Malignancies  58 (14.0%) 114 (11.7%) 1.97 (1.49-2.61)
Hyperthyroidism  14 (3.4%)  29 (3.0%) 1.63 (0.95-2.79)
Hypertension 183 (44.1%) 385 (39.6%) 1.01 (0.82-1.21)
Heart failure 130 (31.3%) 209 (21.5%) 1.84 (1.50-2.27)
Low intake vitamin K   9 (2.2%)  17 (1.7%) 1.85 (0.95-3.60)
* Univariate analyses of relative risks were performed with a Cox proportional-hazards model. Relative risks cannot be calculated with the 
numbers in this table because controls may later become cases.
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DISCUSSION
We found that several NSAIDs increased the risk of overanticoagulation, and that allelic variants 
of CYP2C9 modified this risk. The fact that we found an association with acenocoumarol but not 
with phenprocoumon may be explained by the fact that the CYP2C9 enzyme plays a minor role 
Table 2. Association between overanticoagulation (INR ≥ 6.0) and use of NSAIDs
NSAID Cases Cohort* IR† RRcrude (95%CI)
‡ RRadj.
§ (95%CI)
n = 415 n = 973
Celecoxib  0   16  - P = 0.78
Diclofenac 15 1143  2.6 2.36 (1.40-3.97) 2.25 (1.33-3.80)
Diclofenac/misoprostol  1  174  1.9 0.73 (0.10-5.27) 0.31 (0.04-2.27)
Flurbiprofen  0  100  - P = 0.66
Ibuprofen  6  402  1.7 2.64 (1.17-5.96) 2.47 (1.09-5.61)
Indometacin  1   52  0.6 2.73 (0.37-20.1) 1.61 (0.22-11.9)
Ketoprofen  0   26  - P = 0.68
Meloxicam  0   11  - P = 0.85
Nabumetone  0   96  - P = 0.64
Naproxen  8  591  2.2 2.49 (1.23-5.03) 2.44 (1.20-4.97)
Piroxicam  1   59  5.8 1.87 (0.25-13.8) 1.98 (0.25-15.5)
Rofecoxib  1   24 20.2 3.99 (0.53-30.2) 4.67 (0.61-35.7)
Sulindac  2   26 60.8 14.2 (3.34-60.2) 15.4 (3.47-68.6)
Tiaprofenic acid  0   10  - P = 0.88
* In this time-dependent analysis, exposure in case patients and in the rest of the cohort is assessed at the time of the outcome in each case 
patient (index date). Because control patients can be used multiple times, the number of assessments in the reference group is much larger than 
the number of individuals. Hence, crude relative risks cannot be calculated with the numbers in Table 2.
† Expressed as the number of patients with an INR ≥ 6.0 per 10,000 days on a regimen of combined use of a coumarin and an NSAID.
‡ If none of the cases was exposed, P-values were given instead of relative risks.
§ Adjusted for gender, age, hepatic dysfunction, malignancies, heart failure, CYP2C9 genotype, and use of antibacterial drugs.
Table 3. Association between overanticoagulation (INR ≥ 6.0) and NSAIDs stratified by CYP2C9 genotype
RR adj.
* (95%CI)
Total study population
CYP2C9 wild type; NSAIDs (−) 1.00 (reference)
CYP2C9 variant allele; NSAIDs (−) 1.12 (0.90-1.39)
CYP2C9 wild type; NSAIDs (+) 1.62 (1.03-2.57)
CYP2C9 variant allele; NSAIDs (+) 2.14 (1.50-3.06)
P-value for statistical interaction CYP2C9*NSAIDs P = 0.009
Population with CYP2C9 wild type
CYP2C9 wild type; NSAIDs (−) 1.00 (reference)
CYP2C9 wild type; NSAIDs (+) 1.62 (1.03-2.57)
Population with CYP2C9 variant allele
CYP2C9 variant allele; NSAIDs (−) 1.00 (reference)
CYP2C9 variant allele; NSAIDs (+) 3.76 (2.09-6.79)
* Adjusted for gender, age, hepatic dysfunction, malignancies, heart failure, and use of antibacterial drugs.
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in the metabolism of phenprocoumon [16]. It should be emphasized, however, that the number 
of patients on phenprocoumon in this study was relatively small.
Unfortunately, there were too little exposed cases to study effect modification by CYP2C9 
genotype for the individual NSAIDs and for the separate genotypes. Because in vitro 
investigations and clinical studies have identified many NSAIDs as substrates of CYP2C9 [17-
27], we pooled all NSAIDs in one exposure category. When we restricted our analyses to NSAIDs 
that are known CYP2C9 substrates we found, however, comparable risk estimates.
We are aware of only one similar but smaller study that suggested that a variant CYP2C9 
genotype did not influence the NSAID-acenocoumarol interaction [28]. The sample size of that 
study was, however, too small to study the effect of the CYP2C9 polymorphisms on this drug 
interaction properly and no adjustments were made for potentially confounding factors.
Some potential limitations of our cohort study should be considered. Selection bias was 
probably negligible because we identified all users of coumarin anticoagulants in a defined 
population. Furthermore, our study population was in Hardy-Weinberg equilibrium, suggesting 
that no selection has occurred among genotypes, which might otherwise have explained the 
observed association. Information bias may have occurred by over-the-counter (OTC) use of 
NSAIDs. This would lead, however, to a conservative estimation of the association. Moreover, it 
would not influence the interaction between CYP2C9 polymorphisms and NSAIDs. We adjusted 
for all known potential confounders and excluded confounding by indication, because there 
was no statistically significant difference in the indication for NSAIDs between cases and users 
of these agents in the remainder of the cohort. Whether the INR assessment on the index 
date was earlier than according to plan was taken into consideration because patients who 
are prescribed a known potentially hazardous combination are more likely to be monitored at 
short intervals. Adjustment for this did, however, not change our results. We did not adjust our 
results for NSAID dosages nor for the concomitant use of other drugs than antibacterial drugs, 
because there were no reasons to assume that other drugs would act as a confounder.
In conclusion, in this population-based cohort study among outpatients of an anticoagulation 
clinic using acenocoumarol or phenprocoumon, several NSAIDs were associated with 
overanticoagulation. The risk of overanticoagulation was modified by allelic variants of CYP2C9. 
Awareness of this drug interaction and more frequent monitoring of the INR of patients 
receiving these drugs are warranted. As warfarin is also mainly metabolized by CYP2C9, it is 
likely that our results also apply to warfarin.
REFERENCES
 1. Harder S, Thürmann P. Clinically important drug interactions with anticoagulants. Clin Pharmacokinet 
1996; 30: 416-44.
 2. Freedman MD, Olatidoye AG. Clinical significant drug interactions with the oral anticoagulants. 
Drug Saf 1994; 10: 381-94.
118
C
ha
pt
er
 3
.4
 3. Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. Ann 
Intern Med 1994; 121: 676-83.
 4. Koch-Weser J, Sellers EM. Drug interactions with coumarin anticoagulants. N Engl J Med 1971; 285: 
487-98.
 5. Koch-Weser J, Sellers EM. Drug interactions with coumarin anticoagulants. 2. N Engl J Med 1971; 
285: 547-58.
 6. Commissie Interacterende Medicatie Cumarines. Standaard afhandeling cumarine-interacties (in 
Dutch). Wetenschappelijk Instituut Nederlandse Apothekers (WINAp). The Hague, The Netherlands; 
1999.
 7. Chan TYK. Adverse interactions between warfarin and nonsteroidal antiinflammatory drugs: 
mechanisms, clinical significance, and avoidance. Ann Pharmacother 1995; 29: 1274-83.
 8. Miners JO, Birkett DJ. Cytochrome P450 2C9: an enzyme of major importance in human drug 
metabolism. Br J Clin Pharmacol 1998; 45: 525-38.
 9. Crespi CL, Miller VP. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome 
P450 with NADPH: cytochrome P450 oxidoreductase. Pharmacogenetics 1997; 7: 203-10.
 10. Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE. Allelic variants of human cytochrome 
P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate 
stereoselectivity, and prochiral selectivity of the wild type and I359L mutant forms. Arch Biochem 
Biophys 1996; 333: 447-58.
 11. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism 
catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994; 4: 39-42.
 12. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability 
in the elderly: The Rotterdam Elderly Study. Eur J Epidemiol 1991; 7: 403-22.
 13. Anonymous. Anatomical Therapeutical Chemical (ATC) Classification Index. Oslo: World Health 
Organization Collaborating Centre for Drugs Statistics Methodology; 2003.
 14. Aynacioglu AS, Brockmöller J, Bauer S, Sachse C, Güzelbey P, Öngen Z, et al. Frequency of cytochrome 
P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin 
Pharmacol 1999; 48: 409-15.
 15. Clayton D, Hills M. Time-varying explanatory variables. In: Statistical Models in Epidemiology. 
Oxford, UK: Oxford University Press; 1993. p. 307-18.
 16. Kirchheiner J, Ufer M, Walter EC, Kammerer B, Kahlich R, Meisel C, et al. Effects of CYP2C9 
polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers. 
Pharmacogenetics 2004; 14: 19-26.
 17. Kirchheiner J, Meineke I, Freytag G, Meisel C, Roots I, Brockmöller J. Enantiospecific effects of 
cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of 
cyclooxygenase 1 and 2. Clin Pharmacol Ther 2002; 72: 62-75.
 18. Hamman MA, Thompson GA, Hall SD. Regioselective and stereoselective metabolism of ibuprofen 
by human cytochrome P450 2C. Biochem Pharmacol 1997; 54: 33-41.
 19. Tracy TS, Marra C, Wrighton SA, Gonzalez FJ, Korzekwa KR. Involvement of multiple cytochrome 
P450 isoforms in naproxen O-demethylation. Eur J Clin Pharmacol 1997; 52: 293-8.
 20. Rodrigues AD, Kukulka MJ, Roberts EM, Ouellet D, Rodgers TR. [O-methyl 14C] Naproxen O-
demethylase activity in human liver microsomes: evidence for the involvement of cytochrome 
P4501A2 and P4502C9/10. Drug Metab Dispos 1996; 24: 126-36.
 21. Leemann T, Transon C, Dayer P. Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing 
diclofenac 4’-hydroxylation in human liver. Life Sci 1993; 52: 29-34.
 22. Nakajima M, Inoue T, Shimada N, Tokudome S, Yamamoto T, Kuroiwa Y. Cytochrome P450 2C9 
catalyzes indomethacin O-demethylation in human liver microsomes. Drug Metab Dispos 1998; 26: 
261-6.
 23. Tracy TS, Marra C, Wrighton SA, Gonzalez FJ, Korzekwa KR. Studies on flurbiprofen 4’-hydroxylation: 
additional evidence suggesting the sole involvement of cytochrome P450 2C9. Biochem Pharmacol 
1996; 52: 1305-9.
 24. Hutzler J, Hauer MJ, Tracy TS. Dapsone activation of CYP2C9-mediated metabolism: evidence for 
activation of multiple substrates and a two-site model. Drug Metab Dispos 2000; 29: 1029-34.
 25. Bonnabry P, Leemann T, Dayer P. Role of human liver microsomal CYP2C9 in the biotransformation 
of lornoxicam. Eur J Clin Pharmacol 1996; 49: 305-8.
CYP2C9 genotype and NSAID-coumarin interaction 119
 26. Chesne C, Guyomard C, Guillouzo A, Schmid J, Ludwig E, Sauter T. Metabolism of meloxicam in 
human liver involves cytochromes P4502C9 and 3A4. Xenobiotica 1998; 28: 1-13.
 27. Tang C, Shou M, Rushmore TH, Mei Q, Sandhu P, Woolf EJ, et al. In-vitro metabolism of celecoxib, a 
cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 
2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics. Pharmacogenetics 2001; 11: 
223-35.
 28. Van Dijk KN, Plat AW, van Dijk AAC, Piersma-Wichers M, De Vries-Bots AMB, Slomp J, et al. Potential 
interaction between acenocoumarol and diclofenac, naproxen and ibuprofen and role of CYP2C9 
genotype. Thromb Haemost 2004; 91: 95-101.

Chapter 4
Disease states affecting the coumarin anticoagulant level

Chapter 4.1
The risk of overanticoagulation in patients with heart failure on 
coumarin anticoagulants
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ABSTRACT
Objective: Heart failure has been identified as a risk factor for increased coumarin anticoagulant 
responsiveness in several small-scale experiments. Epidemiological studies quantifying the 
risk of overanticoagulation by heart failure in a non-selected population on coumarins are 
scarce. Therefore, we investigated whether patients with heart failure have an increased risk 
of overanticoagulation and determined the effect of incident heart failure on coumarin dose 
requirements.
Methods: We performed a cohort study in all patients from an outpatient anticoagulation clinic 
treated with acenocoumarol or phenprocoumon between January 1, 1990 and January 1, 2000. 
All cohort members were followed until the first occurrence of an international normalised ratio 
(INR) ≥ 6.0, the last INR-assessment, death, loss to follow up, or end of the study period.
Results: Of the 1077 patients in the cohort, 396 developed an INR ≥ 6.0. The risk of 
overanticoagulation was 1.66 (95%CI: 1.33-2.07) for cases of prevalent heart failure and 1.91 
(95%CI: 1.31-2.79) for incident cases. The decrease in dose requirements in patients with 
incident heart failure showed a significant trend from the 5th INR measurement preceding the 
incident heart failure date to the 3rd measurement after this date.
Conclusion: Heart failure is an independent risk factor for overanticoagulation. Therefore, patients 
with heart failure should be closely monitored to prevent potential bleeding complications.
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INTRODUCTION
Coumarin anticoagulants are used in the primary and secondary prophylaxis of thromboembolic 
disease [1]. They inhibit the production of the vitamin K-dependent coagulation factors by the 
liver [2]. Inherent to their mode of action and narrow therapeutic range, hemorrhage is the 
most common adverse reaction to coumarin anticoagulants. The risk of hemorrhage is strongly 
associated with the intensity of anticoagulation and sharply increases when the international 
normalised ratio (INR) ≥ 6.0 [3, 4]. A number of comorbid conditions are suspected to enhance 
the response to coumarin anticoagulants [5, 6]. In some small-scale experiments in groups up 
to 30 patients in the late 40’s of the last century, heart failure has been identified as a risk factor 
for increased coumarin responsiveness [7, 8]. The mechanism has not been fully elucidated 
but it is speculated that increases in coumarin responsiveness are associated with hepatic 
congestion and redistribution of body water [6-10]. Epidemiological studies quantifying the 
risk of overanticoagulation by heart failure in a non-selected population on coumarins are 
scarce. A recent case-control study suggested that patients with heart failure had an increased 
risk of an INR ≥ 6.0 [11]. In that study, however, the presence of chronic comorbidities was 
only based on diagnoses of general practitioners and no cases of incident heart failure were 
included. Therefore, we conducted a follow-up study in a large population-based cohort among 
outpatients of an anticoagulation clinic on acenocoumarol or phenprocoumon. We studied the 
association between heart failure and overanticoagulation and determined the effect of heart 
failure on the coumarin dosage.
METHODS
Setting
Data were obtained from the Rotterdam Study and from the regional outpatient anticoagulation 
clinic. The Rotterdam Study is a prospective population-based cohort study in 7983 subjects of 55 
years and older and has been approved by the Medical Ethics Committee of the Erasmus Medical 
Centre [12]. The baseline examination was conducted between 1990 and 1993. Participants 
were visited at home for a standardized questionnaire and were subsequently examined at the 
research centre. At baseline, information was obtained on several characteristics, including age, 
gender, smoking, body mass index (BMI), medication use, blood pressure, and verified history 
of heart failure. In the Rotterdam Study, participants are continuously monitored for major 
events that occur during follow-up, including heart failure, through automated linkage with 
files from general practitioners. All available information on these events is copied from the 
medical records for verification of the diagnosis. Furthermore, all drug prescriptions dispensed 
to participants by automated pharmacies are routinely stored in the database since January 
1, 1991. Information on vital status is obtained regularly from municipal health authorities in 
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Rotterdam and from the general practitioners in the study district, and was complete for all 
participants until January 1, 2000. 
The anticoagulation clinic monitors all inhabitants of Ommoord with an indication for 
anticoagulant therapy. The choice of anticoagulant is made by the physician. The optimal 
target range of coumarin anticoagulant therapy, as recommended by the Federation of Dutch 
Thrombosis Centers, lies between 2.5 and 3.5 INR or between 3.0 and 4.0 INR, depending on the 
indication for treatment. Some patients are targeted at a level between 2.0 and 2.5 INR because 
of contraindications. Prothrombin times are monitored each one to six weeks by reference to 
the INR, dependent on the stability of the anticoagulant level. Doses are adjusted on the basis 
of the target range of the INR of the patient by computerised dose calculations. All data on 
dosing, laboratory-, and clinical data as of 1984 are fully computerised. For this study, data were 
used from January 1, 1990 through January 1, 2000. 
Cohort and outcome definition
The study cohort consisted of all participants of the Rotterdam Study who were treated with 
acenocoumarol or phenprocoumon in the study period between the baseline visit of the 
Rotterdam Study and January 1, 2000 and for whom INR data from their treatment history 
were available. If a patient had multiple treatment episodes during the study period, only the 
first episode after the baseline examination was considered. The cohort included patients on 
coumarin anticoagulants without heart failure, patients on coumarins with prevalent heart 
failure at baseline and patients on coumarins who developed heart failure during the study 
period (incident cases). All cohort members were followed up as of their baseline examination 
for patients without heart failure and for cases of prevalent heart failure, and from the date of 
incident heart failure for incident cases until the earliest of an INR ≥ 6.0, death, loss to follow up, 
or January 1, 2000. In case the date of incident heart failure was not during a treatment episode 
with coumarins, follow-up started at the first day of the next treatment episode and heart failure 
was classified as prevalent. The index date was defined at that point in time on which one of the 
endpoints occurred for a participant of this study. The effect of heart failure on the coumarin 
dosage was determined by calculating the average week dosage per INR measurement for the 
subsequent measurements after start of the follow up. This was separately done for prevalent 
and incident cases of heart failure and for the rest of the cohort, and for both acenocoumarol 
and phenprocoumon. For the incident cases of heart failure, for which the follow-up started at 
the date of incident heart failure, we also studied the course of the coumarin dosage from the 
10th INR measurement preceding this date.
Heart failure assessment
Assessment of prevalent heart failure at baseline has been described in detail earlier [13]. Briefly, 
a validated score was used, similar to the definition of the European Society of Cardiology [14]. 
This score was based on the presence of at least two symptoms suggestive of heart failure or 
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treatment for heart failure, in combination with objective evidence of cardiovascular disease. 
This score was, however, not implemented from the first beginning of the Rotterdam Study, 
but was subsequently added. Consequently, this information was obtained in only 5440 
participants. In addition, prevalent heart failure cases were obtained through a database 
containing hospital discharge diagnoses from all hospitals in the Rotterdam area. Furthermore, 
all medical records were screened in retrospect for the occurrence of heart failure in the majority 
of participants. With these three methods, information on prevalent heart failure was available 
for all participants.
Cases of incident heart failure were obtained by continuously monitoring participants of 
the Rotterdam Study for the occurrence of heart failure during follow-up through automated 
linkage with files from general practitioners. All available data on these events, such as hospital 
discharge letters and notes from general practitioners, were copied from the medical records. 
Apart from this systematic follow-up procedure, we used verified hospital discharge diagnoses 
for case finding, gathered from all hospitals in the Rotterdam area as described above. The 
diagnosis of heart failure was classified as definite, probable, possible or unlikely. Definite 
heart failure was defined as a combination of heart failure, such as breathlessness at rest or 
during exertion, ankle oedema and pulmonary reputations, confirmed by objective evidence 
of cardiac dysfunction (chest X-ray, echocardiography). This definition is in accordance with the 
criteria of the European Society of Cardiology [14]. Probable heart failure was defined as heart 
failure diagnosed by a general practitioner, with at least two typical symptoms suggestive of 
heart failure, and at least 1 of the following: history of cardiovascular disease (e.g. myocardial 
infarction, hypertension), response to treatment for heart failure, or objective evidence of cardiac 
dysfunction, while symptoms could not be attributed to another underlying disease, such as 
chronic obstructive pulmonary disease. Two research physicians independently classified all 
information on potential heart failure events. If there was disagreement, a consensus was 
reached in a separate session. Finally, a cardiologist verified all probable and possible cases, and 
all cases in which the two physicians could not reach consensus. If the cardiologist disagreed 
with the research physicians, the cardiologist’s judgement was considered decisive. Only 
definite and probable cases were included in the analyses.
Cofactors
The following baseline patient characteristics were considered as potential determinants for 
affecting the response of the INR to coumarin anticoagulants: gender, age, CYP2C9 genotype, 
hepatic dysfunction (defined as serum aminotransferases > 2x the upper level of normal), 
hypoalbuminemia (≤ 35 g/l), malignancies, hyperthyroidism, hypertension (systolic blood 
pressure ≥ 140 mm Hg and/or diastolic blood pressure ≥ 90 mm Hg or use of antihypertensives) 
and low dietary intake of vitamin K (< 1 µg/kg/day). In addition, we considered the type of 
anticoagulant, the indication for therapy, the target INR level, the number of visits to the 
anticoagulation clinic during the follow-up period, and the use of thiazides or non-steroidal 
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anti-inflammatory drugs (NSAIDs) on the index date as potential confounding factors. Separate 
analyses were performed for prevalent and incident cases of heart failure. 
Statistical analysis
Allele and genotype proportions were tested for deviations from Hardy-Weinberg equilibrium 
(HWE) by using a χ2-test. Independent-sample t-tests and Pearson’s chi-square were used to 
compare baseline characteristics between prevalent or incident heart failure cases and patients 
without heart failure. Incidence rates of overanticoagulation were calculated by dividing 
the number of cases of an INR ≥ 6.0 by the number of days on a coumarin anticoagulant. 
The association between heart failure and overanticoagulation was evaluated using Cox 
proportional hazards regression analysis to estimate relative risks (RR) and 95% confidence 
intervals (95%CI). To adjust for potential confounding, cofactors were included in the model, in 
addition to age and gender, if the point estimate changed by more than 5% upon inclusion of 
the cofactor in the model. For missing data on categorical covariates, we used a missing value 
indicator, whereas for missing data on continuous covariates, we used the median value of the 
respective value as calculated from the total sample. To evaluate the effect of incident heart 
failure on the coumarin dosage, a trend test was performed using a linear regression model 
with the mean dosage as outcome variable. For all statistical analyses p-values below 0.05 were 
considered statistically significant. All statistical analyses were performed with SPSS version 
11.0.1 (SPSS Inc., Chicago, USA).
RESULTS
A total of 1077 individuals on coumarin anticoagulants were included in our study population 
(Table 1). The mean age of these patients was almost 72 years, and 47.4% of the patients were 
men. All patients were of Caucasian origin. There were 636 patients (59.1%) with the wild type 
CYP2C9 genotype (CYP2C9*1/*1 homozygotes), and 323 (30.0%) with a variant genotype (1 
or 2 of the mutant alleles CYP2C9*2 or CYP2C9*3). Allele and genotype proportions were in 
Hardy-Weinberg equilibrium. There were 915 acenocoumarol-treated patients (85.0%), and 162 
patients (15.0%) who used phenprocoumon. Twenty-five patients (2.3%) were targeted at an 
INR between 2.0 and 2.5, 368 patients (34.2%) at an INR between 2.5 and 3.5, and 684 patients 
(63.5%) at an INR between 3.0 and 4.0. Patients had a median of 29 INR assessments during a 
median follow-up time of 245 days (0.7 years). 
There were 234 cases of prevalent and 66 cases of incident heart failure identified during the 
study period. Patients with prevalent heart failure were significantly older and more likely to be 
male than patients without heart failure. They used more often phenprocoumon, were more 
often targeted at the highest INR level and had their INR more frequently measured. Patients 
with incident heart failure were significantly older, were more often targeted at the highest 
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INR level and were more likely to have hypoalbuminemia than patients without heart failure. 
Patients without heart failure used coumarins more often for prophylaxis and treatment of 
venous thrombosis, while patients with prevalent and incident heart failure had more often an 
arterial indication for coumarin anticoagulant therapy. 
During the study period, 396 of the 1077 individuals (37%) had an INR ≥ 6.0. From the 234 
prevalent cases of heart failure 131 individuals (56%) experienced an INR ≥ 6.0, and from the 
66 incident heart failure cases 32 individuals (48%) had overanticoagulation. Table 2 presents 
relative risk estimates for the association between prevalent and incident heart failure and 
overanticoagulation. Prevalent and incident heart failure were both univariately as well as after 
adjustment for confounding factors associated with an increased risk of overanticoagulation. 
Table 1. Characteristics of the study population
Variable Number of patients
(n = 1077)
Gender
 Male 511 (47.4%)
 Female 566 (52.6%)
Age, average (SD)  71.8 (7.9) years
CYP2C9 genotype*
 Wild type genotype† 636 (59.1%)
 Variant genotype‡ 323 (30.0%)
Type of anticoagulant
 Acenocoumarol 915 (85.0%)
 Phenprocoumon 162 (15.0%)
Indication 
 Prophylaxis venous thrombosis 227 (21.1%)
 Treatment of venous thrombosis 368 (14.0%)
 Treatment or prophylaxis of arterial thrombosis 673 (62.4%)
 Prosthetic heart valves  25 (2.3%)
Target INR level
 2.0-2.5 INR  25 (2.3%)
 2.5-3.5 INR 368 (34.2%)
 3.0-4.0 INR 684 (63.5%)
Time between visits (d ± SD)  11.9 (± 16.3)
Hepatic dysfunction  12 (1.1%)
Hypoalbuminemia   2 (0.2%)
Malignancies 123 (11.4%)
Hyperthyroidism  37 (3.4%)
Hypertension 422 (39.2%)
Low intake of vitamin K  16 (1.5%)
Use of thiazides§   4 (0.4%)
* Totals do not add up to 100% because of missing genotypes.
† CYP2C9*1/*1 homozygotes.
‡ Patients with one or more of the variant alleles CYP2C9*2 or CYP2C9*3.
§ Assessed by reference to the index date.
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In Figure 1 the mean weekly dosage of acenocoumarol is shown for the subsequent INR 
measurements after start of the follow-up. Patients with prevalent and incident heart failure 
used lower dosages than patients without heart failure, in spite of the higher target INR levels for 
patients with heart failure. Patients with incident heart failure had even lower acenocoumarol 
dose requirements than patients with prevalent heart failure. Because this difference did not 
disappear in the course of time, this probably reflects the difference in indication and target 
INR level. For phenprocoumon we saw more or less the same picture. For patients with incident 
heart failure the decrease in dosage started on average at the 5th INR measurement preceding 
the incident date and lasted until the 3rd INR measurement after the incident date. A trend test 
revealed a significant dosage decrease between the subsequent INR measurements of 0.23 mg 
per week for acenocoumarol (p for trend <0.001) and 0.34 mg per week for phenprocoumon 
(p for trend <0.001).
Table 2. Relative risks for the association between heart failure and overanticoagulation
N Events IR* RRcrude (95%CI) RRadj.
† (95%CI)
Patients without heart failure 777 233  5.19 1.00 (reference) 1.00 (reference)
Prevalent heart failure 234 131  9.82 1.84 (1.48-2.28) 1.66 (1.33-2.07)
Incident heart failure  66  32 11.78 1.97 (1.36-2.86) 1.91 (1.31-2.79)
* The incidence rate is expressed as the number of cases of overanticoagulation per 10,000 days on a coumarin anticoagulant.
† Adjusted for gender, age, and target INR level.
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Figure 1. Course of the mean acenocoumarol dosage over time. Hf, heart failure
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DISCUSSION
The current study identifies heart failure as an independent risk factor for excessive 
anticoagulation under everyday circumstances. Patients with heart failure had a 1.5 to twofold 
increased risk of an INR ≥ 6.0. Our results are in accordance with the study of Penning-van Beest, 
who found an OR of 1.6 (95%CI: 1.04-2.6) in stable condition and an OR of 3.0 (95%CI: 0.8-12.0) 
in case of a relapse [11]. 
This increased coumarin responsiveness is assumed to be due to impairment of liver function 
resulting from congestion [6-9]. Patients with heart failure were noted to have an increased 
response as hepatic congestion developed [6, 9], and the responsiveness decreased on relief of 
the congestion by corrective cardiac surgery [15] or use of diuretics [16]. Our data also indicate 
that coumarin responsiveness is already slowly increasing during the weeks preceding the 
incident heart failure date, probably due to increasing hepatic congestion. It is speculated that 
the determinants of increased coumarin responsiveness might chiefly be pharmacodynamic 
(associated with impaired clotting factor synthesis) rather than pharmacokinetic (associated 
with decreased hepatic coumarin clearance) [10, 16]. The hypothrombinaemic effect will be 
even larger due to the redistribution of body water in heart failure patients and consequent 
accumulation of unbound coumarin anticoagulant in the vicinity of hepatic receptor sites [10]. 
The clinical implication of these findings lies in the possibility of prevention or early detection 
of excessive anticoagulation, and thus of hemorrhagic complications, by paying special 
attention to this risk factor when monitoring anticoagulant therapy. Patients with heart failure 
should therefore be closely monitored for signs of excess anticoagulation and fluid overload 
and it should be noted whether patients are taking any drugs associated with fluid retention 
(e.g. vasodilators, NSAIDs). 
In our study, selection bias was probably negligible as we identified all users of oral 
anticoagulants in a defined population and because regular INR monitoring makes it unlikely 
that cases were missed. Also, information bias is not likely as all data on heart failure and 
coumarin anticoagulant dosages were recorded similarly without prior knowledge of our study 
hypothesis. Potential confounding by gender, age, CYP2C9 genotype, hepatic dysfunction, 
hypoalbuminemia, malignancies, hyperthyroidism, hypertension, low dietary intake of 
vitamin K, type of anticoagulant, indication for therapy, target INR level, time between the INR 
measurements, and use of thiazides and NSAIDs was dealt with in the multivariate analyses. Use 
of thiazide diuretics on the index date was taken into consideration because current use of these 
drugs was found to increase the bleeding risk of oral anticoagulant therapy by 5.2% [17].
In conclusion, heart failure is an independent risk factor for overanticoagulation. Patients 
with heart failure should therefore be closely monitored for signs of excess anticoagulation and 
fluid overload to prevent potential bleeding complications. 
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Chapter 5
Dietary factors influencing the coumarin anticoagulant level

Chapter 5.1
Deficient dietary intake of vitamin K is associated with an 
increased risk of overanticoagulation

Overanticoagulation by defi cient dietary intake of vitamin K 139
ABSTRACT
A dietary intake of vitamin K of 1 μg/kg body weight per day is required for normal 
functioning of coagulation factors. Possibly, a deficient intake of vitamin K is associated with 
overanticoagulation. We performed a population-based cohort study in a sample of the 
Rotterdam Study to study whether patients with a deficient dietary intake of vitamin K have 
an increased risk of overanticoagulation (international normalised ratio (INR) ≥ 6.0). The study 
cohort consisted of all participants of whom dietary intake data have been collected and who 
were treated with coumarin anticoagulants in the study period from the baseline visit of the 
Rotterdam Study (1990-1993) through December 31, 1998. All cohort members were followed 
from their baseline visit of the Rotterdam Study until the first occurrence of an INR ≥ 6.0, the last 
INR assessment during the study period, death or end of the study period. The intake of vitamin 
K was calculated from the total diet using data on concentrations of vitamin K1 and vitamin K2 
in foods. An intake of vitamin K below 1 μg/kg body weight per day was considered deficient. 
Of the 772 patients in the cohort, 227 developed an INR ≥ 6.0 during the study period. The 
number of patients in the total cohort with a deficient dietary intake of vitamin K was 12 (1.6%). 
Of the cases, seven patients (3.1%) had a deficient dietary intake of vitamin K. The adjusted 
relative risk of overanticoagulation associated with a deficient dietary intake of vitamin K was 
9.6 (95% confidence interval: 4.0-23.0). To minimize the risk of bleeding complications, patients 
on coumarin anticoagulant therapy should be advised to consume vitamin K-rich foods such 
as green, leafy vegetables.
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INTRODUCTION
Coumarin anticoagulants are widely used in the prevention of venous and arterial 
thromboembolism [1]. These drugs induce anticoagulation by antagonizing vitamin K, thereby 
impairing the biological activity of the vitamin K-dependent coagulation factors II, VII, IX and 
X [2]. Hemorrhage is the most common adverse reaction to coumarin anticoagulants. Its 
risk is strongly associated with the intensity of anticoagulation and sharply increases when 
the international normalised ratio (INR) is ≥ 6.0 [3, 4]. For normal functioning of coagulation 
factors, a habitual dietary intake of vitamin K of 1 μg/kg body weight per day is required [5, 
6]. Considering the mode of action of coumarin anticoagulants, it is obvious that a low dietary 
intake of vitamin K will require a low-normal daily dose of coumarins. Because coumarin 
anticoagulant therapy is regularly monitored and the dose of coumarins is adjusted in an 
individual on the basis of the INR, however, there is no reason to assume that a patient’s low 
habitual dietary intake of vitamin K is associated with an increased risk of overanticoagulation. 
In the literature there is only limited information on the association between dietary intake 
of vitamin K and overanticoagulation. Two case reports described overanticoagulation after 
discontinuation of a weekly consumption of 750 to 1000 grams of liver [7, 8]. In a case-control 
study on risk factors for overanticoagulation, the habitual weekly intake of twelve vitamin K1-
rich foods was inversely associated with the risk of overanticoagulation [9].
We conducted a cohort study in a large population of community-dwelling elderly to study 
whether patients with a habitual dietary intake of vitamin K below the amount required for 
normal functioning of coagulation factors, have an increased risk of overanticoagulation.
METHODS
Setting
Data were obtained from the Rotterdam Study and from the regional outpatient anticoagulation 
clinic. The Rotterdam Study is a prospective population-based cohort study of neurologic, 
cardiovascular, locomotor, and ophthalmologic diseases in the elderly. All inhabitants of 
Ommoord, a suburb of the city of Rotterdam in the Netherlands, aged 55 years or over and 
living in the district for at least one year were invited in 1990-1993 to participate in the 
study. The rationale and design of this study have been described elsewhere [10]. The cohort 
comprises 7983 individuals who were all interviewed and investigated at baseline. The regional 
outpatient anticoagulation clinic monitors all inhabitants of Ommoord with an indication for 
anticoagulant therapy. The choice of anticoagulant (phenprocoumon or acenocoumarol) is 
made by the referring physician. The optimal target range of coumarin anticoagulant therapy, 
as recommended by the Federation of Dutch Thrombosis Centers, lies between 2.5 and 3.5 INR 
or between 3.0 and 4.0 INR, depending on the indication for treatment. INR measurements are 
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performed at a mean interval of two to three weeks, the interval being six weeks at a maximum. 
Dosing of the coumarin is performed by a team of specialized physicians routinely working 
at the anticoagulation clinic, with the aid of a computerized dosing program. All laboratory, 
clinical and administrative data as of 1986 are stored in computerized files. For our cohort study, 
the data until December 31, 1998 were used.
Cohort and outcome definition 
The study cohort consisted of all participants of the Rotterdam Study of whom dietary 
intake data have been collected and who were treated with the coumarins acenocoumarol 
or phenprocoumon in the study period between the baseline visit of the Rotterdam Study 
(1990-1993) and December 31, 1998. The cohort included prevalent users at baseline as well as 
incident users during follow-up. All cohort members were followed from their baseline visit of 
the Rotterdam Study until the first occurrence of an INR ≥ 6.0, the last INR assessment during 
the study period, death or end of the study period, whichever came first. In case a patient had 
multiple treatment episodes during follow-up, all episodes in the study period were considered. 
The date on which an INR ≥ 6.0 was encountered was defined as the index date.
Exposure definition
The exposure of interest in this study was habitual dietary intake of vitamin K1 and K2. A 
semiquantitative food frequency questionnaire including 170 foods and beverages was used 
to assess the habitual diet of each participant as consumed during the preceding year. The 
questionnaire has been validated and proven suitable for use in an elderly population [11, 
12]. In order to calculate the intake of vitamin K, we used data on concentrations of vitamin K1 
(phylloquinone) and vitamin K2 (menaquinones: MK4 through MK10) as have been determined 
in a large variety of Dutch foods at the Department of Biochemistry and Cardiovascular 
Research Institute, Maastricht University. The analytical method used has been described in 
detail elsewhere [13]. For foods included in the food frequency questionnaire that have not 
been analysed, concentrations were derived from data published by others [14-19]. This was 
not done for vitamin K2 because of scarcity of data in the literature.
The intake of vitamin K was expressed in μg/kg body weight per day. An intake below 1 μg/
kg body weight per day was considered deficient [5, 6]. If information on weight was missing 
(n = 7), the intake of vitamin K was calculated by reference to the mean weight of male and 
female cohort members. For women an intake below 72 μg/day and for men an intake below 
79 μg/day was considered deficient.
Cofactors
A person’s habitual diet is only one aspect of his or her lifestyle and may be related to body mass 
index (BMI), smoking status and alcohol consumption. In addition, a person’s habitual diet may 
be related to the presence of an impaired liver function, heart failure or malignancies. Since 
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the lifestyle factors and chronic comorbidities mentioned may interfere with anticoagulant 
therapy and enhance the response to coumarins [20, 21], these were considered as potential 
confounders. Furthermore, we considered the phase of coumarin anticoagulant therapy on the 
index date (initiation phase, i.e. day 1 to day 41, or stabilized phase, i.e. ≥ 42 days) and, for 
patients in the stabilized phase, the mean monitoring interval in the three months preceding 
the index date.
Statistical analysis
The cohort included prevalent users of coumarins at baseline as well as incident users during 
follow-up. In addition, the moment on which incident users started anticoagulant therapy 
differed and multiple treatment episodes were considered. Consequently, cohort members 
were not necessarily receiving anticoagulant therapy during the whole follow-up. Therefore, a 
time-dependent Cox proportional hazards regression model was used to compute the relative 
risk (RR) and 95% confidence interval (CI) of overanticoagulation associated with a deficient 
dietary intake of vitamin K. In this model, the status of a particular determinant at the index 
date of each case of an INR ≥ 6.0, is compared to the status of this determinant in all cohort 
members who are alive and at risk for the outcome. The relative risk was adjusted for age and 
gender. Furthermore, we adjusted for all cofactors which were univariately associated with 
an INR ≥ 6.0 if this caused a change in the point estimate of more than 5 percent. Population 
attributable risk percentages were calculated with the formula ((RR-1)/RR) * 100 * proportion 
of exposed cases [22].
RESULTS
The study cohort consisted of 772 patients, with a mean follow-up (± SD) of 1650 ± 764 days. 
Nearly 85% of the patients used acenocoumarol and the remainder phenprocoumon. As all 
vitamin K deficient cases used acenocoumarol, no further distinction is made between the 
two coumarins. During the study period, 227 patients developed an INR ≥ 6.0. The mean 
duration of follow-up (± SD) in the cases was 1532 ± 627 days. Baseline characteristics of the 
cases and the total cohort are shown in Table 1. Men and women had a more or less similar 
risk of an INR ≥ 6.0. Patients of 75 years and older had an increased risk. Furthermore, the risk 
of overanticoagulation was associated with BMI, current smoking, an impaired liver function, 
heart failure and malignancies. Patients with an intermediate intake of alcohol tended to have 
a slightly lower risk of overanticoagulation but the difference with non-use was not statistically 
significant.
The median daily dietary intake of vitamin K in the total cohort was 259 μg, or 3.5 μg/kg body 
weight (Table 2). Subdivided into vitamin K1 and vitamin K2, the median daily intakes were 232 
μg and 26 μg, respectively. Case patients had similar median intakes. The number of patients in 
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Table 1. Baseline characteristics of patients with an INR ≥ 6.0 and the total cohort
Variable Patients with an INR ≥ 6.0 Total cohort
n = 227 n = 772
Sex
 Male 122 (54%) 386 (50%)
 Female 105 (46%) 386 (50%)
Age (years, mean ± SD)  70.7 ± 6.8  69.6 ± 7.1
 55-64 years  44 (19%) 195 (25%)
 65-74 years  111 (49%) 378 (49%)
 ≥ 75 years  72 (32%) 200 (26%)
BMI
 > 25 kg/m2 130 (58%) 499 (65%)
 20-25 kg/m2  89 (40%) 255 (33%)
 < 20 kg/m2   5 (2%)  11 (1%)
Smoking status
 Never smoker  58 (26%) 232 (30%)
 Former smoker 103 (45%) 339 (44%)
 Current smoker  66 (29%) 199 (26%)
Alcohol intake
 None  68 (30%) 225 (29%)
 ≤ 15 g/day 106 (47%) 366 (47%)
 15-30 g/day  30 (13%) 107 (14%)
 > 30 g/day  23 (10%)  74 (10%)
Impaired liver function*   2 (1%)   8 (1%)
Heart failure†  56 (25%) 128 (17%)
Malignancies†‡  37 (16%)  85 (11%)
* Defined as serum aminotransferases or bilirubine > 2x the upper level of normal.
† Assessed by reference to the index date.
‡ A diagnosis of a malignancy prior to the index date or within the first year after the index date.
Table 2. Daily dietary intake of vitamin K (median (interquartile range)) in the patients with an INR ≥ 6.0 and 
the total cohort*
Variable Patients with an INR ≥ 6.0 Total cohort
All cohort members n = 227 n = 772
 Intake of vitamin K (µg) 254 (140) 259 (134)
 Intake of vitamin K (µg/kg) 3.6 (1.9) 3.5 (1.8)
 Intake of vitamin K1 (µg) 228 (137) 232 (128)
 Intake of vitamin K2 (µg) 25 (17) 26 (19)
Vitamin K deficient patients n = 7 (3.1%) n = 12 (1.6%)
 Intake of vitamin K (µg) 64 (37) 57 (28)
 Intake of vitamin K (µg/kg) 0.71 (0.40) 0.73 (0.27)
 Intake of vitamin K1 (µg) 20 (30) 36 (30)
 Intake of vitamin K2 (µg) 15 (9) 16 (21)
* Because of the use of medians, the intake of vitamin K1 and K2 do not add up to the intake of vitamin K.
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the total cohort with a deficient dietary intake of vitamin K was 12 (1.6%). In these patients, the 
median daily intake of vitamin K was 57 μg; that of vitamin K1 was 36 μg; and that of vitamin K2 was 
16 μg. Expressing the intake of vitamin K in μg/kg body weight per day, the intake ranged from 
0.20-1.0 μg/kg body weight per day, with a median of 0.73. Of the cases, seven patients (3.1%) 
had a deficient dietary intake of vitamin K, with a median intake of 0.71 μg/kg body weight per 
day. In the vitamin K deficient cases, the median daily intakes of vitamin K1 and vitamin K2 were 
20 μg and 15 μg, respectively. The crude relative risk of overanticoagulation associated with a 
deficient dietary intake of vitamin K was 9.2 (95%CI: 4.0-20.8) (Table 3). Only in one out of the 
seven patients with a deficient vitamin K intake, overanticoagulation occurred within the first 
week of treatment. After adjustment for potential confounders the relative risk was 9.6 (95%CI: 
4.0-23.0). The population attributable risk percentage of overanticoagulation associated with 
a deficient dietary intake of vitamin K in elderly outpatients of an anticoagulation clinic was 
Table 3. The relative risk of overanticoagulation (INR ≥ 6.0) associated with a deficient dietary intake of 
vitamin K
Variable RRcrude (95%CI)
* RRadjusted (95%CI)
†
Deficient dietary intake of vitamin K 9.2 (4.0-20.8) 9.6 (4.0-23.0)
Sex
 Male 1.0 (reference) 1.0 (reference)
 Female 1.2 (0.9-1.5) 0.8 (0.6-1.1)
Age
 55-64 years 1.0 (reference) 1.0 (reference)
 65-74 years 1.0 (0.7-1.5) 1.1 (0.8-1.6)
 ≥ 75 years 1.5 (1.03-2.2) 1.7 (1.2-2.6)
BMI
 > 25 kg/m2 1.0 (reference) 1.0 (reference)
 20-25 kg/m2 1.6 (1.2-2.1) 1.3 (0.99-1.8)
 < 20 kg/m2 1.2 (0.5-2.9) 1.0 (0.4-2.6)
Smoking status
 Never smoker 1.0 (reference) 1.0 (reference)
 Former smoker 1.0 (0.7-1.4) 1.0 (0.7-1.6)
 Current smoker 1.5 (1.02-2.1) 1.6 (1.05-2.5)
Alcohol intake
 None 1.0 (reference) 1.0 (reference)
 ≤ 15 g/day 0.8 (0.6-1.1) 1.2 (0.8-1.7)
 15-30 g/day 0.6 (0.4-1.01) 1.0 (0.6-1.7)
 > 30 g/day 0.8 (0.5-1.3) 1.0 (0.6-1.6)
Impaired liver function 6.6 (1.5-28.7) 9.7 (2.2-43.0)
Heart failure 1.6 (1.1-2.1) 1.5 (1.1-2.1)
Malignancies 2.3 (1.6-3.3) 2.6 (1.7-3.8)
* Univariate analyses of relative risks were done with the time-dependent Cox proportional hazards regression model. In this model, the status 
of a particular determinant at the index date of each case of an INR ≥ 6.0, is compared to the status of this determinant in all cohort members 
who are alive and at risk for the outcome. Hence, crude RRs cannot be calculated with the numbers in this table.
† Adjusted for sex, age, BMI, smoking status, alcohol intake and impaired liver function (missing value indicators included) at baseline, and 
heart failure and malignancies by reference to the index date.
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2.8%. Adjustment for the phase of coumarin anticoagulant therapy on the index date did not 
substantially change the relative risk. For patients in the stabilized phase, i.e. treated for at 
least six weeks, the relative risk was also adjusted for the mean monitoring interval in the three 
months preceding the index date. The adjusted relative risk of overanticoagulation associated 
with a deficient dietary intake in these patients was 7.1 (95%CI: 2.7-18.6). The corresponding 
population attributable risk percentage was 2.4%.
DISCUSSION
In this population-based cohort study, a deficient intake of vitamin K as calculated from the 
total diet using data on concentrations of vitamin K1 and vitamin K2 in foods, was associated 
with a considerably increased risk of an INR ≥ 6.0. Apparently, when the habitual dietary intake 
of vitamin K is below the amount required for normal functioning of coagulation factors, 
regular monitoring and adjustment of the dose of coumarins does not abolish the risk of 
overanticoagulation. To minimize the risk of bleeding complications, patients on coumarin 
anticoagulant therapy should be advised to consume vitamin K-rich foods such as green, leafy 
vegetables.
In addition to the fact that the intake of vitamin K is insufficient for normal functioning of 
coagulation factors, patients on coumarins with a deficient dietary intake of vitamin K are at 
increased risk of overanticoagulation by antibacterial drugs that may interfere with bacterial 
synthesis of vitamin K in the colon [23]. The contribution of bacterial synthesis of vitamin K in 
the colon to the vitamin K status becomes important when the dietary intake of the vitamin is 
markedly decreased [24, 25]. As none of our vitamin K deficient cases was exposed to antibacterial 
drugs on the index date, we were not able to confirm the increased risk of overanticoagulation 
by antibacterial drugs in patients on coumarins with a deficient dietary intake of vitamin K. If 
overanticoagulation occurs within the first week of treatment, it may be caused by a relatively 
too high starting dose of coumarins. In our study, however, this concerned only one vitamin K 
deficient patient and did not explain the increased risk of overanticoagulation in patients with 
a deficient dietary intake of vitamin K.
Some potential limitations should be considered in the interpretation of our findings. Selection 
bias was probably negligible because we identified all users of coumarin anticoagulants in 
a defined population and because regular INR monitoring makes it unlikely that cases were 
missed. Information bias is also unlikely because all data on exposure and outcome were 
gathered prospectively and recorded similarly for all cohort members without prior knowledge 
of our study hypothesis. Misclassification of exposure may be present since the habitual dietary 
intake of vitamin K was assessed at baseline and may have changed during follow-up. However, 
misclassification of exposure usually leads to a conservative estimate of the relative risk. This 
suggests that the actual risk of overanticoagulation in patients with a deficient dietary intake 
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of vitamin K may be higher. Potential confounding by sex, age, BMI, smoking status, alcohol 
consumption, impaired liver function, heart failure, and malignancies was dealt with in the 
multivariate analyses. Similarly, the phase of therapy on the index date and, for patients in 
the stabilized phase, the mean monitoring interval in the three months preceding the index 
date, were considered. Although our study pertained to the coumarins acenocoumarol and 
phenprocoumon, it is likely that the results can be extrapolated to warfarin because here, 
vitamin K plays a similar role.
In our study population, and in the Netherlands in general, the dietary intake of vitamin K is 
high and vitamin K deficiency is rare. Therefore, the public health impact of a deficient dietary 
intake of vitamin K on overanticoagulation is probably modest considering the population 
attributable risk percentage in elderly outpatients of an anticoagulation clinic of 2.8%. However, 
in the USA, the mean dietary intake of vitamin K1 is much lower and only 80 μg/day in young 
adults and 150 μg/day in older adults [26]. In these populations, the occurrence of an INR ≥ 6.0 
associated with a deficient dietary intake of vitamin K, may concern many more patients.
In conclusion, in this population-based cohort study, outpatients of an anticoagulation clinic 
with a deficient dietary intake of vitamin K had an increased risk of overanticoagulation. Since 
overanticoagulation is associated with an increased risk of hemorrhages, patients on coumarin 
anticoagulant therapy should be advised to consume vitamin K-rich foods such as green, leafy 
vegetables.
REFERENCES
 1. British Committee for Standards in Haematology. Guidelines on oral anticoagulation: third edition. 
Br J Haematol 1998; 101: 374-87.
 2. Sadowski JA, Booth SL, Mann KG, Malhotra OP, Bovill EG. Structure and mechanism of activation of 
vitamin K antagonists. In: Poller L, Hirsch J, editors. Oral anticoagulants. London, UK: Arnold; 1996. 
p. 9-21.
 3. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, Briët E. Optimal oral 
anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11-7.
 4. Van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briët E. Assessment of a bleeding risk index in two 
cohorts of patients treated with oral anticoagulants. Thromb Haemost 1996; 76: 12-6.
 5. Department of Health. Report on Health and Social Subjects No.41: Dietary Reference Values for 
Food Energy and Nutrients for the United Kingdom. London, UK: HM Stationery Office; 1991.
 6. Food and Nutrition Board. Recommended Dietary Allowances. 10th ed. Washington DC: National 
Academy Press; 1989.
 7. Chow WH, Chow TC, Tse TM, Tai YT, Lee WT. Anticoagulation instability with life-threatening 
complication after dietary modification. Postgrad Med J 1990; 66: 855-7.
 8. Kalra PA, Cooklin M, Wood G, O’Shea GM, Holmes AM. Dietary modification as cause of anticoagulation 
instability. Lancet 1988; 2: 803.
 9. Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE. Acetaminophen and other risk factors for 
excessive warfarin anticoagulation. JAMA 1998; 279: 657-62.
 10. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability 
in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 1991; 7: 403-22.
Overanticoagulation by defi cient dietary intake of vitamin K 147
 11. Goldbohm RA, van den Brandt PA, Brants HA, van’t Veer P, Al M, Sturmans F, et al. Validation of a 
dietary questionnaire used in a large-scale prospective cohort study on diet and cancer. Eur J Clin 
Nutr 1994; 48: 253-65.
 12. Klipstein-Grobusch K, den Breeijen JH, Goldbohm RA, Geleijnse JM, Hofman A, Grobbee DE, et al. 
Dietary assessment in the elderly: validation of a semiquantitative food frequency questionnaire. 
Eur J Clin Nutr 1998; 52: 588-96.
 13. Schurgers LJ, Vermeer C. Determination of phylloquinone and menaquinones in food: effect of food 
matrix on circulating vitamin K concentrations. Haemostatis 2000; 30: 298-307.
 14. Shearer MJ, Bach A, Kohlmeier M. Chemistry, nutritional sources, tissue distribution and metabolism 
of vitamin K with special reference to bone health. J Nutr 1996; 126: 1181S-6S.
 15. Suttie JW. Vitamin K and human nutrition. J Am Diet Assoc 1992; 92: 585-90.
 16. Olson RE. Vitamin K. In: Shils ME, Olson JA, Shike M, editors. Modern nutrition in health and disease. 
Malvern, Pennsylvania: Lea & Febiger; 1994. p. 342-7.
 17. Ferland G, MacDonald DL, Sadowski JA. Development of a diet low in vitamin K-1 (phylloquinone). 
J Am Diet Assoc 1992; 92: 593-7.
 18. Booth S. Vitamin K-1 (phylloquinone) content of foods: a provisional table. J Food Compos Anal 
1993; 6: 109-20.
 19. Booth SL, Madabushi HT, Davidson KW, Sadowski JA. Tea and coffee brews are not dietary sources 
of vitamin K-1 (phylloquinone). J Am Diet Assoc 1995; 95: 82-3.
 20. Penning-van Beest FJA, van Meegen E, Rosendaal FR, Stricker BHCh. Characteristics of anticoagulant 
therapy and comorbidity related to overanticoagulation. Thromb Haemost 2001; 86: 569-74.
 21. Penning-van Beest FJA, Geleijnse JM, van Meegen E, Vermeer C, Rosendaal FR, Stricker BHCh. 
Lifestyle and diet as risk factors for overanticoagulation. J Clin Epidemiol 2002; 55: 411-7.
 22. Miettinen OS. Proportion of disease caused or prevented by a given exposure, trait or intervention. 
Am J Epidemiol 1974; 99: 325-32.
 23. Shevchuk YM, Conly JM. Antibiotic-associated hypoprothrombinemia: a review of prospective 
studies, 1966-1988. Rev Infect Dis 1990; 12: 1109-26.
 24. Udall JA. Human sources and absorption of vitamin K in relation to anticoagulation stability. JAMA 
1965; 194: 127-9.
 25. Koch-Weser J, Sellers EM. Drug interactions with coumarin anticoagulants. 2. N Engl J Med 1971; 
285: 547-58.
 26. Booth SL, Suttie JW. Dietary intake and adequacy of vitamin K. J Nutr 1998; 128: 785-8.

Chapter 6
General discussion

General discussion 151
INTRODUCTION
One of the most challenging areas of research in pharmaco-epidemiology and clinical 
pharmacology is to understand why individuals have a different response to drug therapy. 
When several patients are prescribed the same recommended daily dosage of a drug, the 
drug can be efficacious in most, have little or no effect in others, and/or result in adverse drug 
reactions (ADRs) in a small group of patients [1]. ADRs can result in significant patient morbidity, 
mortality, and excess medical care costs [2, 3]. A widely cited meta-analysis estimated that 
anually more than 2 million hospitalized patients have severe adverse drug reactions in the 
United States even when drugs are appropriately prescribed and administered, and that ADRs 
ranked between the fourth and sixth leading causes of death in the United States in 1994 [4]. 
Several reports and policy initiatives have urged greater efforts to reduce the rate of adverse 
events in medical care [3, 5-7]. 
Besides the importance of clinical factors that determine variability in drug response, 
including age, organ function, concomitant diseases, concomitant drug therapy, nutritional 
status, and patient compliance, it is now clear that inherited factors can have an even greater 
influence on the efficacy and toxicity of drugs [8, 9]. Unlike environmental factors, inherited 
determinants generally remain stable throughout a person’s lifetime [10]. The aim of this thesis 
was to determine the importance of genetic variability and several environmental factors on the 
anticoagulant level during therapy with coumarin anticoagulants, a drug group with a narrow 
therapeutic index and a potentially life-threatening bleeding risk. The clinical implications of 
these findings lies in the possibility of prevention or early detection of excessive anticoagulation, 
and thus of bleeding complications, by individualization of drug therapy based on genetic and 
environmental information. The shortcomings and merits of the individual studies presented 
have been discussed in the previous chapters. In this discussion, the main findings are discussed 
and placed in a broader perspective. 
MAIN FINDINGS
Genetic variability and the coumarin anticoagulant level
Clinical observations of inherited differences in drug response were first documented in the 
1950s [11-14], giving rise to the field of pharmacogenetics. This field was initially restricted to 
drug metabolising enzymes. It has recently progressed to drug transporters, receptors, and 
other targets that can modulate drug response. This rapid extension is in close relation with the 
recent completion of the draft sequence of the human genome and the discovery that about 
0.1% of its sequence is polymorphic. The goal of pharmacogenetics for the next years is clearly 
to determine the clinical consequences of the 2-3 million single nucleotide polymorphisms 
(SNPs), and haplotypes. 
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The consequences of genetic variability will depend on the extent to which the function 
of an encoded gene product is affected by the mutation and the frequency with which the 
mutation occurs. Schematically, two situations can be distinghuised [15]. First, frequent SNPs 
(allele frequency >10%), which have a low impact on drug response (relative risk <2). Such 
situations, which are by far the most frequent, have no clinical relevance for a single patient to 
predict the response to a particular drug. CYP3A and MDR1 allelic variants are good examples 
of such frequent situations. Second, rare SNPs, which dramatically alter the expression or the 
activity of a target protein, can sometimes have a real clinical relevance (relative risk >5), usually 
to predict ADRs. There are only few examples that can illustrate this rare situation, one of which 
is the CYP2C9 genetic polymorphism.
In chapter 2.1 we studied the effect of the SNPs CYP2C9*2 (Arg144Cys) and CYP2C9*3 
(Ile359Leu) on the stability of the anticoagulant level during initiation and maintenance phases 
of acenocoumarol and phenprocoumon. In chapter 2.2 we studied the effect of these variant 
alleles on bleeding complications. For acenocoumarol-treated patients, the first INR after a 
standard starting dose tended to be higher in patients with one or more variant alleles than in 
wild type patients. This difference was not present anymore during the second INR measurement, 
probably because in the anticoagulation clinics, doses are adjusted according to the INR value 
obtained during the first measurement. During the rest of the initiation phase, however, patients 
with a variant allele on acenocoumarol appeared to be at a higher risk of overanticoagulation, 
but there was no effect of genotype on bleeding risk. During the maintenance phase carriers 
of variant alleles required significantly lower doses of acenocoumarol, and had a higher risk 
of major bleeding complications than wild type patients. For patients on phenprocoumon, 
there were no differences in these parameters between carriers of variant alleles and wild type 
patients. 
An association between carriership of CYP2C9 allelic variants and lower warfarin dose 
requirements has been convincingly demonstrated [16-26] but little was known about 
the association with acenocoumarol and phenprocoumon. Recently, however, a study in 
patients receiving phenprocoumon found that both SNPs had only minor impact on the 
pharmacokinetics of phenprocoumon [27]. These results are in line with our study. Several 
recent studies have demonstrated along with our results, that carriers of a CYP2C9*3 allele 
also require significantly lower doses of acenocoumarol [28-32]. Whereas the CYP2C9*2 allele 
clearly seems to decrease the metabolism of warfarin, the effect on acenocoumarol dose 
requirements is suggested to be less evident. Different clinical studies demonstrated no, or a 
minor association between the CYP2C9*2 allele and acenocoumarol response [29-33]. We found 
that carriers of a CYP2C9*2 allele had a significantly higher first INR, a higher mean INR and a 
higher risk of overanticoagulation during the rest of the initiation phase, and had a significantly 
lower maintenance dose. These statistically significant associations are possibly due to the 
large number of patients in our study. However, because we found an increased, although 
not statistically significant, relative risk of a major bleeding event in carriers of a CYP2C9*2 
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allele, the effect of this SNP on acenocoumarol pharmacokinetics and pharmacodynamics 
cannot be considered clinically irrelevant. In the literature, there is lack of agreement among 
studies on the risk of genotype on bleeding complications of coumarin anticoagulant therapy 
[16, 17, 19, 21, 26, 29, 34]. The critical question is whether knowledge of an individual’s 
CYP2C9 genotype would lead to improved optimisation of therapy, including a reduced risk 
of bleeding complications. Given the implied and possibly more significant involvement of 
environmental determinants in coumarin effects [23, 24, 32, 35-37], the answer to this question 
is not obvious. Phillips et al have outlined criteria that can be used to evaluate the potential 
impact of pharmacogenetic information in reducing ADRs [38]. The potential effect will be a 
function of medical need, clinical utility, and ease of use. Medical need will be driven primarily 
by the prevalence of variant alleles in the population, the use of a drug in that population, 
the severity of the ADR, and the ability to monitor drug toxicity using current technologies. 
Pharmacogenetic testing will be clinically appropriate only if there is sufficient evidence to link 
variant alleles with valid surrogate markers of drug toxicity or patient outcomes. And finally, 
genetic tests must be easy to use, and clinicians must be able to utilize genotype information 
to improve patient management and outcomes. Based on the high incidence of ADRs caused 
by coumarin anticoagulants, the potential effect of an intervention to reduce ADRs could be 
high because of the high usage of coumarin anticoagulants, the relatively high prevalence of 
poor metabolizers, and the severity of outcomes. For acenocoumarol [39] and warfarin [19, 21] 
the critical link between variant alleles and clinical outcome has now been demonstrated. The 
CYP2C9 enzyme genotype assays are readily performed at the clinical research level and are 
being developed for commercial use [9]. An argument against pharmacogenetic testing could 
be that coumarin anticoagulant therapy is already individualized by regular INR monitoring. 
However, we demonstrated for acenocoumarol that this is not enough to prevent major 
bleeding complications [39]. For acenocoumarol, subsequent studies are needed to determine 
whether clinicians are able to interpret the results and appropriately use the information and 
whether the additional costs of pre-dosing screening is counterbalanced by reduction of costs 
of treatment of bleeding complications. For phenprocoumon, we believe routine genotyping 
is not of additional benefit. CYP2C9 polymorphisms do not seem to play such major role in 
the biotransformation of this drug that knowledge of an individual’s genotype would lead 
to improved optimisation of therapy. For phenprocoumon, a pragmatic approach in which 
high-risk periods are identified and managed by intensified monitoring and pre-emptive 
dose reductions is likely to be a more effective risk reduction strategy than pharmacogenetic 
testing. 
In view of the extent of interindividual variability in dose requirements still observed within 
the various CYP2C9 genotype groups, it is possible that there are also other genetic factors 
involved. Vitamin K is an essential cofactor for the synthesis of several blood coagulation factors. 
It has been suggested that ApoE genotype has profound effects on vitamin K status. Therefore, 
we investigated in chapter 2.4 whether this common genetic polymorphism influenced dose 
154
C
ha
pt
er
 6
requirements and effects of acenocoumarol and phenprocoumon. Although ApoE genotype 
affects dose requirements of acenocoumarol, the clinical consequences of carrying a variant 
allele seem to be mild. Patients with a variant allele had a slightly increased INR but the risk of 
bleeding events seems to be negligible. 
Environmental factors and the coumarin anticoagulant level
Several studies suggest that the impact of environmental factors, such as aging, drug 
interactions, and diet is greater than that of genetic determinants [23, 24, 32, 35-37]. A very large 
number of drugs have been suspected of interacting with coumarin anticoagulants [40-42]. 
Often, this suspicion originated from the interpretation of a single clinical event [40]. Reports of 
such clinical impressions are useful, but they should be considered mere leads and should be 
followed by epidemiological studies. In chapter 3.1 and 3.2 we investigated which antibacterial 
drugs and antifungal agents were associated with overanticoagulation. These drug groups are 
frequently mentioned as risk factors for overanticoagulation in anecdotal reports. The most 
powerful potentiating drugs are those that interfere with the biotransformation of the coumarin 
anticoagulants, such as sulfamethoxazole combined with trimethoprim, and miconazole. Some 
medical textbooks on drug interactions take note of the potential interaction between laxatives 
and coumarin anticoagulants, but epidemiological evidence that this interaction is of practical 
importance was lacking. Our study described in chapter 3.3 showed that the only laxative with a 
moderately increased risk of overanticoagulation was lactulose. In chapter 3.4, we demonstrated 
that there is a pharmacological interaction between nonsteroidal anti-inflammatory drugs 
(NSAIDs) and coumarin anticoagulants, not via platelet inhibition, but again via inhibition of 
the CYP2C9-mediated metabolism of coumarins. For clinical practice, it seems advisable that 
one should frequently monitor for INR changes when adding or deleting any drug suspected 
to cause an interaction with coumarin anticoagulant therapy. A clear contraindication against 
concomitant treatment can be proven only for some drugs. 
Pathophysiological changes may also contribute to altered coumarin responsiveness. In 
the study described in chapter 4.1 we found that heart failure is an independent risk factor 
for overanticoagulation. Our data indicated that coumarin responsiveness is already slowly 
increasing during the weeks preceding the incident heart failure date. An extensive assessment 
of disease states that might increase the bleeding risk related to coumarins needs to be 
conducted and documented before initiating coumarin anticoagulant therapy. Doses should 
be adjusted downward in the presence of disease states such as, e.g. heart failure and patients 
should be closely monitored for signs of overanticoagulation.
The study described in chapter 5.1 showed that patients with a habitual dietary intake of 
vitamin K below the amount required for normal functioning of coagulation factors, i.e. 1 
µg/kg body weight per day, had an increased risk of overanticoagulation. Patients should be 
encouraged to maintain consistency in their vitamin K intake and should strive to meet the 
recommended dietary allowance for vitamin K.
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Gene-environment interactions
That drug response can be modified by an individual’s genotype was demonstrated in two of 
our studies. The combination of genotype and exposure results in a higher risk of an adverse 
outcome than would be expected from the effect of each risk factor alone. We found that the 
relative risk of myocardial infarction in women for CYP2C9 genotype alone was close to unity. The 
relative risk for exposure to CYP2C9 substrates alone was about twofold, whereas the combined 
relative risk for genotype and exposure was 5.0, indicating interaction between genotype and 
exposure (chapter 2.3). In chapter 3.4 we demonstrated that the pharmacological interaction 
between NSAIDs and coumarin anticoagulants, resulting in a higher risk of overanticoagulation, 
was modified by CYP2C9 allelic variants. 
These studies underline that drug response is complex, resulting not only from underlying 
genotypic variability and variability in environmental factors, but also from interactions 
between these factors.
Unknown genetic and environmental determinants
A few recently published studies suggest that environmental factors such as age, drug 
interactions, and diet do not fully account for the non-CYP2C9-associated variability in 
coumarin dose requirements [23, 24, 32]. This strongly suggests that other, currently unknown 
environmental determinants or possibly unidentified genetic variants may be involved, 
especially in the 5’-flanking region or the transcriptional regulatory receptors of the gene 
[43]. In addition, the possibility of genetically determined variability in the various proteins 
involved in the anticoagulant effect, which may contribute to differences in coumarin dose 
requirements, is a largely unexplored area with regard to interindividual variability in coumarin 
responsiveness [44].
Acenocoumarol versus phenprocoumon
Our results suggest less impact of the CYP2C9 polymorphisms on dose requirements and 
anticoagulation stability of phenprocoumon than of acenocoumarol. Thus, if the variability in 
biotransformation is a major cause of the overall incidence of ADRs during use of coumarin 
anticoagulants, the incidence of ADRs should be lower during treatment with phenprocoumon. 
Indeed, we found lower relative risks for all, and for minor bleeding complications in 
phenprocoumon-treated patients. But it should be noted that a direct comparison between 
acenocoumarol and phenprocoumon was not performed, and that the number of patients 
in our studies was limited. Our findings confirm previous observations that longer-acting 
coumarins provide a higher quality of therapy than short-acting coumarins [45-47]. 
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METHODOLOGICAL CONSIDERATIONS
The studies in this thesis raised a number of interesting methodological considerations.
SNP analysis versus haplotype analysis
While it was often brought forward during the last decade that SNPs could predict particular 
clinical outcomes, it is now proposed that SNPs alone are not good predictors of a drug 
response and that haplotype analysis should replace SNP analysis [48]. A haplotype is a group 
of alleles found at linked loci on a single chromosome, usually inherited as a unit. Haplotype 
analysis implicates the simultaneous detection of numerous SNPs on the same gene and, 
therefore, increases the cost for its determination. It should be kept in mind that haplotype 
analysis is an epidemiologic strategy that should be extrapolated to individual risk prediction 
with great caution; most of the time, individual haplotypes are statistical estimations and are 
not observed, unless the subjects are heterozygous at one SNP at most [32]. Furthermore, to 
limit the number of polymorphic markers (“tagging SNPs”) needed to construct and determine 
major haplotypes, minor haplotypes representing a few percent of the studied population will 
be excluded. This might probably represent an important bias because rare clinical outcomes 
are usually associated with rare genetic variants, which will be missed with usual haplotype 
analysis [15]. The predictive value of individual coding SNPs and haplotypes (combinations 
of the 5’-flanking and coding SNPs), were recently compared [15, 32]. The haplotype which 
included the CYP2C9*3 SNP, was associated with a more profound response to coumarin 
anticoagulants. A similar conclusion, however, could be obtained when the CYP2C9*3 SNP was 
taken alone in the analysis (SNP analysis). Haplotypes which include the CYP2C9*2 SNP also do 
not seem to predict more genetic variability than this coding SNP alone [32, 49]. This means 
that most of the information on the genetic variability of CYP2C9 is related to two SNPs and 
haplotype analysis does not seem to provide additional information.
Adequate sample size gene-environment interaction
Efforts to study gene-environment interactions are tempered by the difficulty in obtaining 
adequate sample size [50-52]. In both studies on gene-environment interaction (chapter 2.3 
and 3.4) we therefore classified drug exposure and genotype as being either present or absent. 
An advantage of these dichotomized data is that it gives us direct insights into the relative risk 
estimates for each factor alone and their joint effect. Unfortunately, this reduction into two 
categories results in general in a loss of information by misclassification and is a simplification 
of the complexity of biology. 
Disease misclassification
In several studies we used overanticoagulation as outcome variable. When two subsequent 
INR measurements had a value below 6.0 we assumed that in between the INR value was 
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also below 6.0. Because patients in an anticoagulation clinic are regularly assessed for their 
INR it seems unlikely that in this way many cases of overanticoagulation were missed. When 
the proportion of subjects misclassified on disease does depend on exposure differential 
misclassification occurs, which can either exaggerate or underestimate an effect. This may play 
a role in the associations of several drug interactions with overanticoagulation, since patients 
are instructed to inform the clinic of these occurrences. If considered necessary, the patient’s 
INR is measured earlier than the appointed date. Then, the chance of diagnosing the outcome 
is different for exposed and unexposed individuals. We dealt with this bias by adjustment for 
earlier INR-assessment. 
Repeated measurement analysis
With the development of statistical techniques, it has become possible to analyse longitudinal 
relationships using all available longitudinal data, without summarizing the longitudinal 
development of each subject into one value. Because with these sophisticated statistical 
techniques the outcome variable is repeatedly measured on the same subject, these methods 
adjust for the dependency of observations within one subject. In the study on the effect of 
CYP2C9 variant alleles on the coumarin maintenance dose we simply calculated the mean 
maintenance dose as outcome variable (chapter 2.1). We found the longitudinal methods to 
be much more efficient in detecting a difference in outcome for the different exposure groups 
in our study on the effect of ApoE genotype on the coumarin maintenance dose (chapter 2.4). 
The magnitude of the differences we found were the same with the longitudinal method as 
by calculating a mean dose per subject (data not shown), but the statistical significance of the 
differences with the wild type genotype was much larger with the longitudinal method. 
FUTURE RESEARCH 
In view of the extent of interindividual variability in coumarin dose requirements still observed 
within the various CYP2C9 genotype groups, it is possible that genotyping for additional 
polymorphic genes could be of value. Further studies on this aspect may provide useful 
information. Use of coumarin anticoagulants is still increasing but the development of novel 
oral anticoagulants, such as the direct thrombin inhibitors which do not require coagulation 
monitoring and which plasma concentrations are directly proportional to dose, may lead to a 
decrease of coumarin use in the future. Clinical trials comparing oral direct thrombin inhibitors 
and coumarins are underway [53]. A direct cost-benefit comparison of direct thrombin inhibitors 
with the older and cheaper coumarin anticoagulants combined with CYP2C9 genotyping under 
everyday circumstances would be interesting. As long as we miss such data, coumarins may 
remain useful in the treatment of thromboembolic disorders.
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Coumarin anticoagulants are drugs with a low therapeutic index. Coumarins have a large 
pharmacokinetic and pharmacodynamic interindividual variability, and may cause life-
threatening bleeding complications. Most of the extensive research on coumarin anticoagulant 
therapy has focussed on warfarin. Because of the different pharmacokinetic properties of each 
individual drug, the results of these studies can probably not be directly extrapolated to the other 
coumarin anticoagulants. Therefore, the aim of this thesis was to study the various genetic and 
environmental factors affecting the anticoagulation levels of acenocoumarol or phenprocoumon 
among outpatients of an anticoagulation clinic. The studies described in this thesis have been 
performed in the Rotterdam Study, a prospective population-based cohort study, which was 
initiated to assess prevalence, incidence, and determinants of diseases in the elderly.
Chapter 1 gives a general introduction to coumarin anticoagulant therapy.
In chapter 2, studies on the association between several polymorphisms and dose 
requirements and clinical effects are presented. In chapter 2.1, we investigated the cytochrome 
P450 polymorphisms, CYP2C9*2 and CYP2C9*3, in relation to the international normalised 
ratio (INR) during the first six weeks of treatment and its effect on the maintenance dose in a 
cohort of 1124 patients from the Rotterdam Study who were treated with acenocoumarol or 
phenprocoumon between January 1, 1985 and December 31, 1998. There was a statistically 
significant difference in first INR between patients with variant genotypes and those with 
the wild type. Almost all acenocoumarol-treated patients with a variant genotype had a 
significantly higher mean INR and had a higher risk of an INR ≥ 6.0 during the first six weeks 
of treatment. A clear genotype-dose relationship was found for acenocoumarol-treated 
patients. For patients on phenprocoumon, no significant differences were observed between 
variant genotypes and the wild type genotype. In chapter 2.2, we examined the effect of 
the CYP2C9 polymorphisms on bleeding complications during initiation and maintenance 
phases of coumarin anticoagulant therapy. The design was a population-based cohort study 
in 996 patients on acenocoumarol or phenprocoumon, for whom INR data were available and 
whose CYP2C9 status was known. For patients with the wild type genotype, the rate of minor 
bleeding, major bleeding and fatal bleeding was 15.9, 3.4 and 0.2 per 100 treatment years, 
respectively. For patients with a variant allele, the rate of minor, major and fatal bleeding was 
14.6, 5.4 and 0.5 per 100 treatment years. Patients with a variant allele on acenocoumarol had 
a significantly increased risk of a major bleeding event (relative risk (RR) 1.83, 95%CI: 1.01-3.32). 
We did not find such an association for phenprocoumon. During the initiation phase of therapy 
we found no effect of variant genotype on bleeding risk. That CYP2C9 allelic variants not only 
affect variability in drug response but are also involved in the metabolism of endogenous 
substances, is demonstrated in chapter 2.3. We investigated whether CYP2C9 allelic variants 
and use of CYP2C9 substrates were associated with an increased risk of myocardial infarction 
in 2210 men and 3534 women from the Rotterdam Study. In women, use of CYP2C9 substrates 
was significantly associated with myocardial infarction (RR 2.68, 95%CI: 1.60-4.49). The risk of 
myocardial infarction was fivefold in female users of CYP2C9 substrates with a variant allele. 
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Neither the use of CYP2C9 substrates, nor the variant alleles were associated with an increased 
risk of myocardial infarction in men. The influence of the apolipoprotein E polymorphism on 
coumarin dose requirements, overanticoagulation and bleeding complications are discussed 
in chapter 2.4. In a cohort study among 1637 patients on acenocoumarol or phenprocoumon, 
we found that individuals homozygous for the ε4 allele required a significantly lower dose of 
acenocoumarol than patients with genotype ε3/ε3 to attain the same level of anticoagulation. 
Patients homozygous for the ε2 allele on acenocoumarol required a significantly higher dose 
than patients with genotype ε3/ε3. The effect of the ε4 allele on the coumarin dose was dose-
dependent, while the effect of the ε2 allele was not. No significant dose differences were 
observed for phenprocoumon. 
Chapter 3 focuses on the role of drug interactions in overanticoagulation. Chapters 3.1, 3.2, 
3.3 and 3.4 are based on the same population-based cohort study in a sample of the Rotterdam 
Study. The study cohort consisted of all participants who were treated with acenocoumarol or 
phenprocoumon in the study period from April 1, 1991 through December 31, 1998 (chapter 
3.4 through May 31, 2003) and for whom INR-data were available. All cohort members were 
followed until the first occurrence of an INR ≥ 6.0, the last INR-assessment because of the end of 
their treatment, death or end of the study period. For data on comedication, we used data from 
regional pharmacies where more than 99% of participants fill their prescriptions. In chapter 
3.1 we describe which antibacterial drugs are associated with overanticoagulation. Of the 1124 
patients in the cohort, 351 developed an INR ≥ 6.0. Eight antibacterial drugs were multivariately 
associated with overanticoagulation. Sulfamethoxazole combined with trimethoprim most 
strongly increased the risk of overanticoagulation (RR 20.1; 95%CI 10.7-37.9). Stratification 
showed that the induction period of overanticoagulation varied between different antibacterial 
drugs. In chapter 3.2 we demonstrated that some antifungal agents were associated with a 
strongly increased risk of overanticoagulation. The relative risk varied considerably between 
the different agents and the different routes of administration. The strongest risk increase was 
associated with oral miconazole (RR 36.3; 95%CI: 12.4-108.0). The study described in chapter 
3.3 showed that a potential interaction between laxatives and coumarins is of practical 
importance only for lactulose (RR 3.4; 95%CI: 2.2-5.3). Chapter 3.4 demonstrates that there 
is a pharmacological interaction between nonsteroidal anti-inflammatory drugs (NSAIDs) and 
coumarins and that this interaction is modified by allelic variants of CYP2C9. Apparently, NSAIDs 
may not only induce bleeding by inhibition of platelet function but also via a pharmacokinetic 
interaction with coumarins. Awareness of these drug interactions and more frequent monitoring 
of INR-values during the initial stages of concomitant drug therapy are warranted to minimise 
the risk of bleeding complications. The study described in chapter 3.4 underlines that drug 
response is complex, resulting not only from underlying genotypic variability and variability in 
environmental factors, but also from interactions between these factors.
Several chronic diseases are associated with overanticoagulation. Heart failure has been 
identified as a risk factor for increased coumarin responsiveness in several small-scale 
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experiments. Therefore, we investigated whether patients with heart failure have an increased 
risk of overanticoagulation and determined the effect of incident heart failure on coumarin 
dose requirements (chapter 4). The study cohort consisted of all patients treated with 
acenocoumarol or phenprocoumon between the baseline visit of the Rotterdam Study through 
January 1, 2000. All cohort members were followed until the first occurrence of an INR ≥ 6.0, the 
last INR-assessment, death, loss to follow-up, or end of the study period. Of the 1077 patients in 
the cohort, 396 developed an INR ≥ 6.0. The risk of overanticoagulation was 1.66 (95%CI: 1.33-
2.07) for cases of prevalent heart failure and 1.91 (95%CI: 1.31-2.79) for incident cases. Given 
the high prevalence of heart failure, a 66% risk increase is substantial. The decrease in dose 
requirements in patients with incident heart failure showed a significant trend between the 
5th INR measurement preceding the incident heart failure date and the 3rd measurement after 
this date. Patients with heart failure should be closely monitored to prevent potential bleeding 
complications. 
In chapter 5 we examined whether patients with a deficient dietary intake of vitamin K have 
an increased risk of overanticoagulation. The study cohort consisted of all participants of whom 
dietary intake data have been collected and who were treated with coumarin anticoagulants in 
the study period from the baseline visit of the Rotterdam Study (1990-1993) through December 
31, 1998. All cohort members were followed until the first occurrence of an INR ≥ 6.0, the last 
INR-assessment during the study period, death or end of the study period. The intake of vitamin 
K was calculated from the total diet using data on concentrations of vitamin K1 and vitamin K2 in 
foods. An intake of vitamin K below 1 µg/kg body weight per day was considered deficient. Of 
the 772 patients in the cohort, 227 developed an INR ≥ 6.0 during the study period. The number 
of patients in the total cohort with a deficient dietary intake of vitamin K was 12 (1.6%). Of the 
cases, seven patients (3.1%) had a deficient dietary intake of vitamin K. The adjusted relative risk 
of overanticoagulation associated with a deficient dietary intake of vitamin K was 9.6 (95%CI: 
4.0-23.0). To minimise the risk of bleeding complications, patients on coumarin anticoagulant 
therapy may be advised to consume vitamin K-rich foods such as green, leafy vegetables. 
In the general discussion in chapter 6, the main findings are summarised and some 
methodological issues are discussed. In addition, the implications for coumarin anticoagulant 
therapy and recommendations for future research are given. 

Chapter 7.2
Samenvatting
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Cumarine anticoagulantia hebben een smalle therapeutische breedte en vertonen een grote 
interindividuele variabiliteit in farmacokinetische en farmacodynamische eigenschappen. 
Deze geneesmiddelen kunnen levensbedreigende bloedingen veroorzaken. Het merendeel 
van de vele onderzoeken op het gebied van orale antistollingsbehandeling heeft zich 
geconcentreerd op warfarine. Vanwege de verschillende farmacokinetische eigenschappen 
van de individuele stoffen, kunnen deze resultaten waarschijnlijk niet rechtstreeks worden 
geëxtrapoleerd naar de andere cumarine anticoagulantia. Het doel van dit proefschrift was 
daarom om een aantal genetische en omgevingsfactoren te bestuderen die de intensiteit 
van de antistollingsbehandeling met acenocoumarol of fenprocoumon, bij patiënten van 
een trombosedienst, beïnvloeden. Alle studies die hier worden gepresenteerd zijn uitgevoerd 
binnen het Rotterdamse ERGO-onderzoek (Erasmus Rotterdam Gezondheid en Ouderen), 
internationaal bekend als “the Rotterdam Study”. Dit is een prospectief bevolkingsonderzoek 
naar frequentie en oorzaken van chronische ziekten bij ouderen. 
Na een algemene introductie over cumarine anticoagulantia in hoofdstuk 1, wordt in 
hoofdstuk 2 de invloed van verschillende polymorfismen op de cumarine dosering en op een 
aantal klinische uitkomsten gepresenteerd. In hoofdstuk 2.1 onderzochten we de invloed 
van cytochroom P450 2C9 polymorfismen, CYP2C9*2 en CYP2C9*3, op de international 
normalised ratio (INR, maat voor de intensiteit van de antistolling) gedurende de eerste zes 
behandelingsweken (initiatiefase) en op de onderhoudsdosering in een cohort van 1124 
patiënten die werden behandeld met acenocoumarol of fenprocoumon tussen 1 januari 1985 
en 31 december 1998. Er bleek een statistisch significant verschil te bestaan in de hoogte 
van de eerste INR na een standaard startdosis tussen dragers van een variant allel en mensen 
zonder deze allelen. Patiënten die acenocoumarol gebruikten, hadden gemiddeld een hogere 
INR en meer kans op doorgeschoten antistolling (INR ≥ 6.0) gedurende de initiatiefase. We 
vonden een duidelijke genotype-dosis relatie voor patiënten die acenocoumarol gebruikten. 
Voor patiënten, die fenprocoumon gebruikten, konden we geen verschillen aantonen tussen 
dragers van een variant allel en mensen zonder deze allelen. In hoofdstuk 2.2 bestudeerden 
we het effect van de CYP2C9 polymorfismen op het krijgen van bloedingen gedurende de 
initiatie- en onderhoudsfase van de antistollingsbehandeling. We deden een cohort-onderzoek 
onder 996 patiënten die werden behandeld met acenocoumarol of fenprocoumon, van wie INR 
gegevens beschikbaar waren en van wie de CYP2C9 status bekend was. De risico’s op een kleine 
bloeding, een ernstige bloeding en dodelijke bloedingcomplicaties waren respectievelijk 15.9, 
3.4 en 0.2 per 100 jaren antistollingsbehandeling voor patiënten zonder variant allelen. Voor 
patiënten met een variant allel waren deze risico’s 14.6, 5.4 en 0.5 per 100 behandelingsjaren. 
Dragers van een variant allel - die acenocoumarol gebruikten - hadden een significant hoger 
risico op het krijgen van een ernstige bloeding (relatief risico (RR) 1.83, 95%CI: 1.01-3.32). Voor 
fenprocoumon vonden we deze associatie niet. Gedurende de initiatiefase bleek er geen effect 
te zijn van het genotype op het bloedingsrisico. Dat het CYP2C9 genotype niet alleen een 
belangrijke rol speelt bij het metabolisme van geneesmiddelen maar ook bij dat van endogene 
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stoffen werd aannemelijk gemaakt in hoofdstuk 2.3. We onderzochten of dragerschap van een 
CYP2C9 variant allel en gebruik van geneesmiddelen die via CYP2C9 worden gemetaboliseerd, 
geassocieerd was met het krijgen van een hartinfarct bij 2210 mannen en 3534 vrouwen in 
het ERGO-onderzoek. Gebruik van CYP2C9 substraten was bij vrouwen geassocieerd met het 
krijgen van een hartinfarct (RR 2.68, 95%CI: 1.60-4.49). Het relatieve risico op een hartinfarct was 
5 maal zo hoog bij vrouwelijke dragers van een variant allel die eveneens CYP2C9 substraten 
gebruikten ten opzichte van vrouwen zonder variant allel die deze geneesmiddelen niet 
gebruikten. Bij mannen werd geen associatie gevonden. De invloed van het apolipoproteine 
E polymorfisme op de cumarine dosering, en het optreden van doorgeschoten antistolling en 
bloedingcomplicaties wordt in hoofdstuk 2.4 besproken. In een cohort-onderzoek onder 1637 
patiënten die acenocoumarol of fenprocoumon gebruikten, toonden we aan dat mensen die 
homozygoot zijn voor het ε4 allel een significant lagere dosis acenocoumarol nodig hebben 
dan patiënten met genotype ε3/ε3. Patiënten die behandeld worden met acenocoumarol en 
homozygoot zijn voor het ε2 allel hebben een significant hogere dosis acenocoumarol nodig 
dan patiënten met genotype ε3/ε3. Het effect van het ε4 allel bleek dosis-afhankelijk te zijn, dat 
van het ε2 allel niet. Voor patiënten, die fenprocoumon gebruikten, werden geen significante 
verschillen in dosering aangetoond tussen de verschillende genotypen.
Hoofdstuk 3 gaat over de rol van geneesmiddelinteracties bij doorgeschoten antistolling. De 
hoofdstukken 3.1, 3.2, 3.3 and 3.4 zijn gebaseerd op dezelfde prospectieve cohort-analyse bij 
een deel van de ERGO-deelnemers. Het studiecohort bestond uit alle deelnemers die werden 
behandeld met acenocoumarol of fenprocoumon in de studieperiode van 1 april 1991 tot 31 
december 1998 (voor de studie in hoofdstuk 3.4 tot 31 mei 2003). Alle cohortleden werden 
gevolgd tot het eerste optreden van een INR ≥ 6.0, de laatste INR-bepaling, overlijden of einde 
van de studieperiode. Gegevens over geneesmiddelengebruik waren afkomstig van lokale 
apotheken, bij wie meer dan 99% van de deelnemers de geneesmiddelen betrekt. In hoofdstuk 
3.1 onderzochten we welke antibiotica zijn geassocieerd met doorgeschoten antistolling. 
Van de 1124 patiënten in het cohort ontwikkelden er 351 een INR ≥ 6.0. Acht antibiotica 
waren geassocieerd met doorgeschoten antistolling. Sulfamethoxazole in combinatie met 
trimethoprim (co-trimoxazol) verhoogde het risico op doorschieten het sterkst (RR 20.1; 95%CI: 
10.7-37.9). Stratificatie liet zien dat de periode tussen het starten van de behandeling met 
antibiotica en het doorschieten varieerde tussen de verschillende antibiotica. 
In hoofdstuk 3.2 toonden we aan dat enkele antischimmel-middelen waren geassocieerd 
met een sterk verhoogd risico op doorgeschoten antistolling. Het relatieve risico varieerde 
sterk tussen de verschillende middelen en de verschillende toedieningsroutes. Het risico op 
doorschieten was het meest verhoogd bij miconazol per os (RR 36.3; 95%CI: 12.4-108.0). De 
studie die in hoofdstuk 3.3 wordt beschreven laat zien dat de theoretische interactie tussen 
laxantia en cumarines alleen van praktisch belang is voor lactulose (RR 3.4; 95%CI: 2.2-5.3). 
Hoofdstuk 3.4 laat zien dat er een farmacokinetische interactie is tussen nonsteroidal anti-
inflammatory drugs (NSAIDs) and cumarines en dat het effect van deze interactie anders is 
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voor dragers van een CYP2C9 variant allel. Het zich bewust zijn van deze geneesmiddel-
interacties en het frequenter controleren van de INR in de beginfase van gelijktijdig gebruikte 
geneesmiddelen wordt aangeraden om het risico op bloedingscomplicaties te beperken. De 
studie beschreven in hoofdstuk 3.4 onderstreept nog eens dat geneesmiddelenrespons een 
complex fenomeen is, niet alleen ten gevolge van genetische verschillen en verschillen in 
omgevingsfactoren, maar ook ten gevolge van interacties tussen deze factoren. 
Verschillende chronische ziekten worden geassocieerd met een doorgeschoten antistoll
ingsbehandeling. In experimenten met een beperkt aantal patiënten in de jaren ’50 van de 
vorige eeuw werd gevonden dat patiënten met hartfalen een grotere respons op cumarine 
anticoagulantia vertoonden. Wij bevestigden deze associatie in een cohort-onderzoek onder 
alle patiënten die acenocoumarol of fenprocoumon gebruikten in de studieperiode tussen de 
aanvang van het ERGO-onderzoek (1990-1993) en 1 januari 2000 (hoofdstuk 4). Alle cohortleden 
werden gevolgd tot het eerste optreden van een INR ≥ 6.0, de laatste INR-bepaling, overlijden of 
einde van de studieperiode. Van de 1077 patiënten in het cohort ontwikkelden er 396 een INR 
≥ 6.0. Het relatieve risico op doorgeschoten antistolling geassocieerd met prevalent hartfalen 
was 1.66 (95%CI: 1.33-2.07) en met incident hartfalen 1.91 (95%CI: 1.31-2.79). Gezien de hoge 
prevalentie van hartfalen, kan een risicotoename van 66% als substantieel worden beschouwd. 
De afname in cumarine dosering om dezelfde intensiteit van antistolling te behouden, zet in op 
de 5e INR-bepaling voorafgaand aan de incidente datum van het hartfalen en duurt voort tot de 
3e INR-bepaling na deze datum. De INR van patiënten met hartfalen moet frequenter worden 
gecontroleerd om doorschieten van de antistolling en potentiële bloedingcomplicaties te 
voorkomen. 
In hoofdstuk 5 onderzochten we of patiënten met een deficiënte voedingsinneming van 
vitamine K een verhoogd risico op het doorschieten van de antistolling hadden. We voerden 
hiertoe een cohort-onderzoek uit bij een deel van de ERGO-deelnemers. Het studiecohort 
bestond uit alle deelnemers van wie voedingsgegevens waren verzameld en die werden 
behandeld met cumarine anticoagulantia in de studieperiode tussen de aanvang van het ERGO-
onderzoek en 31 december 1998. Alle cohortleden werden gevolgd tot het eerste optreden van 
een INR ≥ 6.0, de laatste INR-bepaling, overlijden of einde van de studieperiode. De inneming 
van vitamine K werd berekend over de totale voeding op basis van de vitamine K1- en K2-
gehalten van voedingsmiddelen. Een vitamine K-inneming beneden 1 µg/kg lichaamsgewicht 
per dag werd als deficiënt beschouwd. Van de 772 patiënten in het cohort ontwikkelden er 227 
een INR ≥ 6.0. Het aantal patiënten in het totale cohort met een deficiënte voedingsinneming 
van vitamine K was 12 (1.6%). Van de patiënten met een doorgeschoten antistolling hadden 
er zeven (3.1%) een deficiënte inneming van vitamine K. Het gecorrigeerde relatieve risico op 
doorgeschoten antistolling geassocieerd met deficiënte voedingsinneming van vitamine K 
was 9.6 (95%CI: 4.0-23.0). Teneinde het risico van bloedingcomplicaties zo klein mogelijk te 
houden zou patiënten op cumarine antistollingsbehandeling kunnen worden geadviseerd om 
vitamine K-rijke voedingsmiddelen te eten, zoals groene bladgroenten. 
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In de algemene discussie in hoofdstuk 6 worden de belangrijkste resultaten samengevat en 
bespreken we een aantal methodologische aspecten. Vervolgens worden de consequenties 
voor de antistollingsbehandeling met cumarine anticoagulantia besproken en worden 
aanbevelingen gedaan voor verder onderzoek.
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Ron van Schaik en Martin van Vliet ben ik bijzonder erkentelijk voor het bepalen van de CYP2C9 
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erkentelijk voor alle ondersteuning. 
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voor het bieden van de mogelijkheid me een half jaar volledig op het onderzoek te kunnen 
storten. Paul, bedankt voor je enorme collegialiteit en heel veel succes met het afronden van 
je eigen onderzoek. Alle andere collega’s wil ik bedanken voor hun belangstelling en prettige 
samenwerking. 
Beter een goede buur… is ook de afgelopen jaren voor mij weer bevestigd. Jullie hebben mij, 
soms bij nacht en ontij, uit de meest penibele situaties gered. Heel veel dank daarvoor. Ann, 
bedankt voor je vriendschap en de broodnodige afleiding tussen al die uurtjes ploeteren.
Vrienden wil ik bedanken voor hun gezelschap, belangstelling en steun de afgelopen jaren. 
Paranimfen Gysèle Bleumink en Helène Wakkerman-Bootsma, ik ben zeer vereerd dat jullie 
bereid zijn mij terzijde te staan bij de verdediging. Gysèle, ik vond het fantastisch om jouw 
ontwikkeling binnen de afdeling mee te maken. Ik ken weinig mensen die zaken zo snel kunnen 
doorgronden en becommentariëren als jij. Heel veel succes met je verdere carrière en ik hoop 
van harte dat we contact houden. Lieve Helène, fantastisch om op latere leeftijd toch nog een 
zus te krijgen! Jouw optimistische kijk op de wereld, je wijze raad op het gebied van kinderen 
en onze telefonische uurtjes op woensdag waardeer ik zeer. Toch leuk dat je zo lang gedacht 
hebt dat je een ‘secret lover’ had.
Lieve papa en mama, ik wil jullie hartelijk danken voor alle morele steun, het oppassen en de 
nodige afleiding de afgelopen jaren. Jullie trots en onvoorwaardelijke liefde zijn voor mij een 
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de jongens, nog een tijdje kunt verlengen.
Lieve familie en schoonfamilie, ik wil jullie hartelijk bedanken voor alle steun en warme 
belangstelling de afgelopen jaren.
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voor al je liefde en support. Het wordt tijd voor andere zaken na al die promotieperikelen en 
postdoctorale opleidingen, samen met onze popkes!!
Loes.
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